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Glucocorticoids, key hormonal regulators of the stress response, powerfully influence 
inflammation and metabolism. Reducing excessive glucocorticoid exposure is 
beneficial in treating metabolic and cognitive disorders, but manipulating systemic 
endogenous glucocorticoids risks compromising their beneficial effects. The enzyme 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activates glucocorticoids in 
target tissues and thus inhibition of this enzyme presents a clinical opportunity to 
reduce tissue-specific glucocorticoid action. Active glucocorticoids also exert potent 
angiostatic effects by binding the glucocorticoid receptor (GR), and 11β-HSD1 
inhibitors have proven beneficial in models of myocardial infarction by promoting 
angiogenesis. The possibility that 11β-HSD1 inhibitors may increase pathological 
angiogenesis, such as that seen in solid tumours, remains unaddressed. This project 
tested the hypothesis that 11β-HSD1 inhibition promotes tumour growth as a result of 
increased angiogenesis, using murine models of squamous cell carcinoma (SCC) and 
pancreatic ductal adenocarcinoma (PDAC). 
Murine SCC or PDAC cells were injected (1x106 cells/flank) into WT female mice fed 
either standard diet, or diet containing the 11β-HSD1 inhibitor UE2316 (175 mg/kg, 
N=6/group), or into 11β-HSD1 knockout (Del1) mice fed standard diet. Developing 
tumours were measured by callipers over several weeks, before animals were culled 
and tissues collected. SCC tumours grew more rapidly in UE2316-treated mice to 
reach a significantly (P<0.01) larger final volume (0.158 ± 0.037 cm3) than in control 
mice (0.051 ± 0.007 cm3). PDA tumours were unaffected by 11β-HSD1 inhibition or 
deletion. Immunofluorescent co-staining of tumour sections for CD31/α-smooth 
muscle actin revealed no differences in vessel density, and RT-qPCR showed no 
difference in angiogenic factor expression, after 11β-HSD1 inhibition/deletion in 
either tumour type. GR and 11β-HSD1 RNA expression were greater in SCC vs PDAC 
tumours (P<0.001), as was 11β-HSD1 activity (P<0.0001). 
In studies using the aortic ring assay of ex vivo angiogenesis, 11β-HSD1 deletion, but 
not inhibition with UE2316, was shown to prevent glucocorticoid-mediated 
angiostasis. The growth/viability of tumour cell lines was not affected by UE2316 or 
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corticosterone, as assessed by live cell imaging using the Incucyte imaging system. 
RNA-sequencing of SCC tumours revealed that multiple factors involved in the innate 
immune/inflammatory response were reduced in UE2316-treated tumours, and that 
extracellular matrix regulation was also altered by UE2316. Imaging of tumour 
sections using Second Harmonic Generation microscopy confirmed that UE2316 
altered Type I collagen deposition in SCC (P<0.001) but not PDAC.  
11β-HSD1 inhibition can increase tumour growth, possibly via suppression of 
inflammatory/immune cell signalling and alteration of the extracellular matrix, and 
tumours with higher GR and 11β-HSD1 content, such as SCC, may be more at risk. 
Interestingly this investigation found no evidence of increased angiogenesis in vivo or 
ex vivo after UE2316 treatment, suggesting that 11β-HSD1 inhibition does not 
promote angiogenesis in all ischaemic environments. Future work must focus on the 
effects of 11β-HSD1 inhibition on the immune and extracellular matrix component of 
the tumour microenvironment. While promotion of pathological angiogenesis does not 
appear to pose a major threat, 11β-HSD1 inhibitors may still interact with the immune 
and inflammatory environment in tumours to the detriment of health. 
Lay Abstract 
Glucocorticoids are hormones that regulate the body’s response to stress. Exposure to 
sustained high levels of glucocorticoids can be damaging to health, and so reducing 
levels is desirable for treating diseases such as diabetes and Alzheimer’s. However, 
care must be taken not to disrupt glucocorticoid levels throughout the body. 
Glucocorticoids are activated in specific tissues by the enzyme 11β-hydroxysteroid 
dehydrogenase type I (11β-HSD1), and blocking the action of this enzyme is 
considered a safer method for reducing their detrimental effects in targeted areas.  
Glucocorticoids also prevent the growth of new blood vessels (that is, they are anti-
angiogenic). 11β-HSD1 inhibitors therefore promote the growth of new blood vessels 
(angiogenesis) by reducing glucocorticoid levels. While this promotes recovery in 
mice that have suffered a heart attack, it could also cause tumours to grow more 
quickly by increasing their blood supply. This project tested the hypothesis that 11β-
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HSD1 inhibition promotes tumour growth by increasing angiogenesis, using mouse 
models of skin and pancreatic cancer. 
Mouse skin cancer or pancreatic cancer cells were injected into mice which had 
received either (1) no treatment, (2) a drug that stops 11β-HSD1 generating 
glucocorticoids, or (3) genetic deletion of 11β-HSD1. Developing tumours were 
measured by callipers over 11-16 days, before animals were killed and tissues 
collected. Skin tumours grew more quickly in mice given a drug to block 11β-HSD1 
generating glucocorticoids; this meant that the tumours in these mice were bigger than 
in controls. Pancreatic tumours were unaffected by 11β-HSD1 inhibition or deletion. 
The number of blood vessels in tumours, and the angiogenic signals they produced, 
were not affected by 11β-HSD1 inhibition/deletion in either tumour type. Skin 
tumours had more 11β-HSD1 and more of the glucocorticoid receptor than pancreatic 
tumours. 
Adding glucocorticoids to a piece of mouse aorta grown on a plate prevented new 
blood vessels forming. This effect was prevented in aortas from mice lacking 11β-
HSD1, but was not prevented by the drug that blocked 11β-HSD1. The growth and 
survival of cancer cells cultured on a plate were also unaffected by 11β-HSD1 
inhibition and by glucocorticoids. Profiling gene expression in skin tumours showed 
that 11β-HSD1 inhibition reduced immune cell signalling, and affected structural 
components of the tumour, in particular collagen. Imaging of tumour sections 
confirmed that the amount of collagen in skin tumours, but not pancreatic tumours, 
was reduced by 11β-HSD1 inhibition.  
In summary, using a drug to stop 11β-HSD1 generating glucocorticoids can increase 
tumour growth, possibly by suppressing immune signalling and altering the structure 
of the tumour. Tumour types with more 11β-HSD1 and glucocorticoid receptor, such 
as skin cancer, may be more at risk.  Interestingly this investigation found no evidence 
of increased blood vessel growth after 11β-HSD1 inhibition, suggesting that local 
glucocorticoids influence blood vessels differently in the heart and in tumours. While 
11β-HSD1 inhibitors may not promote blood vessel growth, they may still pose a 
threat. Future work must determine the mechanisms by which 11β-HSD1 inhibition 
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1 Introduction  
Glucocorticoids are vital modulators of the physiological stress response, with wide-
ranging effects across almost every major organ system (Sapolsky et al., 2000). These 
steroid hormones have been exploited clinically for over half a century for their anti-
inflammatory and immunosuppressive effects (Hench & Kendall, 1949) and are today 
still commonly used to treat both acute and chronic inflammatory conditions. These 
include rheumatoid arthritis, dermatological conditions, inflammatory bowel disease, 
asthma and multiple sclerosis (Coutinho and Chapman, 2011). Their potent 
immunosuppressive effects are also exploited clinically in the treatment of leukaemia 
and immunosuppression before organ transplant (Coutinho and Chapman, 2011; Lin 
and Wang, 2016).  
In terms of physiology, when a stressor is encountered, the hypothalamic-pituitary-
adrenal (HPA) axis is activated, leading to a rise in circulating cortisol (in man) or 
corticosterone (in rats and mice) (Sapolsky et al., 2000). Negative feedback to both the 
hypothalamus and the pituitary ensures basal systemic glucocorticoid levels are 
maintained within a predictable range, with a diurnal peak and nadir under circadian 
control (Oakley and Cidlowski, 2013). The major role of glucocorticoids is in the 
regulation of energy metabolism; glucocorticoids oppose the effects of insulin, 
inducing gluconeogenesis and increasing free energy stores to fuel skeletal muscle 
metabolism (Walker, 2007). Glucocorticoids also exert myriad effects on other 
systems in the body, influencing reproductive function, memory, vascular tone, 
immunity and adiposity (Sapolsky et al. 2000). 
Whilst glucocorticoids are pivotal in coordinating the physiological stress response, 
they can become maladaptive if present at chronically high levels. Consequences of 
excessive glucocorticoid exposure are apparent in Cushing’s syndrome, in which 
glucocorticoid levels are constantly elevated, due either to a pituitary tumour or long-
term therapeutic steroid administration (Whitworth et al., 2000). Patients with 
glucocorticoid excess present with a range of debilitating cardiometabolic disorders, 
including increased visceral adiposity, poor glycaemic control and slow wound healing 
(Walker, 2007). This poor wound healing is attributable in part to the anti-angiogenic 
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effects mediated by active glucocorticoids (Small et al., 2005). For more than three 
decades, glucocorticoids have been known to potently inhibit angiogenesis, though to 
this day the mechanisms involved remain uncertain (Folkman et al., 1983; Small et 
al., 2005). 
Reducing glucocorticoid action is, therefore, clinically desirable in the management of 
metabolic disorders, such as type II diabetes, but manipulating systemic glucocorticoid 
action risks inducing adrenal insufficiency. As well as the tight systemic regulation of 
circulating glucocorticoid concentrations by the HPA axis, intracellular glucocorticoid 
concentrations are controlled at the pre-receptor level by two isozymes: 11β-
hydroxysteroid dehydrogenase (11β-HSD) types 1 and 2 (Seckl & Walker, 2001). 11β-
HSD2 functions as a dehydrogenase in mineralocorticoid target tissues, where it 
converts glucocorticoids to their inactive metabolites and prevents glucocorticoid 
occupancy of the mineralocorticoid receptor (MR). 11β-HSD1 is expressed in 
glucocorticoid target tissues where it acts predominantly as a reductase, activating 
glucocorticoids to amplify their effects at the glucocorticoid receptor (GR) (Chapman 
et al., 2013b).  
Manipulation of the 11β-HSDs presents a novel therapeutic opportunity to control 
tissue-specific glucocorticoid levels, without the risks associated with HPA axis 
perturbation. 11β-HSD1 selective inhibitors have been developed to improve 
glycaemic control in type II diabetes (Anderson and Walker, 2013) and these have also 
shown considerable promise in the treatment of Alzheimer’s disease (Webster et al., 
2017). Pre-clinical evidence has also shown that 11β-HSD1 inhibition can promote 
angiogenesis, improving recovery post-myocardial infarction (Small et al., 2005; 
McSweeney et al., 2010) and reducing intra-adipose tissue hypoxia in obesity 
(Michailidou et al., 2012). Whilst these are encouraging findings, the potential for 11β-
HSD1 inhibitors to promote angiogenesis could also pose a risk in diseases associated 
with pathological angiogenesis, such as proliferative diabetic retinopathy (PDR) and 
solid tumour growth (Chung and Ferrara, 2011). These diseases are more common in 
the elderly, a population that are likely to benefit from the positive effects of 11β-
HSD1 inhibitors on glycaemic control and cognitive function. Therefore, this risk 
cannot be taken lightly.  
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Few studies to date have directly addressed this risk. Recent work in a neonatal retinal 
hypoxia model suggests that 11β-HSD1 inhibition may not pose a threat to PDR 
(Davidson et al., 2017) but evidence suggests that 11β-HSD1 manipulation can 
influence tumour growth (Liu et al., 2016; Cirillo et al., 2017). Tumours require their 
own blood supply if they are to grow beyond 1-2mm in size (Hanahan and Folkman, 
1996). This is achieved via an angiogenic ‘switch’, by which tumours stimulate the 
excessive growth of a disorganised and tortuous neovasculature (Carmeliet, 2003). 
Targeting this blood supply is an important focus of cancer research (Carmeliet & Jain 
2011; Folkman 2001). Furthermore, glucocorticoids are known to inhibit tumour 
angiogenesis and growth in certain contexts (Folkman et al. 1983; Yano et al. 2006). 
The question of whether local glucocorticoid regeneration plays an important role in 
regulating tumour angiogenesis and growth forms the focus of this thesis.  
1.1 Glucocorticoid production 
1.1.1 Synthesis, secretion and clearance 
Glucocorticoids are part of the corticosteroid family of steroid hormones. They are 
synthesised from cholesterol, predominantly in the zona fasciculata of the adrenal 
cortex, via a pathway catalysed by members of the cytochrome P450 (CYP) oxidative 
enzyme family located on the inner membrane of the endoplasmic reticulum (ER) 
(Figure 1.1) (Parente, 2001). Cortisol is the major glucocorticoid produced in the 
human adrenal gland, whilst in rats and mice corticosterone is the major glucocorticoid 
as rodent adrenal glands lack the enzyme 17α-hydroxylase (Luu-The et al., 2005). The 
zona glomerulosa of the adrenals produces mineralocorticoids (Curnow et al., 1991), 
the other major class of corticosteroid which are primarily involved in the regulation 
of sodium retention, blood volume and blood pressure. Aldosterone is the primary 
mineralocorticoid (Briet and Schiffrin, 2010).  
Glucocorticoids are released from the adrenals into the blood stream where they 
circulate bound to plasma proteins. Under non-stressed conditions, less than 6% of 
circulating cortisol is unbound in humans, with 80-90% bound to corticosteroid 
binding globulin (CBG) and the remainder bound to albumin (Lewis et al., 2005).  
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Clearance of glucocorticoids occurs predominantly in the liver, where they are 
inactivated via one of several enzymatic pathways before excretion in the urine (Nixon 
et al., 2012). The key route of relevance to this project is interconversion of active 














Figure 1.1 – Glucocorticoid synthesis in rodents and humans. The enzymatic pathway by 
which glucocorticoids are produced from cholesterol, in the zona fasciculata of the adrenal 
cortex. Rodents lack CYP17 (17α-hydroxylase) and thus do not produce those steroids shown 
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1.1.2 Systemic regulation  
Adrenal glucocorticoid release is under the control of the HPA axis. Upon the 
triggering of the stress response, neurons of the paraventricular hypothalamus release 
corticotropin releasing hormone (CRH) which in turn stimulates the corticotrophs of 
the anterior pituitary gland to release adrenocorticotropic hormone (ACTH) into the 
systemic circulation. ACTH stimulates increased adrenal production of 
glucocorticoids by both enhancing the delivery of cholesterol into the inner 
mitochondrial membrane, and by increasing the expression of steroidogenic enzymes. 
The HPA axis is maintained by a negative feedback system; corticosteroids bind the 
GR in the hypothalamus to inhibit CRH release, and in the pituitary to reduce CRH 
action and prevent ACTH secretion (Briassoulis et al., 2011; Oakley and Cidlowski, 
2013).  
Under non-stressed conditions, glucocorticoid release is regulated in a circadian 
fashion by the suprachiasmatic nucleus of the hypothalamus (Malisch et al., 2008). 
Human plasma cortisol levels are at their nadir between 8pm and midnight, peaking 
around 7-11am and declining throughout the day (Weitzman et al., 1971; Nomura et 
al., 1997; Chan and Debono, 2010). This circadian pattern is reversed in rodents, with 
plasma corticosterone levels at their lowest early in the morning (Harris et al., 2001; 
Oster et al., 2006). Typical nadir human serum cortisol levels are <50 nmol/l rising to 
peak levels of ~500 nmol/l (Parente, 2001; Debono et al., 2009; Jung et al., 2014), 
while cortisone ranges from ~10 - 60 nM (Nomura et al., 1997). In mice, baseline 
corticosterone ranges from ~25nmol/l at nadir to ~600nmol/l, and 11-
dehydrocorticosterone (11-DHC) from ~2.5 - 10nM, but levels vary between strains 
(Kotelevtsev et al., 1997; Harris et al., 2001; Yau et al., 2007; Benedetti et al., 2012; 
Gong et al., 2015). Aldosterone circulates at a lower concentration than cortisol in 
humans; levels in human plasma are ~100 - 800 pmol/L (Fischbach and Dunning, 
2009). 
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1.2 Glucocorticoid action 
1.2.1 Receptor binding 
Upon reaching target cells, glucocorticoids dissociate from their transport proteins and 
diffuse directly through the plasma membrane due to their lipophilic structure. They 
then bind to intracellular steroid hormone receptors in the cytoplasm, which form 
homodimers and are translocated to the nucleus where they bind DNA response 
elements and regulate transcription (Walker, 2007). Around ~2% of the human 
genome is regulated by glucocorticoids (Reddy et al., 2009). Glucocorticoids bind to 
both the GR (type 2 corticosteroid receptor) and the MR (type I corticosteroid 
receptor). GR is ubiquitously expressed whilst MR is expressed in the kidney, colon, 
vasculature, hippocampus, heart, and adipose tissue (Walker, 2007). The GR binds 
cortisol with high affinity (KD = ~20-25nM) compared with aldosterone (Hollenberg 
et al., 1985; Mulatero et al., 1997). The MR binds both glucocorticoids with relatively 
similar affinity (KD = ~0.5-1.3nM) (Krozowski and Funder, 1983; Arriza et al., 1987). 
As cortisol circulates at a 100-1000-fold higher levels than aldosterone, the MR is 
usually tonically occupied by cortisol in the absence of pre-receptor metabolism 
(Arriza et al., 1987). Glucocorticoids may also exert some rapid non-genomic effects 
via cell surface receptors (Tasker et al., 2006).  
GR and MR are both ligand-activated transcription factors (Parker, 1993). Upon 
binding their ligands, receptors dissociate from their associated heat shock proteins 
and are translocated to the nucleus where they form homodimers. These homodimers 
bind to specific sequences of DNA in the promoter regions of target genes, termed 
glucocorticoid response elements (GREs). Receptor-ligand complexes are able to 
activate transcription (transactivation) or to repress transcription (transrepression) of 
target genes (McKenna and O’Malley, 2002; Walker, 2007). Some of the 
immunomodulatory effects of glucocorticoids are mediated via direct protein-protein 
binding of GR to other transcription factors, such as nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) – this transrepression does not depend on GREs 
(Coutinho and Chapman, 2011). 
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1.2.2 Effects of glucocorticoids 
Glucocorticoids are vital modulators of the physiological stress response and, as such, 
interact with most major organ systems, exerting a huge range of physiological effects 
that have been reviewed thoroughly elsewhere (Andrews and Walker, 1999; Sapolsky 
et al., 2000; Walker, 2007; Coutinho and Chapman, 2011). Background of relevance 
to the present project can be categorised as effects on the cardiovascular system, the 
immune system and inflammatory response and metabolism.  
 The cardiovascular system 
 Cardiac output 
Glucocorticoids prepare the body for stressful conditions, and their effects on the 
cardiovascular system reflect this. Glucocorticoids increase arterial pressure, heart rate 
and, consequently, cardiac output. They also induce dynamic changes in blood flow to 
favour skeletal muscle over the gastrointestinal and renal systems (Galosy et al., 1981).  
The importance of glucocorticoids in regulating blood pressure can be seen in 
endocrine disorders; hypertension is a symptom of Cushing’s syndrome whilst 
hypotension is evident in cases of adrenal insufficiency (Sapolsky et al., 2000; 
Whitworth et al., 2000; Goodwin and Geller, 2012). These effects are mediated 
predominantly by the permissive effect of glucocorticoids on sympathetic function, 
which include increased production of enzymes involved in adrenaline synthesis and 
reduced expression of enzymes involved in catecholamine breakdown at 
neuromuscular junctions (Dailey and Westfall, 1978; Kennedy and Ziegler, 1991; 
Sapolsky et al., 2000). 
 Vessel tone 
Both GR and MR are expressed in cardiovascular tissues, including in cardiomyocytes 
of the myocardium (Lombès et al., 1992; Fraccarollo et al., 2011; Lother et al., 2011; 
Rog-Zielinska et al., 2013, 2015) and the arterial wall (Hadoke et al., 2006; Walker, 
2007). GR and MR have been detected in the medial layer of mouse vessels (Christy 
et al., 2003) and rabbit (Kornel et al., 1982; Lombès et al., 1992). MR has been 
detected in cultured rat smooth muscle cells and fibroblasts (Meyer and Nichols, 1981) 
and glucocorticoid and mineralocorticoid binding demonstrated in human smooth 
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muscle cells (Scott et al., 1987) and endothelium (Inoue et al., 1999; Oberleithner et 
al., 2003). By acting at the GR, glucocorticoids increase smooth muscle 
responsiveness to noradrenaline (Sudhir et al., 1989). This is likely mediated by 
reduced prostaglandin synthesis (Handa et al., 1984). As GR activation has been 
shown to prevent the release of prostaglandins from rabbit endothelial cells 
(Rosenbaum et al., 1986), this may indicate a paracrine mechanism between the layers 
of the vessel wall.  Glucocorticoids also bind GR to inhibit acetylcholine-induced 
vasodilation of the endothelium via reduced nitric oxide (NO) synthesis (Mangos et 
al., 2000). GR activation also contributes to hypertension by increasing expression of 
angiotensin type II receptors in rat vascular smooth muscle cells (VSMCs) (Sato et al., 
1994; Provencher et al., 1995) but paradoxically has also been shown to downregulate 
levels of the powerful vasoconstrictor endothelin-1 (Provencher et al., 1995).  This 
latter effect may be associated with the regulation of vascular inflammation rather than 
vessel tone. The matter is complicated by action of glucocorticoids at the MR, which 
are sometimes paradoxical (Adler and Williams, 2007) – MR activation in the 
endothelium can enhance arterial vasodilatation via endothelial NO synthesis (Liu et 
al., 2003; Uhrenholt et al., 2003) but in the smooth muscle, MR activation causes 
vasoconstriction (Arima et al., 2004). In healthy vessels, these two opposing actions 
likely balance one another, but in vessels in which the endothelium is damaged, the 
vasodilatory effects at the endothelium may be lost (Adler and Williams, 2007). 
 Inflammation and fibrosis in vascular tissues 
MR activation causes perivascular and cardiac inflammation with associated fibrosis 
(Funder, 2005; Joffe and Adler, 2005). MR antagonists, such as spironolactone or the 
more selective eplerenone, are used clinically to treat congestive heart failure and left 
ventricular hypertrophy (LVH) (Pitt et al., 1999; Soberman and Weber, 2000). Whilst 
the detrimental effects of MR activation are mediated by aldosterone (particularly in 
combination with high-salt diet), tonic occupancy of the MR is predominantly by 
cortisol.  
Both long-term treatment with exogenous glucocorticoids and chronic over-
production of endogenous glucocorticoids (as present in Cushing’s syndrome) are 
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associated with an increased risk of atheromatous disease (reviewed by Walker, 2007). 
Glucocorticoids influence a variety of factors likely to influence this process. 
 Angiogenesis 
Angiogenesis, the growth of new vessels from the existing vasculature, is potently 
inhibited by glucocorticoids. Folkman et al. (1983) were the first to describe the 
angiostatic effects of glucocorticoids, discovered during their studies of tumour 
angiogenesis. Steroids were shown to inhibit vessel growth in the presence of heparin 
leading to the conclusion that steroids may interact with endogenous heparins to 
tonically inhibit new vessel growth (Folkman and Ingber, 1987). In separate studies, 
glucocorticoids were shown to inhibit VSMC proliferation, possibly via decreased 
sensitivity to mitogenic stimulation (Longenecker et al., 1982, 1984). The mechanism 
of angiostasis was not determined, but during this initial period of interest the 
mechanism was proposed to involve disruption of the capillary basement membrane, 
possibly related to reduced collagen deposition (Maragoudakis et al., 1989).  
These early studies used supraphysiological concentrations of glucocorticoids. More 
recently, physiological glucocorticoid concentrations have been shown to inhibit 
angiogenesis both in vitro and in vivo (Small et al., 2005). Importantly, these effects 
were shown to be mediated via the GR, as the GR antagonist RU38486 abolished the 
angiostatic effects of glucocorticoids whereas spironolactone had no effect. The 
mechanism involved remains unclear. Corticosteroids decrease expression of vascular 
endothelial growth factor (VEGF) in cultured human VSMCs (Nauck et al., 1998) and 
in human proximal renal tubular epithelial cells (Leonard et al., 2005). Glucocorticoids 
alter cytoskeletal arrangement in endothelial cells (Logie et al., 2010) and increase 
expression of the angiostatic protein thrombospondin-1 (Rae et al., 2009; Logie et al., 
2010). Importantly, when TSP-1 was blocked using siRNA, cortisol no longer caused 
angiostasis in vitro (Rae et al., 2009). Yano et al. (2006) also demonstrated the 
angiostatic (and consequently anti-tumour) effects of glucocorticoids in a murine 
model of prostate cancer.  
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 The immune system and inflammatory response 
 Therapeutic use 
Glucocorticoids are used therapeutically to suppress the immune system before organ 
transplantation and to treat a range of inflammatory and auto-immune conditions, such 
as rheumatoid arthritis, psoriasis and asthma (Maxwell et al., 1994). In the clinic, 
therapeutic glucocorticoids are usually synthetic derivatives of the endogenous 
glucocorticoids, structural alterations of which confer variable characteristics in terms 
of receptor binding and metabolism by the 11β-HSDs (Diederich et al., 2004). For 
example, dexamethasone and prednisolone are commonly used synthetic 
glucocorticoids which are relatively selective and potent GR agonists. Dexamethasone 
and prednisolone are metabolised by 11β-HSD2 but crucially 11-dehydroDex retains 
potency at the GR (Best et al., 1997; Diederich et al., 2004). 
Glucocorticoids exert their anti-inflammatory and immunosuppressive effects on most 
cells of the immune system by downregulation of a huge range of pro-inflammatory 
chemokines and cytokines, including many interleukins (IL), interferon gamma (IFN-
γ) and tumour necrosis factor alpha (TNF-α), as well as mediators of inflammation 
such as histamine and adhesion molecules. They reduce T cell activation and 
proliferation and promote the pro-inflammatory Th1 response while suppressing the 
anti-inflammatory Th2 response. They also alter the balance of leukocyte survival and 
apoptosis, and prevent leukocyte infiltration into sites of inflammation (Sapolsky et 
al., 2000; Coutinho and Chapman, 2011). These actions are mediated by binding at the 
GR (Cronstein et al., 1992). The importance of glucocorticoids in constraining the 
immune and inflammatory responses is evident in mice administered endotoxin; 
adrenalectomised mice do not survive doses of endotoxin that control mice can 
withstand, and dexamethasone pre-administration completely prevents lethality 
(Bertini et al., 1988). 
 Pro-inflammatory actions of glucocorticoids 
Whilst high dose clinically-administered glucocorticoids exert anti-inflammatory and 
immunosuppressive effects, physiologically they can exert immunostimulatory 
effects. Sapolsky et al. (2000) described the effects of glucocorticoids on the stress 
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response in terms of four criteria: permissive; suppressive, preparative and 
stimulatory. Glucocorticoids have been reported to have permissive inflammatory 
effects by elevating TNF-α and IL-6 concentrations in plasma after lipopolysaccharide 
(LPS) administration (Barber et al., 1993); these cytokines promote the growth and 
activation of T-cells (Kuhweide et al., 1990). Likewise, Wiegers et al. (1993, 1994, 
1995) showed that physiologically-relevant concentrations of corticosterone (500-
1000nM) directly enhanced T-cell growth in vitro (Wiegers et al., 1993, 1994, 1995) 
and in vivo (Wiegers et al., 1993) in rat tissues.  
The explanation Wiegers et al. (1993) offer for this differential effect between 
pharmacological and physiological glucocorticoids is that low concentrations of 
glucocorticoids enhance the T-cell response via T-cell MR activation, while high 
concentrations of glucocorticoids may inhibit this response via T-cell GR activation. 
In further support of this theory, MR blockade in obese mice reduced the expression 
of pro-inflammatory mediators such as TNF-α and MCP-1 (Guo et al., 2008). Sapolsky 
et al. (2000) highlight the importance of re-interpreting previous studies that made use 
of synthetic glucocorticoids with a low affinity for MR, and studies that made use of 
the GR antagonist RU38486, in light of this theory. Increased immune cell responses 
after GR blockade could result from preferential activation of MR rather than removal 
of the suppressive GR-mediated effects (Sapolsky et al.,  2000). 
Whilst MR-mediated effects may explain enhanced T-cell activation by 
glucocorticoids, they cannot explain some of the observed pro-inflammatory actions 
of glucocorticoids. Low concentrations of corticosterone (100 pM) administered to rat 
macrophages stimulated them to produce pro-inflammatory cytokines, chemokines 
and NO, an effect that was not attributable to activation of the MR as lentiviral 
inactivation of the MR had no effect (Lim et al., 2007). Thus both GR and MR may 
play a role in mediating the pro-inflammatory effects of glucocorticoids, particularly 
in macrophage populations which express both receptors (Liu et al., 1999; Barish et 
al., 2005). Of note, the same study found high concentrations of glucocorticoids (1 
µM) potently inhibited this inflammatory activation (Lim et al., 2007), again 
demonstrating the importance of glucocorticoid concentration when considering 
effects.  




Though focus has thus far centred on their role in inflammation, the name 
glucocorticoid is derived from the key role that glucocorticoids play in glucose 
homeostasis. Glucocorticoids in most respects oppose the action of insulin by 
mobilising energy stores for use in combating a stressor. Glucocorticoids rapidly 
elevate blood glucose through a combination of mechanisms: they stimulate hepatic 
gluconeogenesis and glycogenolysis by elevating glucagon levels, and promote insulin 
resistance to redirect glucose from storage sites to active muscle (Sapolsky et al., 
2000). These effects last for longer than the acute metabolic effects elicited by 
adrenaline. Longer-term elevation of glucocorticoid levels also stimulates lipolysis 
and proteolysis to mobilise fatty acids and amino acids as alternative energy sources 
(Peckett et al., 2011; Wang et al., 2016). 
The maladaptive effects of chronic glucocorticoid excess on metabolism are apparent 
in Cushing’s syndrome, which is characterised by central obesity, dyslipidaemia, 
muscle wasting, hyperglycaemia and insulin resistance (Walker, 2007). While short-
term glucocorticoid action mobilises energy stores and opposes insulin, chronic 
elevation of glucocorticoids causes increased insulin secretion and can lead to 
redistribution of fat from subcutaneous to intraabdominal depots associated with 
increased risk of adverse cardiometabolic consequences (Dallman et al., 2004). The 
preferential storage in these depots may be due to the higher levels of GR expression 
in omental compared to subcutaneous adipocytes (Veilleux et al., 2010).  
Glucocorticoids thus influence and regulate a wealth of integral physiological 
processes across the body. Manipulating glucocorticoid action could be of benefit to 
myriad metabolic, cardiovascular, cognitive and systemic inflammatory disorders. The 
tissue-specific regulation of glucocorticoids by 11β-HSD1 and 2 offers a novel 
therapeutic opportunity to regulate the levels of glucocorticoids reaching target tissues. 
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1.3 The 11β-hydroxysteroid dehydrogenases  
1.3.1 Function 
Glucocorticoids are systemically governed by the HPA axis and plasma protein 
binding. On a local level, they are subject to pre-receptor regulation by the 11β-HSD 
isozymes, allowing for tissue-specific differences in glucocorticoid activity. 11ß-
HSD1 is a dihydronicotinamide adenine dinucleotide phosphate (NADP(H))-
dependent bidirectional oxidoreductase which acts predominantly as a reductase in 
vivo (Cai et al., 2001; Seckl and Walker, 2001; Dover et al., 2007), though in vivo 
dehydrogenase activity has been reported (Morris et al., 2003). It is highly expressed 
in glucocorticoid target tissues such as liver, brain, adipose and vascular tissues, where 
it amplifies local glucocorticoid concentrations to increase binding at the GR (Seckl 
and Walker, 2001).  
11βHSD-2 functions uniformly as a nicotinamide adenine dinucleotide phosphate 
(NADP+)-dependent dehydrogenase, converting cortisol (and corticosterone in 
rodents) to inactive 11-keto metabolites (Stewart and Krozowski, 1999). It acts 
primarily to allow selective access of aldosterone to the MR, but also has a protective 
role in the placenta (Edwards et al., 1993). Loss of 11β-HSD2 function (as seen in the 
syndrome of apparent mineralocorticoid excess; SAME) mimics the effects of 
excessive aldosterone on cardiovascular tissues (Funder, 2005).  The respective 

























Figure 1.2 – Systemic and local glucocorticoid regulation. The Hypothalamic-Pituitary-
Adrenal (HPA) axis maintains systemic glucocorticoids within tight parameters under normal 
healthy conditions through the regulated release of CRH and ACTH. The isozymes 11β-
hydroxysteroid dehydrogenase (11β-HSD) 1 and 2 control pre-receptor metabolism of local 
glucocorticoids in specific tissues. 11β-HSD1 acts predominantly as a reductase in vivo, 
converting cortisone to cortisol, using NADPH as a co-factor. 11β-HSD2 catalyses the reverse 






















Both 11β-HSD1 and 2 are microsomal isozymes of the short chain alcohol 
dehydrogenase superfamily (Stewart and Krozowski, 1999). 11β-HSD1 (in human and 
mouse) is a 292 amino acid protein with a molecular mass of 34kDa (Chapman et al., 
2013b). The type I isozyme is encoded by the Hsd11b1 gene located on chromosome 
1 and is highly conserved between species (Zhou et al., 2012). The enzyme is 
comprised of a cofactor binding site, a substrate binding site facing the luminal space 
(Odermatt & Klusonova, 2015), and a highly hydrophobic N-terminal domain that 
anchors the enzyme to the membrane of the smooth ER where it is located. It has an 
affinity of ~ 2µM for cortisol (Zhou et al., 2012) and a huge range of reported affinities 
for cortisone (Km: ~150nM - 20µM, Chapman et al., 2013b).  
1.3.3 Discovery of the 11β-HSD isozymes 
Extra-adrenal interconversion of cortisone and cortisol was first demonstrated over 60 
years ago (Amelung et al. 1953). Over three decades later, the first evidence of 11β-
HSD emerged, though at this time there was thought to be only one enzyme (Lakshmi 
& Monder, 1988). Two groups published simultaneously on the role of 11β-HSD in 
SAME, sufferers of which exhibit sodium retention, hypokalaemia and hypertension 
without an associated elevation in circulating aldosterone. This syndrome could be 
explained by congenital deficiency of 11β-HSD (or its inhibition by the liquorice 
derivative glycyrrhetinic acid) allowing inappropriate access of glucocorticoids to the 
MR (Edwards et al., 1988; Funder et al., 1988). Stewart et al. (1988) described the 
first adult case of 11β-HSD insufficiency, in which the patient presented with 
hypertension, hypokalaemia and suppressed renin-angiotensin-aldosterone system 
(RAAS) activity due to excessive MR activation by cortisol in the kidney and likely 
also in the blood vessel wall. This syndrome could be treated using dexamethasone, 
which selectively activated the GR and suppressed the HPA axis. A second interesting 
case study (Conn et al., 1968) describes a patient presenting with these same 
symptoms. It was deduced that excessive liquorice consumption (2-3 36 g bars per day 
for 7 years) was responsible, as its removal from the patient’s diet led to recovery. At 
the time, this was considered to be due to direct mineralocorticoid action by liquorice-
derived compounds, but glycyrrhetinic acid has since been confirmed to be a liquorice 
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derivative that potently inhibits 11β-HSD activity (Stewart et al., 1987). Subsequent 
purification and cloning revealed the distinct expression sites and substrate affinities 
of the type I and type II isozymes (Monder & Lakshmi 1989; Stewart et al. 1991; 
Albiston et al. 1994). 
1.3.4 Activity 
Whilst 11β-HSD2 is unidirectional in its dehydrogenase activity (Brown et al., 1996), 
there has been some debate over the predominant activity of 11β-HSD1 (Seckl & 
Walker 2001; Morris et al., 2003), with varying results seen between studies. Early 
studies examining 11β-HSD1 purified from rat liver showed bidirectional activity; 
however, the enzyme showed predominant reductase activity across a number of intact 
cell lines, including hepatocytes (Jamieson et al., 1995), adipocytes (Bujalska et al., 
1997), VSMCs (Brem et al., 1995) and skin fibroblasts (Hammami & Siiteri, 1991).  
Some cell lines, such as Leydig cells (Phillips et al. 1989; Leckie et al. 1998), have 
generated contrasting results, though developmental stage of these cells may cause a 
switch in activity  (Ge et al., 1997). Culture conditions and metabolic conditions may 
also influence activity (Zhou et al., 2012), making it difficult to interpret some 
contradictory evidence. 
Critically, the same cells showing predominant reductase activity in culture often 
displayed bidirectional activity when homogenised (Brem et al., 1995; Jamieson et al., 
1995), suggesting that 11β-HSD1 only exhibits bidirectional activity when released 
from the intracellular compartment. 11β-HSD1 is located within the SER luminal 
compartment in close proximity with another enzyme - hexose-6-phosphate 
dehydrogenase (H6PDH). H6PDH interacts with its substrate glucose-6-phosphate 
(G6P) and generates a large pool of NADPH. The abundance of NADPH then drives 
the reductase activity of 11β-HSD1 activity in intact cells (Lavery et al., 2006; Walker 
et al., 2007; Atanasov et al., 2008; Zhang et al., 2009), resolving the differential 
activity between intact and disrupted tissues. 
Evidence of high cortisol-to-cortisone ratio in the hepatic circulation in humans also 
suggests predominance of reductase activity in vivo (Walker et al., 1992). The 
generation of 11β-HSD1 knockout (KO) mice at the University of Edinburgh 
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demonstrated that 11β-HSD1 is the sole enzyme capable of reducing 11-keto 
metabolites to their active counterparts (Kotelevtsev et al., 1997). The enzyme has 
several other substrates, including bile acids and xenobiotics. It is not within the scope 
of this introduction to cover these but they have been reviewed in detail elsewhere 
(Zhou et al., 2012; Chapman et al., 2013b). 
1.3.5 Regulation 
Several factors regulate 11β-HSD1 expression. Sexual dimorphism of hepatic enzyme 
expression is apparent in rats, with male animals expressing more 11β-HSD1 due to a 
pulsatile release in pituitary growth hormones as opposed to the continuous release in 
females (Low et al., 1994). Note that this is not the case in mice (Rajan et al., 1995); 
thus there are both inter-species and inter-gender differences in 11β-HSD1 expression. 
Glucocorticoids themselves increase expression of the enzyme in many cultured cell 
types, including: adipocytes (Engeli et al., 2004), fibroblasts (Hammami and Siiteri, 
1991), hepatocytes (Jamieson et al., 1995) and neuronal cells (Rajan et al., 1996). In 
intact tissues this only remains true for some tissue types (adipose for example) 
(Balachandran et al., 2008) whilst in tissues such as liver, enzyme expression is 
reduced by exposure to glucocorticoids (Smith et al., 1982).  
Pro-inflammatory stimuli such as TNF-α and IL-1 stimulate increased 11β-HSD1 
expression across a range of cell types in vitro, including stromal mesenchymal cells 
(Ahasan et al., 2012) and keratinocytes (Itoi et al., 2013). Furthermore, transgenic 
mice expressing TNF-α show increased hepatic 11β-HSD1, suggesting that 
inflammation may promote enzyme expression in vivo (Ignatova et al., 2009). Co-
administration of pro-inflammatory cytokines with glucocorticoids appears to 
augment this effect (Sun and Myatt, 2003; Ahasan et al., 2012). There is evidence to 
suggest this may not hold true in the murine vasculature, as Dover et al. (2007) did not 
see increased 11β-HSD1 expression or activity ex vivo or in vivo after introducing an 
inflammatory stimulus. Importantly, pro-inflammatory stimuli do not necessarily 
increase enzymatic expression in immune cells (Freeman et al., 2005).  
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1.3.6 Key sites of expression 
11β-HSD1 expression is typically high in glucocorticoid target tissues, and enzyme 
expression is associated with GR expression in many tissues (Whorwood et al., 1992). 
Distribution of 11β-HSD1 is generally similar in mice and humans, with the exception 
of the testis (Tannin et al., 1991; Rajan et al., 1995). mRNA expression is highest in 
liver, with activity also high in adipose tissue (Bujalska et al., 1997), vasculature and 
heart (Walker et al., 1991; Dover et al., 2007), ovary (Benediktsson et al., 1992), brain 
(Lakshmi et al., 1991), uterus and placenta (Burton et al., 1998; Waddell et al., 1998), 
skeletal muscle (Whorwood et al., 2002), as well as immune and inflammatory cells 
(Thieringer et al., 2001; Gilmour et al., 2006) and fibroblasts (Lee et al., 2013; 
Tiganescu et al., 2013; Terao et al., 2014). 
 11β-HSDs in the vasculature 
Early suggestions of a role for 11β-HSD in the vasculature arose from studies using 
glycyrrhetinic acid to inhibit the enzyme in the skin; this potentiated the 
vasoconstrictor response to cortisol suggesting enhanced activation of the GR in 
smooth muscle (Teelucksingh et al., 1990). 11β-HSD1 expression was later confirmed 
in rat vascular smooth muscle, with higher expression in smaller resistance vessels 
than in aorta (Walker et al. 1991). 11β-HSD2 has also been detected in human VSMCs 
(Smith et al., 1996) and both isozymes have been reported in rat endothelial cells 
(Brem et al., 1998). Hadoke et al. (2001), using 11β-HSD1 and 11β-HSD2 KO mice, 
found that 11β-HSD2 KO reduced the release of endothelium-derived-NO, inhibiting 
vasorelaxation. This suggests that 11β-HSD2 is the predominant isoform in the 
endothelium. This effect was reversible with the addition of L-arginine (Christy et al., 
2003). Christy et al. (2003) confirmed that 11β-HSD1 expression co-localised with α-
smooth muscle actin (α-SMA) while 11β-HSD2 expression co-localised with 
angiopoietin receptor 2 (TIE-2) expression, further suggesting this differential 
distribution in the vessel wall. The same study also suggested that the effects of 11β-
HSD2 deletion on vasomotor function may be mediated, at least in part, by renal 
enzyme loss. 11β-HSD2 was also the only isozyme detected in endometrial endothelial 
cells (Rae et al., 2009). 
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 11β-HSDs in immune and inflammatory cells 
Given the powerful immunomodulatory effect of glucocorticoids, the expression of 
the 11β-HSDs in immune and inflammatory cell types has been studied extensively. 
11β-HSD1 is not expressed in human monocytes until their differentiation into 
macrophages; enzyme expression is increased 10-fold by exposure to pro-
inflammatory cytokines (IL-4/IL-13), and induction is inhibited by IFN-γ, a functional 
antagonist of ILs (Thieringer et al., 2001). 11β-HSD2 is undetectable, or present at 
very low levels, in macrophages and monocytes (Gilmour et al., 2006; Chapman et al., 
2013b). Wild-type (WT) murine macrophages can convert 11-DHC to corticosterone, 
promoting phagocytosis of apoptotic neutrophils in WT mice. This effect is not seen 
in macrophages from 11β-HSD1 KO mice, demonstrating a functional role for 11β-
HSD1 in the resolution of inflammation (Gilmour et al., 2006). This finding suggests 
that 11β-HSD1 inhibition could impede the resolution of inflammation.  
Activation of human macrophages, but not monocytes, with LPS polarises them to a 
‘classically activated’ M1 phenotype and enhances 11β-HSD1 expression, whereas 
alternative activation (M2) has no effect on expression of this enzyme (Chapman et 
al., 2013b). Furthermore, phagocytosis of apoptotic neutrophils reduces 11β-HSD1 
expression in macrophages (Chapman et al., 2009), suggesting that the enzyme plays 
a dynamic role in the inflammatory process. Dendritic cell differentiation induces 11β-
HSD1 expression. Interestingly, this expression is maintained by signals associated 
with innate immune activation (TNF-α, LPS), but is markedly decreased by CD40, a 
surface marker associated with activated antigen presenting cells (Freeman et al., 
2005). 11β-HSD1 is also expressed both in neutrophils and in mast cells (Chapman et 
al., 2013a; Coutinho et al., 2016). 
Murine lymphocytes show only low levels of 11β-HSD1 activity and no 11β-HSD2 
activity, though 11β-HSD1 activity is increased in response to activation or 
polarisation to Th1 or Th2 states (Zhang et al., 2005). Not only does this imply a 
physiological role for pre-receptor glucocorticoid regulation in the mounting of the 
immune response, it also offers a therapeutic opportunity to control aspects of 
lymphocyte function without perturbing the HPA axis.  





To appreciate the effects of 11β-HSD1 manipulation on angiogenesis, an 
understanding of blood vessel development is required. In the developing embryo, 
many endothelial progenitor cells assemble to form a simple network of capillaries, in 
a process termed vasculogenesis. The remodelling of the vasculature to form a 
complex network of mature vessels is called angiogenesis, though there is some 
mechanistic crossover between these two processes (Carmeliet, 2003). As vessels 
mature, they acquire mural cells, including pericytes and VSMCs, which provide 
structural integrity and stability. This process is called arteriogenesis. Angiogenesis is 
complex, and its regulation in adult life is governed by a balance of stimulatory and 
inhibitory factors (Carmeliet, 2005b), some of which act upon many cell types and 
several of which act specifically upon the vascular endothelium (Yancopoulos et al., 
2000).  
Blood vessels are vital in providing oxygen and nutrients for healthy tissues, for 
providing a means by which immune cells can travel between sites, and for allowing 
the transport of waste metabolites for excretion (Carmeliet and Jain, 2011). Finding a 
means by which to promote angiogenesis after ischaemic events, while highly 
desirable clinically (Isner, 2002), has proven challenging due to the myriad factors 
involved in orchestrating the complex angiogenic process. Furthermore, aberrant 
angiogenesis forms part of the pathology of several diseases, including proliferative 
diabetic retinopathy, rheumatoid inflammatory conditions and tumour growth 
(Folkman, 1995). Efforts to prevent angiogenesis have seen more success, with several 
angiogenesis inhibitors now in use; yet these are still limited in their efficacy. This 
section will provide an overview of physiological angiogenesis (for thorough reviews 
see Carmeliet & Jain 2011; Potente et al. 2011). Tumour vessels are abnormal and 
tumour angiogenesis will be described in more detail in Section 1.6.3. 
1.4.2 Vasculogenesis 
Vasculogenesis describes the formation of the primitive vascular network in the 
developing embryo. The early vascular plexus originates from the mesoderm, based 
Chapter 1 - Introduction 
42 
 
on signalling by members of the fibroblast growth factor (FGF) family. Both 
haematopoietic and endothelial cell lineages share a common precursor – the 
haemangioblast - as evidenced by experiments showing that deletion of VEGF 
Receptor 2 (VEGFR2) disrupts both haematopoietic and angioblastic lineages 
(Shalaby et al., 1997). 
In the yolk sac, heamangioblasts form cell aggregates, the inner cells of which are 
haematopoietic in origin and the outer of which are angioblastic. VEGF signalling is 
pivotal in determining angioblast cell fate at this stage; deletion of a single copy of the 
VEGF gene results in embryonic lethality with associated aberrant vessel formation in 
the yolk sac (Carmeliet et al., 1996; Ferrara et al., 1996). Signalling via VEGF 
receptors 1 and 2 (encoded by the Flt1 and Kdr genes, respectively) influences cell 
fate. VEGFR1 suppresses commitment to the haemangioblast lineage (Fong et al., 
1999), a limiting mechanism vital in the functional assembly of vessels during 
vasculogenesis, while VEGFR2 is critical for endothelial cell formation and migration 
(Shalaby et al., 1997). VEGFR3 is expressed in embryonic vasculature, but later 
becomes largely confined to the lymphatic system with the notable exception of 
endothelial sprouting (Tammela et al., 2008). VEGF signalling functions in 
combination with molecules determining the interaction between endothelial cells and 
the extracellular matrix (ECM) to guide the process of vasculogenesis (Carmeliet, 
2000). Even at this early stage, genetically-determined molecular differences can 
influence long term endothelial cell fate (Swift and Weinstein, 2009); Ephrin 
signalling, for example, governs arterial/venous commitment (Gale and Yancopoulos, 
1999). Once formed, angioblasts can migrate to form a new vascular plexus at a distant 
site (Risau, 1997).  
The molecular processes of vasculogenesis were originally thought to be independent 
from angiogenic processes in adult life, but the consensus has now shifted (Carmeliet 
and Jain, 2011), such that now there is interest in ‘therapeutic vasculogenesis’ 
(reviewed extensively in Luttun et al. 2002). This concept is based on findings such as 
the secretion of potent pro-angiogenic factors by circulating endothelial progenitor 
cells derived from monocytes and macrophages (Rehman et al., 2003). The 
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involvement of endothelial progenitor cells in tumour angiogenesis is now subject to 
debate (Patenaude et al., 2010); discussed further in Section 1.6.4.3). 
1.4.3 Angiogenesis 
Vasculogenesis results in the formation of a homogenous vascular plexus, which 
undergoes sprouting and is remodelled extensively to form a functional and complex 
vascular bed – this is the process of angiogenesis (Potente et al., 2011). Angiogenesis 
occurs most commonly as sprouting angiogenesis, during which an angiogenic 
stimulus causes new vessels to bud and branch off from existing vessels. Less 
commonly, networks can be formed via intussusception, which involves pillars of 
ECM splitting vessels. This process occurs under specific circumstances, such as lung 
development (Risau, 1997), but its relevance to typical adult angiogenesis is unclear 
(Carmeliet and Jain, 2011).  
Endothelial cells in mature vessels are quiescent and experience relatively low cell 
turnover, maintained by the coordinated signalling of VEGFs (Lee et al., 2007; 
Stockmann et al., 2008; Tvorogov et al., 2010) and FGFs (Murakami et al., 2008), as 
well as Notch (Benedito et al., 2009; Jakobsson et al., 2010) and angiopoietin-1 (ANG-
1) (Sato et al., 1995; Suri et al., 1996; Saharinen et al., 2008). Several of these signals 
are released in a paracrine fashion by stabilising pericytes. In this quiescent state, 
endothelial cells form a tight monolayer secured with claudins and VE-cadherin, and 
share a basement membrane with their supporting mural cells (Eble and Niland, 
2009).They are oxygen-sensitive, dynamically responding to signals from the hypoxia 
inducible factors (HIF) to regulate flow (Carmeliet and Jain, 2011).  
Upon sensing an angiogenic stimulus (such as VEGF, FGFs, ANG-2, or chemokines), 
vessels undergo a process comprised of several distinct steps; basement membrane 
disintegration, endothelial cell migration, channel formation and vessel maturation and 
survival (Figure 1.3).  
 
 


















Figure 1.3 – Sprouting angiogenesis. Physiological angiogenesis can be divided into four 
major processes; i) Basement membrane (BM) disintegration, in which an angiogenic stimulus 
promotes the redistribution of cell junctions, the breakdown of the underlying BM, and the 
loss of mural cell coverage; ii) Endothelial cell (EC) migration, in which the coordinated 
signalling of VEGF and Notch/DLL4 confers tip and stalk cell identity; iii) channel formation, 
in which ECs communicate with the ECM to produce a lumen and new BM; and iv) vessel 
maturation, in which mural cells are recruited and cell become perfused, promoting EC 
survival and quiescence. Non-perfused vessels are pruned and regress. Adapted from 
Francavilla et al., 2009. 
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 Basement membrane disintegration 
When a vessel receives an angiogenic signal, be it part of an inflammatory or hypoxic 
event, vasodilation occurs (mediated by NO) and vessels become hyper-permeable due 
to the redistribution of VE-cadherin and other junctional proteins. This allows plasma 
proteins to extravasate and deposit a provisional ECM (Carmeliet, 2000). Supporting 
pericytes detach from the vessel wall and break away from the basement membrane. 
ANG-2 stimulates this detachment (Augustin et al., 2009), whilst matrix 
metalloproteases (MMPs) degrade the basement membrane (Carmeliet and Jain, 
2011). This has the added benefit of liberating sequestered growth factors, such as 
VEGF and FGF (Arroyo and Iruela-Arispe, 2010). Targeting MMP2 and 9 has been 
seen to inhibit angiogenesis (Brooks et al., 1998; Liu et al., 2014). Evidence from the 
rat aortic ring assay also suggests that VEGF and ANG-1 stimulate the recruitment of 
innate immune cells from the adventitia of large vessels which contribute further pro-
angiogenic cytokines (Aplin et al. 2006).  
 Endothelial cell migration 
VEGF signalling at VEGFR2 causes endothelial cells to upregulate Delta like 
canonical notch ligand-4 (DLL4) expression. The endothelial cells that expresses the 
most DLL4 becomes the ‘tip cell’, which leads the migration of endothelial cells into 
the new ECM by extending numerous filopodia (Phng and Gerhardt, 2009). These 
extensions sense environmental cues like ephrins and semaphorins that guide their 
migration (Carmeliet and Jain, 2011). Tip cell identity is specified by Notch pathway 
signalling (Eilken and Adams, 2010), and endothelial cells dynamically compete for 
this role (Jakobsson et al., 2010). High expression of DLL4 in the tip cell allows for 
activation of notch signalling in the adjacent endothelial cells, which suppresses tip 
cell behaviour and confers the identity of ‘stalk cell’. Disruption of Notch-DLL4 
signalling results in excessive branching and filopodia (Thurston et al., 2007). Stalk 
cells also express high levels of VEGFR1 which function as a VEGF trap and prevent 
further branching (Jakobsson et al., 2010). Several other upstream pathways, such as 
Wnt/β-catenin, also feed into this process by regulating DLL4 expression (Corada et 
al., 2010). 
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 Channel formation 
Stalk cells are able to form the vascular lumen required for perfusion, as well as 
producing junctional proteins with adjacent cells and depositing basement membrane 
to stabilise the new vessel (Phng and Gerhardt, 2009). The mechanism of lumen 
formation may depend on the vascular bed in question (Zeeb et al.,  2010; Potente et 
al., 2011). Cadherins are required for lumen formation, evidenced by cadherin-
deficient mice which die during embryogenesis due to impaired lumen formation 
(Carmeliet et al., 1999). VE-cadherin is a key player in that it links endothelial cells to 
one another and also interacts with F-actin, a cytoskeletal fibre that is vital for forming 
the vessel lumen (Zeeb et al., 2010). Endothelial cell polarity is also vital for lumen 
formation, as the apical surface must form the lumen whilst the basolateral surface 
interacts with the ECM and mural cells. This polarity is mediated by cell-cell and cell-
ECM interactions, and may involve transport of intracellular vesicles. The process of 
lumen formation is reviewed extensively by Zeeb et al., (2010). 
 Vessel maturation and survival 
For a new vessel to become functionally mature, it must produce a basement 
membrane and inter-cell junctions, as well as recruiting mural cells to provide integrity 
and to maintain endothelial cell survival and quiescence (Potente et al., 2011). 
Endothelial cells differentiate based on signals from the surrounding tissue and thus 
differ based on the vascular bed in question (Dyer and Patterson, 2010). Blood flow 
introduces mechanical shear stress, which is sensed by Kruppel-like factor 2 (KLF2), 
and enhances vessel maintenance via upregulation of nitric oxide synthase (NOS) and 
anticoagulation factors (Potente et al., 2011). Nutrients and oxygen delivered by the 
blood also reduce VEGF signalling to encourage quiescence. Non-perfused vessels 
will regress (Carmeliet and Jain, 2011). 
Two types of mural cell associate with vessels. Pericytes are supporting cells that 
interact directly with capillaries and immature vessels to provide the vessel with 
integrity and maintenance signals, and also interact with the surrounding ECM 
(Gaengel et al., 2009). VSMCs are associated with mature arteries and veins and are 
separated from endothelial cells by ECM (Gaengel et al., 2009). The phenotypic 
crossover between these two fibroblast-like cell types, and the lack of specific markers, 
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leaves the possibility for interconversion between the two open to debate (Adams and 
Alitalo, 2007). Transforming growth factor β (TGF-β) signalling enhances mural cell 
induction, migration and proliferation (Pardali et al., 2010). Typically, the NG2 
proteoglycan and α-SMA are used to demarcate these cells experimentally. A variety 
of integrated signals drive mural cell recruitment, but a key player is platelet-derived 
growth factor B (PDGF-B) which binds the PDGF receptor-B receptor on mural cells 
(Adams and Alitalo, 2007; Gaengel et al., 2009). 
Once recruited, mural cells produce signals that act on endothelial cells in a paracrine 
fashion. ANG-1 is released by mural cells and binds to the TIE2 receptor on 
endothelial cells, tightening endothelial junction to enhance vessel stability. These 
tight junctions allow vessels to effectively regulate vessel wall permeability and the 
extravasation of cells. Cadherins, occludins and members of the claudin family are all 
important in forming tight junctions (Cavallaro and Dejana, 2011). Recent evidence 
has shown that ANG-1 may play a more important role after injury, whilst in quiescent 
vessels it may be dispensable (Jeansson et al., 2011). Ephrin-B2 and Notch signalling 
are also required for association of mural cells with endothelial cells, and deficiency 
of either causes vascular defects (Gridley, 2010; Pitulescu and Adams, 2010).  
Once in a quiescent state, survival is a priority for endothelial cells. Autocrine release 
of VEGF reinforces endothelial cell survival (Warren and Iruela-Arispe, 2010). FGFs 
are also important in annealing adherens junctions, which link the cytoskeleton, 
between endothelial cells. Loss of FGF signalling subsequently results in vessel 
disintegration (Murakami et al., 2008). The aforementioned TIE2/ANG-1 signalling, 
Notch pathway and mechanical shear stress are also key in maintaining survival and 
quiescence (Potente et al., 2011).  
1.4.4 Dynamic regulation of angiogenesis 
Once a functional vascular bed is established, it remains under regulation by a variety 
of environmental stimuli. HIFs regulate perfusion of vessels by stabilising VEGF 
mRNA and enhancing VEGF signalling during hypoxia (Ema et al., 1997; Iyer et al., 
1998). In normoxic conditions, oxygen-sensing prolyl hydroxylase domain proteins on 
endothelial cells label HIFs for degradation, but in hypoxia this does not occur, 
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allowing them to dynamically regulate endothelial cells shape in low oxygen 
conditions (Majmundar et al., 2010).  
Metabolic stimuli can also regulate angiogenesis, and endothelial cell metabolism is 
currently a subject of considerable interest (Vandekeere et al., 2015). The observation 
that inhibiting mitochondrial respiration does not prevent angiogenesis challenged the 
notion that endothelial cells favour oxidative metabolism. Rather, upon stimulation by 
VEGF, endothelial cells increase the expression of the glycolytic activator 
phosphofructokinase-2/fructose-2,6-bisphosphatase 3. 85% of glucose metabolism in 
active endothelial cells is via glycolysis (De Bock et al., 2013). Blockade of this 
enzyme can also suppress pathological angiogenesis in ocular and inflammatory 
models (Schoors et al., 2014). This offers endothelial cells several advantages; it 
allows endothelial cells to vascularise anoxic tissues, which would otherwise be 
impossible with oxidative phosphorylation; it allows cells to quickly produce a larger 
yield of adenosine triphosphate (ATP) (per unit time glycolysis allows for increased 
ATP production, despite reduced glucose efficiency); and it also produces by-products 
suitable for increasing vessel biomass (Eelen et al., 2015; Vandekeere et al., 2015). 
Inhibition of 6-phosphofructo-1-kinase, a rate limiting enzyme of glycolysis, also 
suppressed tumour glycolysis and growth (Clem et al., 2008). Ongoing research is also 
likely to provide further insight into the importance of fatty acid oxidation in regulating 
angiogenesis (Schoors et al., 2015). 
1.4.5 Arteriogenesis 
Once a functional network is in place, some vessels undergo arteriogenesis. This 
involves further muscularisation of the vessel by migration and growth of recruited 
VSMCs. Flow is of great importance, as evidenced by the earlier muscularisation of 
coronary arteries proximal to the aorta as compared to veins (Jain, 2003). Pathological 
arteriogenesis can also occur, such as that seen in the 20-fold enlargement of collateral 
arterioles after occlusion of a supply artery (Schaper, 2009). This pathological 
response, and much pathological angiogenesis, requires the involvement of the 
inflammatory system. Contralateral flow induces monocyte migration and results in 
the breakdown of the vessel wall by proteinases. This is followed by an upregulation 
of factors that induce regrowth of smooth muscle and subsequent vessel enlargement. 
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The response of resistance arteries to flow is determined by vimentin and linked to the 
ECM (Carmeliet, 2000). 
1.4.6 Pathological angiogenesis 
Developmental angiogenesis forms the mature vasculature network. In adult life, 
physiological angiogenesis is limited to discrete processes, such as the menstrual 
cycle, pregnancy, skeletal growth and wound healing (Chung and Ferrara, 2011). 
Pathological angiogenesis is associated with conditions including PDR and age-related 
macular degeneration, rheumatoid arthritis, psoriasis, and tumour growth (Carmeliet, 
2003; Chung and Ferrara, 2011). In the case of pathological angiogenesis, reperfusion 
and restoration of adequate nutrients and oxygen does not resolve the angiogenic 
response, which can result in uncontrolled aberrant angiogenesis.  
Whilst both developmental and adult angiogenesis involve a highly coordinated 
cascade of stimulatory and inhibitory angiogenic factors (Chung and Ferrara, 2011), 
there are also key differences. Angiogenesis in adults must also remodel vessels that 
are quiescent and tightly encapsulated by smooth muscle as opposed to loosely 
assembled and active as during development. Inflammation is also frequently involved 
in pathological angiogenesis; monocyte/macrophages, platelets, mast cells and 
leukocytes are attracted to sites of inflammation, where they produce a variety of pro-
angiogenic factors (Möhle et al., 1997; Coussens et al., 1999; Schaper, 2009; Newman 
and Hughes, 2012). Pathological interaction with the tumour microenvironment is also 
of relevance is cancer; this is discussed further in Section 1.6.4.  
 Manipulating angiogenesis in pathology 
In the context of ischaemic injury, wound healing and obesity, enhanced angiogenesis 
can facilitate recovery (Vernieri et al., 2001; McSweeney et al., 2010; Michailidou et 
al., 2012; Tiganescu et al., 2013; Gordon et al., 2014), whilst anti-angiogenic therapies 
are required for the treatment of heavy menstrual bleeding, cancer and several diseases 
of the eye (Folkman et al., 1983; Rae et al., 2009). Attempts to manipulate 
angiogenesis therapeutically are challenging, due primarily to the immense complexity 
of the angiogenic response – targeting or promoting any single part of this process is 
unlikely to result in a solution (Koh et al., 2010).  
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 Promoting angiogenesis 
Previous attempts to promote angiogenesis therapeutically (for the treatment of 
coronary and peripheral artery disease) have focussed on manipulation of the VEGF 
pathway; however pro-angiogenic VEGF-based therapies have seen limited success 
due to the poor quality and disorganised nature of the neovasculature that forms (Mac 
Gabhann et al., 2010; Zachary and Morgan, 2011). More recent attempts to use 
therapeutic stem cell injection have shown more promise but are still in their infancy 
and remain controversial in terms of their mechanism of action (Hou et al., 2016). 
Shifting focus onto targets other than VEGF ligands may also improve the prospects 
of pro-angiogenic therapy in the future (Mac Gabhann et al., 2010). 
To consider increased vessel density alone as an indicator of successful pro-angiogenic 
therapy is overly simplistic, as increased vessel quality (integrity, perfusion, mural cell 
coverage) is also vital for effective revascularisation (Falcón et al., 2009). This is the 
principle behind the concept of vessel normalisation (Carmeliet and Jain, 2011; Goel 
et al., 2012), which has gained momentum in recent years. An increase in vessel 
density is only of long-term benefit to an ischaemic tissue if this vasculature matures 
appropriately (Eelen et al., 2013), and thus vessel normalisation involves stimulating 
those features of angiogenesis that promote mural cell recruitment and maturation of 
the vessel. This approach could potentially be effective in treating ocular conditions 
and, controversially, tumours; both are associated with an aberrant leaky vasculature 
which contributes to the pathology. In retinopathies, the tortuous, leaky nature of the 
vasculature leads to unresolved hypoxia and blindness, whilst in tumours it hampers 
the effectiveness of radiotherapy and drug delivery (Carmeliet and Jain, 2011). As 
mentioned above, targeting endothelial cell metabolism is currently the subject of 
much interest, after the observation that the majority of endothelial cell energy is 
generated by glycolysis (De Bock et al., 2013), and that inhibiting this process can 
suppress tumour growth (Clem et al., 2008).  
 Inhibiting angiogenesis 
Anti-angiogenic therapies have seen more success than pro-angiogenic therapies. 
Judah Folkman was the pioneer of the modern clinical approach to targeting tumour 
angiogenesis (Folkman, 1972). Several anti-angiogenic drugs are already in use for 
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treating cancer and eye diseases. The first of these was Bevacizumab, a VEGF-specific 
antibody, which improved overall survival in lung, colorectal and breast cancer 
patients (Jain et al., 2006). Several tyrosine kinase inhibitors that block VEGF receptor 
signalling in endothelial and cancer cells are also in use, and have shown improved 
survival in gastrointestinal stromal tumour, renal-cell-carcinoma and hepatocellular 
carcinoma patients (Ferrara, 2009). Unfortunately, anti-angiogenic therapies are still 
hampered by toxicity when delivered in combination with chemotherapy (Jain et al., 
2006) and are also ineffective in patients who are refractory or develop resistance 
(Carmeliet and Jain, 2011). Perhaps most worrying are reports of adaptation and 
increased cancer malignancy after inhibition/deletion of VEGF in pre-clinical models 
(Ebos et al., 2009; Pàez-Ribes et al., 2009). In pathologies other than cancer, 
Ranibizumab (an antibody that blocks the VEGF-A isoform) and pegaptanib (a VEGF 
aptamer) have both been approved (in 2006) for use in treating age-related macular 
degeneration (Ferrara, 2009; Carmeliet and Jain, 2011).  Overall, while not entirely 
unsuccessful, anti-angiogenic therapies have, as yet, failed to meet expectations in the 
clinic (McIntyre and Harris, 2015).    
1.5 11β-HSD1 inhibition and the vasculature 
1.5.1 11β-HSD1 inhibitors 
Clearly, manipulation of local glucocorticoid concentrations is a highly desirable 
clinical intervention in terms of enhancing glycaemic control, regulating local 
inflammation and treating cardiometabolic disorders generally. Inhibition of 11β-
HSD1 offers a novel therapeutic avenue for reducing tissue glucocorticoid exposure 
without risking affecting the systemic stress response.  
For centuries, Japanese herbal medicine made use of the liquorice plant extract, 
Glycyrrhizin, which is itself a potent 11β-HSD inhibitor and could explain some of the 
anti-tumour effects of such medicines (Motoo and Sawabu, 1994). In 1995, the non-
selective 11β-HSD inhibitor carbenoxolone was shown to improve insulin sensitivity 
in man via reduced binding of hepatic GR (Walker et al., 1995). Further beneficial 
effects have been shown on blood glucose (Alberts et al., 2002; Alberts et al., 2003) 
and lipid handling (Berthiaume et al., 2007) using the 11β-HSD1 selective inhibitors 
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BVT.2733 and compound A, respectively. As well as these general cardiometabolic 
benefits, 11β-HSD1 inhibition using compound 544 also markedly reduced the 
progression of atherosclerosis (Hermanowski-Vosatka et al., 2005).  
A number of 11β-HSD1 inhibitors progressed to clinical trial (reviewed extensively 
by Anderson and Walker, 2013), but have shown only mild improvements in terms of 
glycaemic control, lipid handling, blood pressure and weight loss. More recently, 11β-
HSD1 inhibitors are showing promise in the improvement of cognitive function (Sooy 
et al., 2010, 2015; Yau et al., 2015), with UE2343 (Xanamem) currently in Phase II 
clinical trials (Webster et al., 2017). In this section, the preclinical data on 11β-HSD1 
inhibition or deletion in the vasculature are introduced. 
 Atherosclerosis 
11β-HSD1 inhibition reduces atherosclerotic plaque formation in mice 
(Hermanowski-Vosatka et al., 2005; Nuotio-Antar et al., 2007). Though several 
studies report reduced low-density lipoprotein and improved glycaemic control, 
different inhibitors show variability; the 11β-HSD1 inhibitor 2922 showed no effect 
on atheroma (Lloyd et al., 2009).  
Though 11β-HSD1 deletion confers an atheroprotective phenotype in mice (Morton et 
al., 2001; Kipari et al., 2013), evidence suggests that the enzyme may have a direct 
role in regulating vascular inflammation distinct from plasma lipid profile and blood 
pressure. 11β-HSD1 KO Apolipoprotein E-deficient (11βHSD1-/-/apoE-/-) mice 
showed a significant reduction in plaque size, necrotic core area and macrophage 
content compared to apoE-/- mice (Garcia et al., 2013; Kipari et al., 2013). 
Transplantation of 11βHSD1-/-/apoE-/- bone marrow into apoE-/- mice conferred these 
atheroprotective features onto recipients, demonstrating the importance of leukocyte-
derived 11β-HSD1 in this process (Garcia et al., 2013; Kipari et al., 2013). 
Furthermore, extracted peritoneal macrophages from 11βHSD1-/-/apoE-/- mice had 
significantly reduced cholesterol content, although 11βHSD1 deletion did not affect 
inflammatory cell migration in this study (Garcia et al., 2013).  
Perhaps most interestingly, gene expression analysis revealed a decrease in toll-like 
receptor (TLR) signalling and an attenuation of the inflammatory state in 11βHSD1-/- 
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mice, with a reduction in the amount of pro-inflammatory cytokines (e.g. TNF-α, 
MCP-1) released by 11βHSD1-/- peritoneal macrophages in response to stimulation 
with oxidised low density lipoprotein (LDL) (Garcia et al., 2013). Similar data have 
been reported elsewhere, including reduced monocyte chemoattractant protein 1 
(MCP-1) and vascular cell adhesion molecule 1 (VCAM-1) expression, along with 
decreased T-cell infiltration into atherosclerotic plaques from 11βHSD1-/-/apoE-/- mice 
(Luo et al., 2012; Kipari et al., 2013). The effects of glucocorticoids on MCP-1 appear 
to vary between inflammatory cell types and VSMCs, where in contrast, GR binding 
has been shown to decrease MCP-1 expression (Dhawan et al., 2007). Overall, these 
findings strongly suggest that 11β-HSD1 influences inflammation in the vascular wall 
and that enzymatic inhibition may decrease inflammation in an atherosclerotic context.  
 Neointimal proliferation 
Restenosis after coronary angioplasty is a clinical problem when treating occlusive 
vascular disease. It is caused by neointimal proliferation of VSMCs and, thus, 
glucocorticoids have been considered to be of potential benefit based on their anti-
proliferative effects on VSMCs (Longenecker et al., 1982, 1984; Berk et al., 1988, 
1991; Goncharova et al., 2003). 11β-HSD1 inhibition in this context, therefore, could 
potentially be pathogenic. 
Cai et al. (2001) found that pro-inflammatory cytokines (IL-1β or TNF-α) induced 
greater expression of 11β-HSD1 in VSMCs, supporting a potential role for the enzyme 
in regulating local inflammation; although this finding could not be replicated in intact 
aortic tissue or in vivo (Dover et al., 2007).  Iqbal et al. (2012) demonstrated that both 
glucocorticoid binding to GR, and MR antagonism can reduce neointimal 
proliferation. Importantly, they also found that 11β-HSD1 deletion reduced neointimal 
proliferation, with an associated reduction in macrophage infiltration and increased 
collagen content. This effect was seen only in double KO (11β-HSD1-/- apoE-/-) mice 
with a hyperlipidaemic phenotype which promotes lesion formation, suggesting that 
this effect was due to systemic rather than local enzyme deletion. Overall, it is unlikely 
that 11β-HSD1 in the vascular wall affects neointimal proliferation. 
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 Promotion of angiogenesis 
Glucocorticoids are anti-angiogenic (Folkman et al., 1983). This manifests clinically 
as poor wound healing associated with Cushing’s disease (Gordon et al., 1994) and 
increased risk of heart failure associated with chronic glucocorticoid therapy 
(Souverein et al., 2004). Given these effects and the potential role for 11β-HSD1 in 
regulating vascular inflammation, 11β-HSD1 inhibition or deletion was hypothesised 
to enhance angiogenesis. Small et al. (2005) were the first to test this using 
physiological concentrations of glucocorticoids. Ex vivo aortic rings showed reduced 
vessel outgrowths after exposure to both 11-DHC and corticosterone, an effect that 
was blocked with GR antagonist RU38486 but not the MR antagonist spironolactone. 
Both carbenoxolone and 11β-HSD1 deletion protected aortic rings from the angiostatic 
effects of 11-DHC, suggesting that conversion of the inactive substrate results in 
angiostasis. In vivo subcutaneous sponges showed enhanced angiogenesis after mice 
were given RU38486 and reduced angiogenesis when sponges were impregnated with 
cortisone or cortisol. In 11β-HSD1 KO animals, cortisone did not inhibit sponge 
angiogenesis, and both RU38486 and 11β-HSD1 deletion increased angiogenesis in 
dermal wounds. These data support the ex vivo observations and suggest they are 
highly relevant in vivo. Of note, Terao et al. (2011) also reported enhanced wound 
healing after 11β-HSD1 inhibition; however, they attribute this effect to increased 
proliferation of keratinocytes rather than enhanced angiogenesis. 
The most striking data concerning angiogenesis comes from studies using the induced 
myocardial infarction (MI) model in mice. Both GR antagonism (Small et al., 2005) 
and 11β-HSD1 deletion increase myocardial revascularisation after coronary artery 
ligation resulting in improved recovery (Small et al., 2005; McSweeney et al., 2010; 
White et al., 2015; Mylonas et al., 2017). The same finding has been reproduced using 
the selective 11β-HSD1 inhibitor UE2316 delivered at the time of injury (McGregor 
et al., 2014). Given the clinical burden of heart failure after MI, these results show 
promise for 11β-HSD1 inhibitors.  
Inflammatory cells play a crucial role in angiogenesis. After myocardial injury, 
macrophages secrete pro-angiogenic TGF-β and VEGFA, and promote angiogenesis, 
myofibroblast infiltration and collagen deposition (van Amerongen et al., 2007). 11β-
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HSD1 KO mice showed increased recruitment of neutrophils (McSweeney et al., 
2010; Mylonas et al., 2017) and macrophages to the healing infarct after coronary 
artery ligation, with an increase in MCP-1 and IL-8 mRNA and an increased number 
of ‘alternatively activated’ YM-1-positive macrophages, suggesting a pro-reparative 
phenotype (McSweeney et al., 2010). Enhanced neutrophil recruitment was associated 
with reduced expression of C-X-C chemokine receptor 4 (CXCR4) in neutrophils in 
11β-HSD1 KO mice, a cell surface receptor which enhances bone marrow retention of 
neutrophils (Mylonas et al., 2017). After 28 days, vessels in the healing infarct had 
increased α-SMA coverage in 11β-HSD1 KO mice, suggesting maturity and stability. 
The beneficial effect of 11β-HSD1 inhibition/deletion on recovery post-MI cannot be 
attributed to 11β-HSD1 expressed in vascular smooth muscle or cardiomyocytes, as 
mice with targeted deletion of the enzyme in these cell types did not recover faster 
than wild type control mice after myocardial injury (White et al., 2015; Mylonas et al., 
2017). Experiments using bone marrow chimeric 11β-HSD1 KO mice confirmed the 
importance of the enzyme in host tissues rather than donor myeloid cell lineages 
(Mylonas et al., 2017). Cardiac fibroblasts from the infarcted hearts 11β-HSD1 KO 
animals expressed more CXC-motif ligand (CXCL) 2 and CXCL5 than WT controls, 
and exposure of these cells in culture to corticosteroids reduced expression of CXCL2 
and CXCL5 (Mylonas et al., 2017). Thus, the mechanism for enhanced recovery after 
MI is likely to involve enhanced expression of chemoattractant proteins from cardiac 
fibroblasts as a result of reduced GR binding, resulting in enhanced neutrophil 
recruitment and polarisation of macrophages towards a pro-reparative phenotype. 
Potentially the enhanced angiogenesis seen in the myocardium is a consequence of an 
altered inflammatory environment rather than a direct influence of 11β-HSD1 on 
vascular remodelling. Indeed, the 11β-HSD1 inhibitor compound A has been shown 
to reverse cardiac hypertrophy in a VEGF-based transgenic model intended to 
uncouple reversal of hypertrophy from neovascularisation (Gordon et al., 2014). In 
these studies, 11β-HSD1 expression was increased in hypertrophied myocardium and 
its inhibition was proposed to alter cardiac muscle myofilament composition. Thus, 
there remains some debate surrounding cardiac mechanisms, and the importance of 
angiogenesis in this context is unclear. 
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11β-HSD1 KO mice with diet-induced obesity show increased angiogenesis, resulting 
in reduced hypoxia and reduced fibrosis in their adipose tissue (Michailidou et al., 
2012). HIF-1α signalling, Col1a1 mRNA, picrosirius red staining and α-SMA staining 
were all reduced in adipose tissue of 11β-HSD1 KO animals. In vivo, 11β-HSD1 KO 
adipose tissue showed a greater vessel-to-adipocyte ratio.  Ex vivo, aortic rings showed 
a greater angiogenic response when exposed to 11β-HSD1 KO periaortic fat 
conditioned media (PACM) compared to WT PACM. In keeping with these findings, 
11β-HSD1 KO adipose tissue also showed increased expression of pro-angiogenic 
mediators VEGF, apelin and angiopoietin-like protein 4 (ANGPTL4), expression of 
which was further increased by the addition of a peroxisome proliferator-activated 
receptor-γ (PPAR-γ) agonist (Michailidou et al., 2012). Interestingly, 11β-HSD1 
expression in mouse embryonic fibroblasts is decreased by HIF-1α (Lee et al., 2013), 
and fibroblastic preadipocytes show enriched 11β-HSD1 expression in adipose tissue, 
suggesting once again that this enzyme may be of particular importance in fibroblasts. 
It is important to note the distinction in proposed mechanism between MI (an acute 
ischaemic event) and obesity (a chronic inflammatory environment). Although 
enhanced angiogenesis is reported in both scenarios, reported data concerning 
inflammation are polarised. In the myocardium, enhanced neutrophil and macrophage 
recruitment are at the centre of the improved functional recovery. In adipose tissue 
from 11β-HSD1 KO animals, a decrease in inflammatory signalling (MCP-1 
expression, T-cell infiltration and macrophage infiltration) has been reported (Wamil 
et al., 2011), similar to that seen in atherosclerosis (Luo et al., 2012). Itoi et al. (2013) 
observed enhanced IL-6 production after exposing keratinocytes to a low cortisol 
concentration (0.1 pM) but attenuated IL-6 levels when using a high cortisol 
concentration (10 µM). Thus the context of inflammation may be pivotal in predicting 
the response to 11β-HSD1 inhibition (this concept is reviewed more thoroughly in 
Chapman et al., 2013a). An important similarity to note in both contexts is that of 
altered fibrosis and the potential importance of 11β-HSD1 in fibroblasts.  
1.5.2 11β-HSD1 inhibition and pathological angiogenesis 
Whilst angiogenesis can promote recovery and attenuate ischaemia, it can also 
contribute to the pathology of a disease. The involvement of local glucocorticoid 
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metabolism has been examined in three such contexts. Endometrium from women 
experiencing heavy menstrual bleeding was found to express higher levels of 11β-
HSD2 and reduced levels of the anti-angiogenic factor thrombospondin-1 (TSP-1) 
(Rae et al., 2009). The angiostatic effects of cortisol on endothelial tube-like structure 
formation were blocked with the addition of siRNA against TSP-1, presenting a 
possible mechanism – increased 11β-HSD2 in endometrial stromal cells reduces the 
amount of glucocorticoids accessing the GR in adjacent endothelial cells, causing them 
to secrete less TSP-1 and, thus, enhancing pathological angiogenesis. Note that the 
proposed mechanism here has a paracrine action, unlike the autocrine hypotheses 
suggested in the myocardium and adipose tissue. 
Recently, 11β-HSD1 inhibition has been investigated in the context of the retina to 
assess its potential for worsening PDR. Surprisingly, the 11β-HSD1 inhibitor 
compound 544 reduced pathological neovascularisation in the retinas of neonatal mice 
exposed to hypoxic conditions, despite the absence of the enzyme from the retinal 
vasculature (Davidson et al., 2017), possibly as a result of off-target effects. Critically, 
no differences were seen in retinal vasculature between 11β-HSD1 KO and WT mice, 
suggesting that 11β-HSD1 inhibitors are unlikely to exacerbate PDR.  
Inflammatory arthritis is characterised by pathological angiogenesis as the expansion 
of the synovium increases the demand for nutrients and oxygen (Paleolog, 2002). 
Zhang et al. (2017) recently demonstrated that resolution of joint inflammation was 
impaired in mice with macrophage-specific deletion of 11β-HSD1 compared to WT 
littermates, to a similar degree as was previously seen in global 11β-HSD1 KO animals 
(Coutinho et al., 2012). This was associated with a two-fold increase in VE-cadherin 
mRNA, suggesting a potentially altered vessel phenotype, although no changes were 
seen in VEGF mRNA (also the case in previous papers reporting increased 
angiogenesis, such as McSweeney et al. (2010)). The same mice showed an enhanced 
angiogenic response on subcutaneous insertion of a polyurethane sponge, suggesting 
that myeloid 11β-HSD1 plays an important role in the pro-angiogenic phenotype after 
enzyme inhibition. 
Aberrant angiogenesis is also a hallmark of cancer (Hanahan and Weinberg, 2011) and 
its induction occurs during the transition from hyperplasia to neoplasia (Folkman et 
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al., 1989). Solid tumours, like healthy tissue, require a system of nutrient transfer to 
thrive. Above a few millimetres in size, this transfer must be in the form of vasculature 
as distances are too great for simple diffusion to suffice (Folkman, 1995). A concern 
is that 11β-HSD1 inhibition could enhance tumour angiogenesis, leading to increased 
tumour growth and metastasis. This concern has barely been addressed in the literature 
thus far. Liu et al. (2016) reported an anti-angiogenic and anti-tumour effect of 11β-
HSD1 overexpression in murine hepatocellular carcinoma (HCC), both in vitro and in 
vivo.  The same study also demonstrated reduced 11β-HSD1 expression in malignant 
tissue compared to non-neoplastic liver (a commonly reported phenomenon), and 
argued that loss of 11β-HSD1 in malignancy enhances glycolysis and subsequent 
tumour growth.  
1.6 Cancer  
1.6.1 Hallmarks of cancer 
Cancer describes a collection of diseases characterised by uncontrolled cell 
proliferation and invasiveness.  As one of the leading cause of death globally (after 
ischaemic heart disease and stroke), it is the focus of intense research to reduce the 
impact it has on wellbeing and the burden it places on health organisations.  Cancers 
can affect almost any tissue in the body, but are considerably more common in highly 
proliferative tissues. Cancers with high mortality include lung, liver, colorectal, 
stomach and breast cancer, and progression to metastasis greatly decreases the chances 
of long-term survival after treatment (World Health Organisation, 2017). 
In 2000, Hanahan and Weinberg (2000) published their seminal paper ‘Hallmarks of 
Cancer’ which defined the common features of malignancy. Those hallmarks are 
cancerous tissue’s ability to: sustain proliferative signalling; evade growth 
suppressors; activate invasion and metastasis; enable replicative immortality; resist 
cell death; and induce angiogenesis. In 2011, this paper was updated to reflect the 
progress made over the previous decade. Emerging hallmarks now also include the 
ability to deregulate cellular energetics and to avoid immune destruction (Hanahan and 
Weinberg, 2011). Targeting these hallmarks offers the best chance of curing cancer, 
though the picture is complicated immensely by the vast heterogeneity between cancer 
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types and subtypes, and by the resistance and adaptation many cancers show in 
response to therapy. 
1.6.2 Tumour formation 
Typically, cancerous tissues arise from healthy tissues through a series of genetic and 
environmental insults, resulting in loss-of-function mutations in tumour suppressor 
genes and gain-of-function mutations in oncogenes, driving a malignant phenotype 
(Weinberg et al., 1999), with associated replicative immortality linked to telomerase 
expression (Blasco, 2005). This process has been likened to Darwinian evolution, in 
the sense that mutations conferring a survival advantage to cells are typically 
maintained and lead to clonal selection of a tumour cell population (Nowell, 1976; 
Hanahan and Weinberg, 2000). TP53, for example, is a prototypical tumour suppressor 
gene; it integrates signals relating to cell stress (oxygen and glucose availability, DNA 
damage, etc.) and can halt progression of the cell cycle if quality standards are not met 
(Hanahan and Weinberg, 2011). 
Leukaemias (cancers of the blood), do not typically form solid tumours, whereas 
cancer in other tissues results in the formation of a primary tumour, comprised of 
tumour cells and an array of supporting mesenchymal, inflammatory and vascular cell 
types that form the tumour microenvironment. Interest in the tumour 
microenvironment has intensified in the last decade, and has provided new avenues for 
treatment that target more subtle components of the tumour (Hanahan and Coussens, 
2012). In this section, the components of the tumour microenvironment, and their 
influence on tumour growth, will be introduced.  
1.6.3 Tumour angiogenesis 
During the very early stages of development, tumours can achieve nutrient and waste 
exchange via simple diffusion. As the tumour grows beyond 1-2 mm in size however, 
an ‘angiogenic switch’ (Hanahan and Folkman, 1996b) is required and the tumour 
must develop its own blood supply to maintain its growth and to successfully 
metastasise. A powerful driver for this process are the HIFs, which stimulate cells of 
the tumour to release VEGF (Dayan et al., 2008). HIF can become upregulated in 
tumours as a result of mutations in tumour-suppressor genes or oncogenes (Chung and 
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Ferrara, 2011), leading to sustained high levels of VEGF and pathological 
angiogenesis. The resultant vasculature is tortuous, hyper-permeable and lacking in 
sufficient mural cell coverage, creating regions of hypoxia and necrosis which in turn 
stimulate further angiogenesis (Verdegem et al., 2014). Unlike physiological 
angiogenesis, tumour angiogenesis is not self-limiting (Polverini and Leibovich, 
1984). 
Vessels in tumours are heterogenous, with six classifications of vessel types now in 
use; mother vessels; three types of daughter vessels; feeder arteries and draining veins 
(reviewed by Nagy et al., (2010)). Whilst it is not within the scope of this introduction 
to describe each type individually, the vasculature overall is characterised by irregular 
vessel diameter, thin walls comprised of abnormally shaped endothelial cells with 
compromised basement membrane, and variable mural cell coverage. These features 
have been observed in a variety of preclinical models (Morikawa et al., 2002; Baluk 
et al., 2003; Ozawa et al., 2005; Hagendoorn et al., 2006) and in clinical samples (Less 
et al., 1997). Another process unique to tumour angiogenesis is vascular mimicry, 
whereby tumour cells are able to adopt an endothelial-like phenotype and form 
functional channels, creating ‘mosaic vessels’ and further complicating the therapeutic 
targeting of tumour angiogenesis (Hess et al., 2006; Lin et al., 2007). This vascular 
mimicry has principally been observed in melanoma (Hendrix et al., 2003). 
Cells can often be identified by markers they express on their surface. Tumour 
endothelial cells express different markers from their ‘normal’ counterparts, 
presenting an opportunity for targeted therapies (reviewed by Ruoslahti, (2002)). As 
well as the tumour and tumour endothelial cells, an array of stromal cells also release 
proangiogenic factors to further stimulate the angiogenic process. These include 
immune inflammatory cells, fibroblasts and pericytes.  
1.6.4 The tumour microenvironment  
Tumour cells are characterised by their unconstrained replication and invasiveness, the 
result of acquired mutations. While autocrine growth signals within tumour cells are 
dysregulated, the paracrine effects of other cell types within the tumour also have a 
powerful influence upon tumour growth (Hanahan and Weinberg, 2011). These cell 
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types include endothelial cells, fibroblasts and immune/inflammatory cell types. 
Whilst many of these supporting cells are likely to migrate from the surrounding 
healthy tissues, it is also now thought that bone-marrow-derived progenitor cells 
migrate into tumours and contribute to immune inflammatory, fibroblast and mural 
cell populations (Mishra et al., 2008; Fang and Salven, 2011; Quante et al., 2011). 
 Fibroblasts in tumours 
Fibroblasts comprise one of the most prevalent and important regulatory cell types in 
the stroma of carcinomas. Outside of cancer, fibroblasts may be categorised as one of 
two types: normal tissue-derived fibroblasts are responsible for laying down the 
fibrous ECM; myofibroblasts are a specialised cell type found in large quantities in 
wounds and at sites of chronic inflammation (Kalluri, 2016), where their role is to 
promote tissue repair. The majority of the fibroblasts forming part of the tumour 
stroma are referred to as cancer-associated fibroblasts (CAFs) (De Wever et al., 2008) 
though some normal fibroblasts are present and produce ECM that forms the palpable 
tumour mass. CAFs are similar to myofibroblasts; they display an ‘activated’ pro-
reparative phenotype, but in the chronic inflammatory setting of a tumour they can 
contribute to lesion growth through pathological stromal ECM deposition. Unlike 
typical myofibroblasts, which return to a ‘normal’ phenotype after resolution of 
inflammation, CAFs maintain their activated state to drive tumour progression (Shiga 
et al., 2015). The growth factors, chemokines and proteases they release can promote 
tumour cell proliferation, angiogenesis and metastasis (Orimo et al., 2005; Karnoub et 
al., 2007; Mishra et al., 2011; Quante et al., 2011; Dumont et al., 2013; De Wever et 
al., 2014; Kalluri, 2016). 
Evidence exists to suggest CAFs promote an immunosuppressive tumour 
microenvironment (Harper and Sainson, 2014). Yet evidence to the contrary also 
exists, and there is now debate as to whether CAFs could in fact promote anti-tumour 
immune cell infiltration (Özdemir et al., 2014; Rhim et al., 2014); CAFs adopt a pro-
inflammatory phenotype early during neoplasia development (Erez et al., 2010) and 
their depletion causes intra-tumour immunosuppression and enhanced tumour growth 
in carcinomas (Özdemir et al., 2014), highlighting the importance of appreciating the 
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complex interplay between different components of the tumour microenvironment and 
their impact on tumour growth.   
 Inflammatory and immune cells in tumours 
Cells of both the innate and adaptive immune systems infiltrate tumours, much as they 
would a wound. Tumours can be thought of as wounds that do not heal and, as such, 
present a chronic inflammatory situation (Flier et al., 1986). Chronic inflammatory 
conditions themselves are a risk factor for later dysplasia (Schäfer and Werner, 2008). 
While acute inflammation functions to clear cellular debris and repair tissue, chronic 
inflammation in cancer is associated with pathological fibrosis, angiogenesis and 
neoplasia. A vast array of immune and inflammatory cell types are present within 
tumours, and these are review extensively by Grivennikov et al. (2010). 
The immune system, when functioning correctly, eradicates threats within the body, 
including many tumour types. Avoiding this anti-tumour response is a feature of 
malignancy (Hanahan and Weinberg, 2011), and tumours that do form have found a 
way to evade immune destruction. An abundance of evidence exists to support anti-
tumour immunity (see Kim et al., 2007; Cirillo et al., 2017). Evidence for this is seen 
in the increased incidence of cancers, in particular those associated with oncogenic 
viruses but also several with no infectious cause, after immunosuppression (Vajdic and 
van Leeuwen, 2009). Immunosuppression for renal transplant has been associated with 
increased incidence of non-melanoma skin cancer (such as squamous cell carcinoma) 
(Glover et al., 1997; Euvrard et al., 2003; Moloney et al., 2006). In one study, this was 
associated with reduced circulating CD4+ T-cells (Ducloux et al., 1998). In rare cases, 
transmission of donor malignancy to the immunocompromised host via organ 
transplant has been reported, suggesting that the immunocompromised host was 
unable to destroy the transmitted tumour cells (Strauss and Thomas, 2010). 
In preclinical models of tumourigenesis, depletion of immune cell populations (such 
as cytotoxic T-cell and natural killer (NK) cells) also increases the growth of some 
tumour types (Kim et al., 2007). IFN-γ secreted by cells of the innate immune system 
(cytotoxic T-cells) and NK cells is able to destroy tumour cells, and IFN-γ-insensitive 
tumour cells showed increased in vivo growth and reduced rejection when implanted 
Chapter 1 - Introduction 
63 
 
into mice (Dighe et al., 1994).  Similarly, mice lacking IFN-γ or all of the IFN family 
members showed enhanced tumourigenicity and more rapid tumour growth compared 
to immunocompetent WT mice (Kaplan et al., 1998), suggesting the existence of an 
IFN-γ-dependent tumour surveillance system. Further studies using transgenic mice 
have demonstrated the importance of an interplay between lymphocytes and IFN-γ in 
mediating anti-tumour immunity (Shankaran et al., 2001). PDV cells (a squamous cell 
carcinoma cell line) also grew more readily in mice lacking γδ T-cells (Girardi et al., 
2001). 
Immune and inflammatory cells can also promote tumour progression. M1 
macrophages and neutrophils are the major cell types associated with the classical 
inflammatory response, while M2 ‘alternatively’ activated macrophages and myeloid 
progenitor cells are associated with a reparative phenotype. It is the latter of these two 
responses that is thought to enhance tumour growth (Mantovani et al., 2002). Cells of 
the innate immune system, including macrophages, neutrophils and dendritic cells, can 
promote tumour progression by producing myriad growth factors, cell survival signals, 
angiogenic factors, cytokines and chemokines, ECM modifying proteases and 
inductive signals (reviewed by Coffelt et al., 2010; DeNardo et al., 2010). Mast cells 
and tumour associated macrophages (TAMs) encourage tumour angiogenesis directly 
through release of angiogenic factors and proteinases (e.g. MMP 9, IL-6 and TNF-
alpha) which remodel the ECM (Hori et al., 1996). They also indirectly stimulate 
tumour cells to release their own proangiogenic molecules (Sica et al., 2002; 
Carmeliet, 2003). The lymphocytes of the adaptive immune system may play an 
important role in recruiting such tumour-promoting myeloid cells.  
As well as these differentiated immune inflammatory cells, an important emerging 
player is the myeloid-derived suppressor cell (MDSC), a myeloid progenitor 
associated with suppression of anti-tumour immunity. Through production of arginase 
1 (ARG1) and inducible nitric oxide synthase (iNOS), these MDSCs promote tumour 
progression by reducing the anti-tumour function of NK cells and cytotoxic T cells 
(Murdoch et al., 2008). These cells exhibit functional and phenotypic crossover with 
Tie-2 expressing monocytes (TEMs); both cell types are known to promote tumour 
angiogenesis, suggesting that myeloid cells can both stimulate tumour growth by 
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increasing blood supply and by suppressing anti-tumour immunity (De Palma et al., 
2005; Qian and Pollard, 2010). Furthermore, Varga et al. (2008) found that 
glucocorticoids upregulated monocytes with a phenotype similar to MDSCs – 
immunosuppressive and anti-inflammatory. Such cells are thought to contribute to 
tumour progression (Sica and Bronte, 2007). 
In mice lacking monocytes, tumour growth is drastically reduced (Sica et al., 2002) 
and NSAIDs have also been shown to reduce tumour angiogenesis (Dermond and 
Ruegg, 2001). The story is complicated by evidence that macrophages can inhibit 
angiogenesis in some contexts (Carmeliet, 2003), possibly via TSP-1 (Salvesen and 
Akslen, 1999). Mast cells too have been shown to increase with an accompanying 
reduction in angiogenesis in haemangiomas treated with glucocorticoids (Hasan et al., 
2000).  
 Vascular cell types in tumours 
Whilst endothelial cells in the adult vasculature are normally maintained in a quiescent 
state, tumour angiogenesis involves an ‘angiogenic switch’ which renders vessels 
constantly active and stimulates continual sprouting angiogenesis (Hanahan and 
Folkman, 1996a). This switch is often tripped in the pre-malignant stages of 
tumourigenesis, suggesting it is an important target from an early stage (Menakuru et 
al., 2008). Tumours typically alter the balance of angiogenic factor expression to 
favour pro-angiogenic factors (e.g. VEGF-A) over anti-angiogenic factors (e.g. TSP-
1) (Baeriswyl and Christofori, 2009). Increased expression of VEGF-A, as well as 
other growth factors such as the FGFs, can be driven by both the hypoxic environment 
in a tumour or by oncogenic activation (Carmeliet, 2005a). This chaotic unbalanced 
angiogenic stimulus results in tortuous, leaky vessels that branch excessively, are often 
enlarged, and are prone to microhaemorrhage (Nagy et al., 2010). 
Patterns of neovascularisation vary drastically between tumour types. Pancreatic 
ductal adenocarcinoma (PDAC) tumours grown in mice, for example, display large 
avascular regions and are overall hypovascularised (Olive et al., 2009) whereas other 
tumour types (such as renal carcinomas) are highly angiogenic (Hanahan and 
Weinberg, 2011). The source of major angiogenic stimuli can also vary between 
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tumour types, with immune inflammatory cells having a greater influence over 
angiogenesis in certain tumours, whilst in others tumour cells themselves stimulate the 
process.  
Bone marrow-derived cells, including cells of the innate immune system 
(macrophages, mast cells, neutrophils), can also powerfully stimulate pathological 
angiogenesis and the tripping of the angiogenic switch (De Palma et al., 2007; Qian 
and Pollard, 2010). Necrosis within tumours can lead to the recruitment of immune 
inflammatory cells, which can in turn stimulate angiogenesis and tumour growth. 
Bone-marrow-derived vascular progenitor cells may also become intercalated within 
vessels and contribute to angiogenesis, though the extent of this contribution is now 
thought to be minimal (Patenaude et al., 2010; Fang and Salven, 2011). 
Supporting pericytes also function differently between normal and cancerous blood 
vessels. Mural cell coverage is markedly reduced in most tumours, as the chaotic 
nature of tumour angiogenesis does not result in functional maturation. Pericytes, 
however, do associate with tumour vessels and may in fact play an important role in 
angiogenesis (Raza et al., 2010). Whilst pericytes are recruited to tumour vessels, they 
do not adhere as tightly as in normal vessels, and remain slightly detached (Morikawa 
et al., 2002; Abramsson et al., 2003). Tumour vessels are highly dependent on pericyte 
coverage for their integrity and provision of endothelial survival factors like VEGF 
(Reinmuth et al., 2001). Inhibiting pericyte PDGFβ receptor signalling with kinase 
inhibitors prevents the binding of PDGF-B (released from endothelial cells), a vital 
signal for recruiting pericytes (Gaengel et al., 2009). This approach has been shown to 
reduce growth in several tumour models by reducing coverage and stability of tumour 
vessels (Shaheen et al., 2001; Bergers et al., 2003). Whilst these results are promising, 
there is a risk that compromising vessel integrity could encourage metastasis, and 
overexpression of PDGFβ has been shown to reduce tumour growth in models of 
pancreatic and colorectal cancer (McCarty et al., 2007). 
1.6.5 Glucocorticoids and tumours 
Glucocorticoids have been in used for the treatment of lymphoid cancers for over 70 
years (Pearson and Eliel, 1950; Inaba and Pui, 2010). Synthetic glucocorticoids, such 
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as dexamethasone, are effective in this setting but their associated side-effects 
(metabolic disorder, muscle wasting, osteoporosis etc.) limit their usefulness (Pufall, 
2015). In treatment of these haematopoietic cancers, the curative mechanism is thought 
to be predominantly upregulation of pro-apoptotic signalling pathways such as Bim 
(Wang et al., 2003; Pufall, 2015). In terms of other cancer types, glucocorticoids have 
shown moderate beneficial effects in the treatment of endocrine responsive tumour 
types (breast and prostate cancer), either as monotherapy or in conjunction with 
cytotoxic drugs (Lin and Wang, 2016). These beneficial effects are poorly understood 
but may involve cooperation between GR and the estrogen receptor (ER, breast cancer) 
(Karmakar et al., 2013) or the androgen receptor (AR, prostate cancer) (Sahu et al., 
2013).  
As well as their use to treat malignancy itself, glucocorticoids are also commonly 
prescribed for the side effects associated with chemo- and radiotherapy, such as loss 
of appetite and weight, fatigue, vomiting and pain (Lin and Wang, 2016). 
Controversially, many preclinical studies suggest that dexamethasone inhibits the 
apoptotic effects of chemotherapy. This has been seen in tumours or tumour cells from 
a range of cancer types, predominantly carcinomas. These include: bladder, renal and 
testicular carcinoma (Zhang et al., 2006b); glioma (Gorman et al., 2000; Benedetti et 
al., 2003); breast (Mikosz et al., 2001; Wu et al., 2004) and ovarian cancer (Sui et al., 
2006); cervical carcinoma (Rutz et al., 1998; Kamradt et al., 2000); HCC and 
colorectal cancer (Zhang et al., 2006b); lung carcinoma (Bergman et al., 2001; Gassler 
et al., 2005; Gündisch et al., 2012) and pancreatic cancer (Zhang et al., 2006a). A 
comprehensive study of multiple solid tumour types by Zhang et al. (2007) led to the 
conclusion that dexamethasone induces chemotherapy resistance in the majority of 
solid tumours. No clinical studies have been able to validate these pre-clinical 
observations as yet (Lin and Wang, 2016). It is also important to bear in mind that the 
majority of these studies used pharmacological doses of dexamethasone (which is 
itself highly potent and selective for the GR), thus the same cannot necessarily be 
assumed when manipulating systemic glucocorticoids at physiologically relevant 
concentrations. 
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GC-mediated resistance to cell death in breast cancer was found to be via upregulation 
of survival factors such as serine/threonine survival kinase 1 (Mikosz et al., 2001; Wu 
et al., 2004). Feng et al. (2012) also found that chronic restraint stress led to the 
induction of serum- and glucocorticoid-induced protein kinase, which attenuated p53 
tumour-suppressor function and promoted tumour colorectal cancer xenograft growth. 
As well as influencing cell survival, glucocorticoids are also likely to alter the anti-
tumour immune response (Flint et al., 2017). The concept of glucocorticoids 
influencing immunological resistance to tumours stretches back over 40 years (Rettura 
et al., 1973). The complexity of anti-tumour immunity is vast and a huge amount 
remains to be discovered. However, the last decade has seen great progress (Fearon, 
2017; Flint et al., 2017). CXCR3 is now considered a vital mediator of T-cell migration 
into tumours (Mikucki et al., 2015). The interaction of key chemokines such as 
CXCL9-11, and their various receptors, are central to the process of immune control 
in cancer. Cancer cells, myeloid cells, endothelial cells and CAFs may all be involved 
(reviewed by Fearon (2017)). Colorectal cancer can generate immunoregulatory 
glucocorticoids to reduce anti-tumour immunity (Sidler et al., 2011). Furthermore, 
administration of physiologically-relevant levels of corticosterone abolished the 
beneficial effects of immunotherapy on murine pancreatic cancer (Flint et al., 2016). 
Both studies suggest that manipulation of physiological glucocorticoids could affect 
anti-tumour immunity.  
IL-6 stimulates the growth of cancer cells, promotes tumour angiogenesis and is 
influenced by cortisol (Bernabé et al., 2011), making it an important therapeutic target. 
This is particularly true of squamous cell carcinoma (SCC), discussed in more depth 
in Section 1.6.5.1.1. Bernabé et al., (2011) found that stress levels of corticosterone 
elevated IL-6 levels, while pharmacological levels decreased IL-6 expression in SCC. 
Elevated IL-6 levels predict poor prognosis in SCC (Duffy et al., 2008). Reducing the 
disruptive influence of IL-6-producing pro-inflammatory CAFs on downstream 
chemokine signalling has been proposed in PDAC (Flint et al., 2016), a tumour type 
with a relatively high proportion of CAFs (Öhlund et al., 2017). The same approach 
has shown promise in melanoma (Jobe et al., 2016).   
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Tumour cells undergo a shift towards aerobic glycolysis during their transition towards 
malignancy (Hanahan and Weinberg, 2011); a process termed the Warburg effect 
(Warburg, 1956). The impact of glucocorticoids on glucose availability is therefore a 
concern, as the increased amount of available glucose could stimulate enhanced 
glycolysis and increased proliferation of cancer cells. This has been suggested to occur 
during treatment of glioblastoma with corticosteroids (Seyfried et al., 2010) although 
it has not yet been thoroughly investigated. The same argument is of relevance to 
tumour angiogenesis, as endothelial cells are also highly glycolytic (De Bock et al., 
2013; Vandekeere et al., 2015) and inhibiting glycolysis suppresses tumour growth 
(Clem et al., 2008). 
Determining the influence of glucocorticoids on intra-tumour immunity and 
inflammation is highly complex, not only because of the sometimes contrasting effects 
of immune inflammatory cells on tumour progression, but also due to the differential 
effects of glucocorticoids on inflammation, depending on concentration (Bernabé et 
al., 2011; Itoi et al., 2013) and inflammatory context (Chapman et al., 2013a). 
Likewise, different cancer subtypes express variable levels of GR and of the 11β-
HSDs, affecting their sensitivity to glucocorticoids (reviewed by Azher et al., (2016)). 
Viaje et al. (1977) demonstrated the anti-tumour effects of synthetic glucocorticoids 
in preventing the induction of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced 
mouse skin cancer, but did not examine the role of anti-inflammatory steroid in 
established carcinoma progression. 
Despite this large body of evidence suggesting that glucocorticoids can promote 
tumour progression, there are also findings in the contrary. Over three decades ago, 
Folkman et al., (1983) performed their pioneering experiments demonstrating the 
angiostatic and anti-metastatic effects of glucocorticoids (in combination with heparin) 
on tumours. More recently, Yano et al. (2006) demonstrated that dexamethasone (1-
1000nM) suppressed VEGF and IL-8 production via binding at the GR in vitro, and 
glucocorticoids have shown suppressive effects in preclinical models of ovarian cancer 
via activation of mIR-708, leading to suppressed metastasis (Lin et al., 2015). 
Furthermore, mice injected with 1µg dexamethasone showed reduced growth of 
xenograft tumours in vivo, though potential metastases were not investigated. Work by 
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Schiffelers et al. (2005) also found that prednisolone encapsulated in liposomes could 
accumulate within colon-carcinoma and melanoma-derived tumours and inhibit their 
growth. Of note, these studies, like others (Crowley et al., 1988), did not observe an 
inhibitory effect of glucocorticoids on tumour cell growth in vitro and did not see a 
change in tumour vessel number, potentially implicating other cells of the 
microenvironment (immune inflammatory cells/fibroblasts) in the anti-tumour 
process. The role of local glucocorticoid signalling within the tumour 
microenvironment has been subject to increasing interest in recent years (for reviews 
see Volden and Conzen, 2013; Azher et al., 2016; Lin and Wang, 2016).  
In some circumstances, it is overly simplistic to view the effects of glucocorticoids on 
tumour as ‘positive or negative’ alone. In bladder cancer, for example, dexamethasone 
binding at the GR was shown to, on the one hand, inhibit apoptosis and slightly 
augment the growth of xenografts in mice, but on the other hand it reduced the 
expression of MMP 2/9 and IL-6, and prevented epithelial-mesenchymal-transition 
(EMT), leading to reduced invasiveness (Zheng et al., 2012).  
 11β-HSDs and tumours 
An abundance of evidence indicates that glucocorticoids can affect tumour growth. 
However, the majority of this work has focussed on delivery of pharmacological doses 
of synthetic glucocorticoids, as opposed to manipulation of endogenous levels. The 
role of the 11β-HSDs in tumour growth has only attracted relatively recent interest 
(Azher et al., 2016; Liu et al., 2016; Cirillo et al., 2017). Glucocorticoids exert a 
powerful influence on the immune system, the inflammatory response, fibrosis and 
ECM deposition, and angiogenesis. Thus, 11β-HSD1 inhibition and subsequent 
changes in local glucocorticoid levels could affect almost every aspect of the tumour 
microenvironment, as well as potentially glucose handling in the highly metabolically-
active tumour cell population (Figure 1.4).  
Review of cancer genomics data sets available via the cBioPortal for Cancer Genomics 
(Cerami et al., 2012) reveals amplification of HSD11B1 expression in 8-10% of breast 
and hepatobiliary cancer studies, while around 8% of cutaneous melanomas show 
either mutation (4%) or amplification (4%) of the gene. Altered expression of 
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HSD11B1 is also apparent in around 5% of studies on endometrial cancers, non-
Hodgkin lymphomas, non-small cell lung cancers and melanomas. Of note, around 3-
5% of oesophageal and lung SCC studies and around 2% of PDAC studies show 
amplified HSD11B1 expression. Examination of HSD11B2 in the same data sets 
reveals amplification of the gene in 2-3% of adrenocortical carcinoma and bladder 
cancer studies, loss of the gene in around 2% of prostate and ovarian cancers and 
altered gene expression in 1.5-2% of esophogastric, breast and endometrial cancers. 
Overall, alterations in expression are marginally more common for HSD11B1 (3.3% 
of samples) than for HSD11B2 (1.1% of samples). 
Only one recent study has directly addressed the impact of 11β-HSD1 overexpression 
on tumour growth (Liu et al., 2016). In this study, decreased 11β-HSD1 expression 
was seen in HCC samples as compared to healthy liver tissue, and was predictive of 
poor prognosis. The liver is a key glucocorticoid-sensitive organ involved in regulating 
systemic glucose homeostasis (Kuo et al., 2015). Liu et al., (2016) report that 11β-
HSD1 overexpression impaired glucose uptake and glycolysis in HCC cells in vitro, 
and also reduced angiogenic sprouting and HUVEC migration, in keeping with the 
known physiological effects of glucocorticoids (Small et al., 2005; Kuo et al., 2015). 
In terms of direct effects on tumour cells, overexpression of 11β-HSD1 (via lentivirally 
induction) significantly decreased HCC cell mobility and invasiveness in vitro. 11β-
HSD1 overexpression also attenuated growth potential of HCC cells, an effect that was 
reversed by the GR antagonist mifepristone, suggesting it was mediated via increased 
cortisol availability. Injection of 11β-HSD1 overexpressing HCC cells into Balb/C 
nude mice resulted in decreased tumour growth, weight, vessel density and 18F-
fludeoxyglucose (FDG) accumulation in vivo (Liu et al., 2016). Analysis of factors 
expressed by cells showed that 11β-HSD1 overexpression reduced HIF-1α and VEGF 
expression, as well as several MMPs (2, 3, 9, 12 and 14) and ANGPTL4, suggesting 
an anti-angiogenic effect likely as a result of increased glucocorticoid levels. These 
findings strongly implicate glucose homeostasis as a mechanism, though a significant 
shortcoming of this study is the use of Balb/C mice; although necessary for use in 
conjunction with human cells, these mice lack a functional T-cell response and thus 
conclusions cannot be drawn relating to the inflammatory immune response. This is 
especially important in light of recent evidence demonstrating that locally produced 
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cortisol binds GR to inhibit anti-tumour CD8+ T-cell proliferation (Cirillo et al., 
2017). It is likely that 11β-HSD1 inhibition will have differential effects on different 
tumour types depending on the function of the original healthy tissue. 
Alterations in the expression of the 11β-HSD isozymes is likely to be of great 
importance in malignancy. Rabbitt et al. (2002) generated osteosarcoma cell lines 
which overexpressed either 11β-HSD1 or 2 and saw decreased or increased 
proliferation, respectively, leading them to conclude that activated glucocorticoids 
constrain tumour cell proliferation, and that the 11β-HSDs provide pre-receptor 
control of this process. A second group has published similar findings (Woitge et al., 
2001). Of note, these changes in enzyme expression and proliferative potential were 
not accompanied by a change in GR expression.  These findings suggest that a switch 
in enzyme expression may occur as part of both pathophysiology and normal 
development. 11β-HSD2 for example is expressed in bone during development 
(Condon et al., 1998), while 11β-HSD1 expression increases with age (Cooper et al., 
2002). The opposite may be true in malignant tissues; a consistent observation across 
a variety of tumour types is that expression of the type I isozyme is decreased and the 
type II isozyme increased in comparison to healthy tissue. 11β-HSD2 has even been 
suggested as a putative oncogene that enhances proliferative and neoplastic potential 
in GR-rich tissues, while gene therapy to increase 11β-HSD1 expression could prove 
effective as an anti-tumour therapy (Rabbitt et al., 2003b).  
This pathophysiological ‘switch’ has been reported in adrenal carcinoma and adenoma 
(Coulter et al., 1999), colon carcinoma (Pácha et al., 2002; Takahashi et al., 2008), 
myeloid leukaemia (Gingras and Margolin, 2000), prostate (Dovio et al., 2009), 
osteosarcoma (Bland et al., 1999; Cooper et al., 2000) and HCC (Liu et al., 2016).  In 
breast (Hundertmark et al., 1997; Koyama et al., 2001) and endometrial (Koyama and 
Krozowski, 2001) cancer cell lines, the same patterns have been reported and 
inhibition of 11β-HSD2 activity reduced cell proliferation (Hundertmark et al., 1997; 
Koyama and Krozowski, 2001). High 11β-HSD2 activity is also seen in ovarian cancer 
(Temkin et al., 2006) and potentially enhances tumour progression by reducing the 
anti-inflammatory effects of cortisol. Importantly, the same effect has been observed 
in human pituitary tumours (Korbonits et al., 2001; Rabbitt et al., 2003a). This is of 
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particular relevance as the pituitary is responsible for negative regulation of ACTH 
release; thus enhanced inactivation of cortisol by elevated 11β-HSD2 is likely to blunt 
negative feedback and increase systemic cortisol levels. This process has been 
implicated in the pathophysiology of Cushing’s syndrome (Korbonits et al., 2001). A 
notable exception are the SCCs; in these cancers, 11β-HSD1 expression is reduced 
compared to healthy skin, but is still detectable (Gronau et al., 2002) whereas 11β-












Figure 1.4 – Potential tumour-promoting effects of 11β-HSD1 inhibition. The tumour 
microenvironment is composed of tumour cells (TCs), cancer associated fibroblasts (CAFs), 
immune/inflammatory cells, and blood vessels (comprised of endothelial cells (ECs) and their 
supporting mural cells (pericytes/smooth muscle cells)). Most of these cell types contain 11β-
HSD1, and the supporting literature suggests that inhibition of the enzyme may promote TC 
glycolysis and proliferation, a loss of tumour constraining extracellular matrix and anti-tumour 
immunosurveillance, and promotion of angiogenesis via increased inflammatory stimuli and 








11β-HSD1 inhibition may: 
• Promote 
angiogenesis 
Paracrine effect of reduced 
cortisol may: 




11β-HSD1 inhibition may: 
• Promote M2 
macrophage 
polarisation 
11β-HSD1 inhibition may: 
• Promote TC 
glycolysis 
• Promote TC 
proliferation 
T-cells Extracellular 
Matrix (ECM) Paracrine effect of reduced 
cortisol may: 
• Suppress anti-tumour 
immunity 
11β-HSD1 inhibition may: 
• Reduce tumour-constraining 
ECM deposition 
• Promote CAF proliferation 
(stimulating angiogenesis) 
Chapter 1 - Introduction 
73 
 
 11β-HSD1 and skin cancer 
11β-HSD1 expression was originally described in the skin by Teelucksingh et al. 
(1990). Over the last decade, the role of de novo steroidogenesis and steroid 
regeneration by 11β-HSD1 in skin, both healthy and diseased, has proven to be of 
particular importance (Cirillo and Prime, 2011; Slominski et al., 2014; Azher et al., 
2016; Terao and Katayama, 2016). 11β-HSD1 is expressed in all layers of the 
epidermis, as well as in dermal fibroblasts (Terao et al., 2011; Tiganescu et al., 2011). 
Pharmacological doses of glucocorticoids potently induce skin atrophy, associated 
with decreased Type I and III collagen deposition (Oishi et al., 2002). Reducing 
physiological levels of glucocorticoids by 11β-HSD1 inhibition/deletion stimulates 
fibrosis (Tiganescu et al., 2013). This is likely the result of increased fibroblast 
proliferation, as 11β-HSD1 inhibition/deletion was seen to increase fibroblast 
proliferation and dermal thickness in mice (Tiganescu et al., 2013; Terao et al., 2014). 
It is worth noting that Terao et al. (2014) did not observe increased fibroblast 
proliferation in vivo in 11β-HSD1 KO mice, only in WT mice given an 11β-HSD1 
inhibitor. This could either suggest off-target effects or that acute inhibition of enzyme 
function may sometimes confer an alternative phenotype to chronic deletion. 11β-
HSD1 inhibition also promoted keratinocyte proliferation and enhanced wound 
healing in mice (Terao et al., 2011). 11β-HSD1 content in skin has been shown to 
increase with age (Tiganescu et al., 2011) and after inflammatory stimuli (Itoi et al., 
2013), and 11β-HSD1 KO mice are protected from the adverse effects of skin aging 
(Tiganescu et al., 2013). Together, the studies above suggest an important role for the 
enzyme in skin homeostasis.  
Binding of glucocorticoids to the GR is thought to be of more importance than binding 
at the MR in terms of keratinocyte proliferation, motility and migration, as transgenic 
overexpression of the GR in mice slows wound healing, reduces macrophage and 
granulocyte recruitment, and reduces IL-1β, TNF and VEGF expression (Stojadinovic 
et al., 2006; Sanchis et al., 2012). Importantly, this effect must be mediated by 
endogenous GCs rather than exogenous synthetic equivalents. Glucocorticoids 
suppress a huge range of IFN-γ related genes (Stojadinovic et al., 2006) and prolong 
epidermal turnover time (Choi et al., 2006). The discovery that keratinocytes contain 
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all the enzymes required for non-adrenal steroidogenesis, and that glucocorticoid 
availability in these cells is under regulation by the 11β-HSDs (Cirillo and Prime, 
2011), brings into question the importance of local glucocorticoid regeneration in skin 
cancer. Evidence suggests that the expression of GR is especially high across a variety 
of SCC cell lines (Budunova et al., 1997; Spiegelman et al., 1997), and is even 
sometimes upregulated in SCC compared to normal epidermis (Budunova et al., 
1997), emphasising the potential glucocorticoid sensitivity of this cancer type. GR 
function may be compromised in tumours, based on the lack of changes in 
metallothionein 1 (Budunova et al., 1997; Spiegelman et al., 1997) and connexin 26 
(GR-regulated genes) (Budunova et al., 1997) after exposure to glucocorticoids in 
tumour cells. Budunova et al. (1997) also saw GR mRNA was decreased in tumour 
cells after exposure to glucocorticoids, an effect interestingly absent in the surrounding 
skin.  
The skin responds dynamically to inflammatory stimuli, with physiologically-relevant 
glucocorticoid concentrations inducing IL-6 expression in keratinocytes and 
pharmacological doses attenuating IL-6 release (Itoi et al., 2013). The same 
differential effects of low and high dose corticosteroids have been seen in SCC cells 
(Bernabé et al., 2011), with low doses stimulating IL-6 release and enhancing tumour 
cell proliferation. IL-6 is associated with angiogenesis and tumour progression 
(Heikkilä et al., 2008) and is correlated with poor prognosis in SCC of the head and 
neck (Duffy et al., 2008), suggesting that manipulating local glucocorticoid levels may 
affect SCC progression. Furthermore, inflammatory mast cells, which express 11β-
HSD1 (Coutinho et al., 2013), are known to promote fibroblast recruitment, 
angiogenesis and tumour progression in SCC (Coussens et al., 1999). There is also 
evidence to suggest that steroid synthesised de novo by malignant keratinocytes may 
promote anchorage independence and promote invasiveness (Kennedy et al., 2015).  
In terms of enzyme expression, basal cell carcinoma (BCC), SCC and seborrheic 
keratosis all show reduced (but detectable) levels of 11β-HSD1 compared to healthy 
skin, potentially due to their hyperproliferative state (Terao et al., 2013). 11β-HSD2 is 
elevated in SK and BCC compared to healthy skin, but is barely detectable in SCC 
(Cirillo et al., 2012; Terao et al., 2013), again highlighting the unusual glucocorticoid 
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regulation in this particular class of cancers. Cirillo et al. (2017) recently reported 
detection of both 11β-HSD1 activity and low levels of 11β-HSD2 in human SCC by 
immunohistochemistry, and argue that inhibition of the type 2 isozyme affects the 
invasiveness of some SCC cell lines; however, they were only able to demonstrate an 
effect on cell behaviour in one of the three SCC lines tested.   
The phenotype and metastatic potential of a tumour is influenced by the non-cellular 
ECM network of the tumour microenvironment (Cretu and Brooks, 2007). Elevated 
11β-HSD1 increases local glucocorticoid availability which reduces collagen 
deposition, which may enhance tumour progression and metastasis (Willhauck et al., 
2006; Cretu and Brooks, 2007). Thus 11β-HSD1 inhibition may promote collagen 
deposition and enhance ECM integrity. Enhancing ECM integrity has previously been 
shown to have a beneficial anti-tumour effect; stromal modulation inhibited tumour 
angiogenesis and the invasiveness of SCC cells – the fibrotic tissue induced led to the 
accumulation of myofibroblasts and collagen and enhanced the production of an intact 
basement membrane (Willhauck et al., 2006). The beneficial alteration in tumour 
phenotype was not related to altered tumour cell proliferation, but was due rather to 
increased ECM condensation and reduction of peritumoural protease activity. VEGFR 
expression was altered, and a corresponding increase in TSP-1 and endostatin 
suggested an additional powerful anti-angiogenic phenotype. This ECM normalisation 
highlights the importance of the non-cellular TME and further implicates 11β-HSD1 
in SCC progression (Tiganescu et al., 2013). 
1.7 Hypothesis and Aims 
The work described in this thesis was designed to test the following hypothesis: 
11β-HSD1 inhibition will promote tumour angiogenesis and, consequently, enhance 
solid tumour growth.  
Specifically, the experiments presented were designed with the following primary 
aims: 
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1. To determine whether pharmacological inhibition or genetic ablation of 11β-
HSD1 promote tumour growth and angiogenesis in murine models of 
squamous cell carcinoma and pancreatic ductal adenocarcinoma. 
2. To determine the effects of pharmacological 11β-HSD1 inhibition and 
exogenous glucocorticoids on ex vivo angiogenesis, and in vitro tumour cell 
growth. 
3. To determine the effects of 11β-HSD1 inhibition on the tumour 
microenvironment and investigate mechanisms by which glucocorticoid 
manipulation might influence tumour growth.
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
Unless otherwise stated all chemicals and reagents were purchased from Sigma-
Aldrich (Gillingham, UK). All High-Performance Liquid Chromatography (HPLC)-
grade chemicals were purchased from VWR (Lutterworth, UK). Scintillation fluid 
(Pro-flow G+) was purchased from Meridian Biotech (Tadworth, UK).  
2.1.2 Buffers  
C buffer:  63g Glycerol, 8.77g NaCl, 186mg Ethylenediaminetetraacetic acid (EDTA), 
3.03g Tris, made up to 500mL with distilled H2O and pH adjusted to 7.7. Stored at 
4°C.    
Phosphate Buffered Saline (PBS): 10 x PBS tablets (Thermo-Fisher Scientific, 
Renfrew, UK) dissolved in 1L dH2O. Stored at room temperature.  
Tris-Buffered Saline (TBS): 6.05g Tris, 8.76g NaCl made up to 800mL with distilled 
H2O and pH adjusted to 7.6. Made up to 1L with distilled H2O and stored at 4°C. 
Homogenisation buffer: 100g Glycerol, 300mg Tris, 186mg EDTA, made up to 
500mL with distilled H2O and pH adjusted to 7.5. Stored at 4°C. 7.7mg 1,4-
Dithiothreitol (DTT) added per 50mL before use. 
Citrate buffer:  Prepared and stored as a 10x solution - tri-sodium citrate (dehydrate) 
29.4g, 1000mL distilled H2O. Diluted 1:10 in distilled H2O, pH adjusted to 6.0 and 
0.1% Tween-20 added before use. 
EDTA 
0.5M solution prepared by adding 93.05 grams EDTA disodium salt dissolved in 
400mL distilled H2O and pH adjusted to 8.0 with sodium hydroxide (NaOH). When 
salt dissolved, solution made up to 500mL with distilled H2O. 




50x stock solution: 242 grams of Tris base dissolved in 750mL distilled H2O + 57.1 
mL glacial acid and 100 milliliters of 0.5 M EDTA. Made up to a final volume of 1L 
with distilled H2O.  
2.1.3 Drugs 
 11β-HSD1 inhibition in vivo 
Studies used the 11β-HSD1 inhibitor UE2316 ([4-(2-chlorophenyl-4-fluoro-1-
piperidinyl][5-(1H-pyrazol-4-yl)-3-thienyl]-methanone), synthesised by High Force 
Ltd (Durham, UK) (Webster et al., 2011).  For in vivo studies, UE2316 was delivered 
ad libitum to animals via an adjusted RM1 diet (175mg/kg UE2316) prepared by 
Special Diet Services (Essex, UK). UE2316 has an IC50 of 162nM for mouse 11β-
HSD1 (Sooy et al., 2010) and no significant off-target activities in selectivity 
screening, including against 11β-HSD2, 17β-HSD1 and GR (Yau et al., 2015). 
 11β-HSD1 inhibition in vitro 
 For in vitro studies, a 20mM UE2316 stock solution was stored at -20°C and diluted 
incrementally to give an appropriate final concentration in experimental solvent. The 
novel 11β-HSD1 inhibitor UE2341 (High Force Ltd.) (Webster et al., 2011) was used 
as an internal standard for mass spectrometry studies. 
 Systemic glucocorticoid manipulation 
Metyrapone (Cambridge Bioscience, Cambridge, UK) was used to inhibit adrenal 
corticosteroid synthesis in mice; the drug was dissolved in saline solution (10mg/mL) 
for intraperitoneal injection and used the same day. Corticosterone was delivered to 
animals via drinking water; 100mg corticosterone was added to 8mL ethanol and 
topped up with 392mL H2O to give a 10x holding stock (250µg/mL) which was diluted 
1/10 (drinking water was replaced every 2-3 days).  
2.1.4 Corticosteroids 
11-dehydrocorticosterone (Kendall’s compound ‘A’) and corticosterone (Kendall’s 
compound ‘B’) were purchased from Steraloids (Newport, USA) and stored at -20°C 
Chapter 2 – Materials and Methods 
80 
 
as 20mM stocks made up in ethanol (for in vitro studies) or methanol (for use in mass 
spectrometry). [9,11,12,12-2H4]cortisol was used as an internal standard in mass 
spectrometry studies. Stocks were diluted incrementally to an appropriate final 
concentration in experimental solvent. Tritiated steroid stocks (corticosterone and 
cortisone) were purchased from PerkinElmer (Wokingham, UK). For systemic 
glucocorticoid manipulation studies, corticosterone was delivered to animals via 
drinking water; 100mg corticosterone was added to 8mL ethanol and topped up with 
392mL H2O to give a 10x holding stock (250µg/mL) which was diluted 1/10 (drinking 
water was replaced every 2-3 days). 
2.1.5 Software 
Table 2.1 shows software details. 
Software Use Manufacturer 
Zen Blue edition 





ImageJ Image analysis See PMID 22743772 
MCID Basic 7.0 Non-fluorescent microscopy MCID 






Nanodrop 100 software 
v3.8.1 
Nanodrop RNA quality ThermoScientific 
Chromeleon v6.5 SP4 
Build 1000 
HPLC output ThermoScientific 
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See PMID 20436464 
Prism v7 Statistical analysis 
Graphpad (San Diego, 
USA) 
Table 2.1 – Software. Software used throughout project 
2.1.6 Plastics 
All sterile tissue culture plastic-ware was purchased from Corning (Wiesbaden, 
Germany). 
2.2 Animals 
C57BL6/J and FVB/N mice were purchased from Envigo (Blackthorn, UK) or Charles 
River (Elphinstone, UK). C57BL6/J mice globally deficient for 11β-HSD1 (Del1) 
were bred in house at the University of Edinburgh (Zhang et al., 2017). All 
experimental animals were female, and aged 9-14 weeks. Groups were age-matched. 
Animals were group housed (5 mice per cage maximum) and given free access to food 
and water unless otherwise stated. All procedures were carried out by a licensed 
individual and in strict accordance with the Animals (Scientific Procedures) Act 1986, 
under project Licence 70/8897 or 60/4523.         
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2.3 Methods        
2.3.1 Cell culture 
 Preparation of reagents 
All reagents were stored in sealed containers according to manufacturer’s advice and 
opened only inside a sterile Class 2 fume hood. Before use, foetal calf serum (FCS; 
Gibco (Invitrogen, Carlsbad, USA) was heat-inactivated by incubation for 30 minutes 
in a 57°C water bath. Where required, FCS was stripped by adding 1g of dextran 
charcoal to 50mL serum and incubating at 4°C on a gentle shaker overnight. Serum 
was spun by centrifuge (180 RCF x 5 min) and passed through a sterile 0.2µm filter 
(Merck-Millipore, Cork, Ireland) three times to minimise particulate contamination. 
Aliquots (1mL) were stored at -20°C. 
 Source of cells 
Studies made use of three immortalised murine cancer cell lines. Two SCC cell lines, 
WT-SCC cells (Serrels et al., 2012) and SCC-B6-1 cells, were generated in-house by 
Dr Alan Serrels using a two-stage 7,12-Dimethylbenz[a]anthracene (DMBA)/TPA 
chemical carcinogenesis protocol as previously described (McLean et al. 2004). 
Squamous cell carcinoma was selected based on multiple reports of altered local 
glucocorticoid profile in this cancer type (Azher et al., 2016). WT-SCC are 
syngeneically compatible with FVB/N mice, however the transgenic mouse line 
available in our group (Del1 - global 11β-HSD1 knockout) are bred on a C57BL6/J 
background. SCC-B6-1 cells served as an SCC cell-line compatible with Del1 mice to 
investigate the effects of enzyme deletion and inhibition. A PDAC cell line, Panc043 
cells, were provided by the Beatson Institute in Glasgow – these cells were originally 
derived from tumours developed using the KrasLSL.G12D/+; p53R172H/+; 
PdxCretg/+ (KPC) model (Hingorani et al., 2005) and were selected as an alternative 
tumour type that grow on the C57BL6/J background.  
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 Cell culture media 
 Panc043  
Panc-043 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% FCS.  
 WT-SCC  
WT-SCC cells were maintained in Glasgow Minimum Essential Medium (GMEM) 
supplemented with 10% FCS, 2mM L-Glutamine, 1mM sodium pyruvate, MEM non-
essential amino acids (Thermo-Fisher) and MEM vitamins. SCC-WT cells are Focal 
Adhesion Kinase (FAK) KO cells which have had FAK re-expressed using 
electroporation, and require selection via the addition of 0.25 mg/mL hygromycin B 
to media. 
 SCC-B6-1  
SCC-B6-1 cells were maintained in Glasgow Minimum Essential Medium (GMEM) 
supplemented with 10% FCS, 2mM L-Glutamine, 1mM sodium pyruvate, MEM non-
essential amino acids (Thermo-Fisher) and MEM vitamins. 
 Freezing media 
Cells were stored at -80°C in the appropriate cell culture medium (see above) + 20% 
FCS + 10% dimethyl sulfoxide (DMSO). 
 Cell maintenance 
 Serial passaging   
All cells were serially passaged (split 1/10 WT-SCC/Panc043 and 1/5 SCC-B6-1, 
every 2-3 days) and maintained at 37°C/5% CO2 in 25mL media in T150 flasks 
(Corning). All cell lines were adherent and were split by replacing media with 4mL 
trypsin (Thermo-Fisher Scientific) and incubating for 5 min at 37°C. Once cells were 
detached, trypsin was inactived by diluting 5:1 with medium, and an appropriate 
volume taken into a new flask. All experimental cells were used at <20 passages.  
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 Cell storage, thawing and freezing 
Cells were stored in liquid nitrogen when not in use. Cells were frozen by trypsinising 
a >70% confluent flask, pelleting the resulting cells by centrifuge (5 min x 180 RCF) 
and re-suspending in 10mL freezing media. 1mL aliquots were added to cryovials and 
stored at -80°C for 24 hours before transfer to liquid nitrogen for long-term storage. 
Cells were thawed quickly in a 37°C water bath and added to 25mL normal cell culture 
medium in a T150 flask. Cells were transferred to a 50mL Falcon tube, pelleted by 
centrifugation (5 min x 180 RCF) and resuspended in 25mL cell culture medium for 
transfer into a T150 flask.  
2.3.2 Solid tumour model 
In vivo studies of tumour growth used a model of subcutaneous tumour development 
(described previously in Serrels et al., 2015). 
 Diet alteration 
Diet was changed 5 days prior to cell injection for all experiments, to allow animals to 
adjust to the new diet. Diet and animals were weighed every 2-3 days from the point 
of diet change.  
 Cell injection 
Tumour cells in suspension were pelleted by centrifugation (180 RCF x 5 min) and re-
suspended in 20mL sterile PBS twice to remove media. Cells were counted by 
haemocytometer before pelleting and re-suspension in Hank’s Balanced Salt Solution 
(HBSS) to give a concentration of 10 x 106  cells/mL. Hair was removed from the 
flanks of mice by shaving and 100µL of cell suspension (1x106 cells) injected 
subcutaneously into each flank to produce 2 tumours per animal. As this procedure is 
relatively non-invasive, no analgaesia is required. 
 Tumour development 
Tumours were allowed to develop over the subsequent 1-6 weeks during which they 
were measured by callipers every 2-3 days. Tumour volume was calculated as the 
volume of an ellipsoid (0.5*length*breadth2). Mice and diet were weighed and mice 
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checked for any unexpected signs of ill health every 2-3 days. Tumour growth data is 
the mean ± SEM of the 2 tumours per animal. For UE2316-diet groups, diet was 
changed 5 days prior to cell injection and mice were weighed from the point at which 
diet was changed. Calliper measurements were blinded where possible by masking of 
cage labels and randomisation of cages by a second individual. 
 Tissue collection 
At the end of the experiment, mice were culled by cervical dislocation and tissues 
harvested. Blood was collected rapidly from the thoracic cavity using a syringe without 
a needle and stored in anti-coagulant EDTA-treated tubes (Sarstedt, Leicester, UK). 
Plasma was separated from whole blood by centrifugation (2000 RCF x 10 min at 4°C) 
for storage at -20°C. Tumours were weighed upon removal and halved (one half was 
snap frozen in liquid nitrogen for storage at -80°C, the other half was fixed in formalin 
for 24 hours before transfer to 70% ethanol before processing and embedding in 
paraffin wax). All other required tissues were removed and snap frozen in liquid 
nitrogen before storage at -80°C. 
2.3.3 Immunohistochemistry 
 Section preparation 
Paraffin embedded tissues were sectioned by microtome (5µm) and dried at 37°C 
overnight on electrostatically-adherent microscope slides (Superfrost plus, Thermo-
Fisher Scientific). 
 Hydration and dehydration of tissue sections 
Sections were rinsed in xylene (2 x 5 min), rehydrated through serial dilutions of 
ethanol (100% x 20s, 100% x 20s, 95% x 20s, 80% x 20s, 70% x 20s) and washed in 
H2O. Basic stains were rehydrated through serial dilutions of ethanol (50% x 20s, 75% 
x 20s, 95% x 20s, 100% x 20s) and rinsed in xylene (5 min) before mounting. 
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 Haematoxylin and Eosin staining 
Rehydrated sections were immersed in Harris haematoxylin (2 min), acid alcohol 
(15s), Scott’s tap water (20s) and eosin (5s), with a thorough H2O rinse between each 
step. Slides were dehydrated and mounted with DPX mountant. 
 Immunofluorescent staining 
Heat-based antigen retrieval was performed by immersing sections in pH6 citrate 
buffer and pressure cooking (5 min). Sections were permeabilised by immersion in 
PBS + 0.4% Triton-X for 15 minutes. Slides were fitted into Sequenza cassettes 
(Thermo-Fisher Scientific) and rinsed with PBS before blocking with 200µL of 1% 
normal goat serum (Biosera, Nuaille, France) for 30 minutes. Slides were incubated 
with 200µL primary antibody (18h, 4°C) with the exception of a negative control, for 
which PBS was added in lieu of antibody. After primary incubation, slides were rinsed 
with PBS and incubated with 200µL secondary antibody (1 hour, room temperature). 
After secondary incubation, slides were rinsed with PBS and incubated with DAPI 
(1/1000 in deionised water x 5 min) before a thorough final rinsing with deionised 
water. Slides were mounted using Fluoromount G (SouthernBiotech, Cambridge, UK) 
and stored at 4°C.  
 Imaging 
Slides were scanned at 200x magnification using an Axioscan.Z1 (Zeiss) digital slide 
scanner. Higher magnification images were obtained using the LSM710 confocal 
microscope (Zeiss). Gain and digital offset values were adjusted using negative control 
samples to remove background autofluorescence, and the same settings then used to 
image all specimens. 
2.3.4 Specific staining protocols 
 Vessel staining 
 CD31/α-SMA immunofluorescent co-stain 
Paraffin-embedded tumours (all types, 2 sections per tumour spaced 50µm apart, 
N=6/group) were stained using the basic protocol described in Section 2.3.3.4, using 
the antibodies detailed in Table 2.2.  
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Antibody Dilution Catalogue # 
CD-31 (primary) 1/300 Ab28364 (Abcam, 
Cambridge, UK) 
Goat anti-Rabbit IgG, 
Alexa Fluor 488 
(secondary) 
1/1000 A-11034 (Molecular 
Probes, Eugene, USA) 
α-SMA-cy3 (conjugated 
primary antibody) 
1/1000 – added with 
secondary antibody 
C6198 (Sigma) 
Table 2.2 – Antibodies used for vessel staining. Antibodies diluted in 200µL 1% goat 
serum/PBS. The conjugated primary and secondary antibodies were co-diluted and added to 
samples simultaneously.    
 CD31 DAB stain 
CD31 staining was performed by L. Boswell based at the Shared University Research 
Facility (SuRF). Staining was performed using the Leica BOND-III automated 
staining system and the Leica Bond Polymer Refine detection kit (Leica, Milton 
Keynes, UK). Rehydrated slides underwent citrate buffer antigen retrieval as above, 
followed by: bond wash (buffer solution purchased from Leica; 10 min), peroxidase 
blocking (5 min, 4% hydrogen peroxide, room temperature), bond wash, CD31 (Table 
2.2) antibody incubation (60 min), polymer incubation (15 min), bond wash, dH2O 
rinse, 3,3′-Diaminobenzidine staining (DAB; 10 min) and haematoxylin 
counterstaining (5 min), bond wash. Sections were then dehydrated and mounted with 
DPX mountant. 
 Vessel quantification 
 Manual vessel counts 
Tumour sections (prepared as described in Section 2.3.4.1.1) were imaged using the 
Axioscan.Z1 slide scanner (Zeiss). Vessels showed a relatively even distribution 
across the tumour, with no consistently predictable region associated with high 
vascular density, leading to the decision to use randomly generated fields of view for 
quantification. Zen Blue software (Zeiss) was used to demarcate 10 randomly selected 
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0.1mm2 fields of view from which vessels were manually quantified. CD31-positive 
only vessels and CD31/α-SMA positive vessels were both quantified to allow the ratio 
of vessels with smooth muscle coverage to be calculated. Two sections from the centre 
of the tumours, spaced 50µm apart, were quantified per tumour. Quantification was 
performed blinded to treatment group. 
 Chalkley counts 
As a secondary measure of vessel density, sections stained for CD31 (prepared as 
described in Section 2.3.4.1.2) were quantified by Chalkley count using the method 
described previously (Hansen et al., 2000). One section (three hotspots) was quantified 
per tumour. Quantification was performed blinded to treatment group. 
 Hotspot quantification 
As a tertiary measure of vessel density, sections were stained for CD31 (prepared as 
described in Section 2.3.5.1.2) and vascular hotspots identified for manual 
quantification (using an adapted version of the protocol described by Weidner, 2008). 
Hotspots were 0.74mm2 in area. Quantification was performed blinded to treatment 
group.  
 Identification of proliferating cells - Ki-67  
 Staining 
Ki67 staining was performed using the general methods described in Section 2.3.3.4 
using the antibodies described in Table 2.3.  
Antibody Dilution Catalogue # 
Ki-67 (primary) 1/100 Ab15580 (Abcam) 
Goat anti-Rabbit IgG, 
Alexa Fluor 488 
(secondary) 
1/1000 A-11034 (Molecular 
Probes) 
Table 2.3 – Antibodies used for Ki67 staining. Antibodies diluted in 200µL 1% goat 
serum/PBS.  





Sections were imaged by slide scanner (x20 magnification) and quantified 
automatically using ImageJ. Whole section images were duplicated and one copy 
converted to binary. This binary imaged was used to create a region of interest 
encompassing the entire section, which was then applied to the original image. The 
‘Measure’ function was then used to generate a read out of stain intensity. 
Fields of view 
Ki67-stained sections were also quantified semi-automatically; 2 sections/tumour 
were scanned at 200x magnification and the most proliferative region selected (this 
was performed by a blinded observer). This region was then imaged at 400x 
magnification and nuclei number calculated by ImageJ. Ki67-positive cells were then 
quantified manually per hotspot by a blinded observer and expressed as a percentage 
of total cells. 
 Identification of inflammatory cells - F4/80  
 Staining 
F4/80 staining was optimised by L. Boswell based at the Shared University Research 
Facility (SuRF). Staining was performed using the Leica BOND-III automated 
staining system and the Leica refine detection kit (Leica). Rehydrated slides underwent 
trypsin-based antigen retrieval (10 min, 37°C, 0.5mg/mL), peroxidase blocking (5 min, 
4% hydrogen peroxide, room temperature), serum blocking (30 min, anti-rat impress 
blocking serum; Vector labs, Peterborough, UK), primary antibody incubation 
(eBiosciences, cat no. 14-4801, 1:300, 30 min), ImmPRESSTM anti-rat Ig reagent 
incubation (30 min, Vector labs), 3,3′-Diaminobenzidine staining (DAB; 10 min) and 
haematoxylin counterstaining (5 min). Sections were then dehydrated and mounted 
with DPX mountant. 




F4/80 stained sections were imaged by slide scanner and whole sections were 
automatically quantified using ImageJ software. 
 Identification of T-cells – CD3 staining 
 Staining 
CD3 staining was performed by L. Boswell based at the Shared University Research 
Facility (SuRF). Staining was performed using the Leica BOND-III automated 
staining system and the Leica Bond Polymer Refine detection kit (Leica). Rehydrated 
slides underwent citrate buffer antigen retrieval as above, followed by: bond wash (10 
min), peroxidase blocking (5 min, 4% hydrogen peroxide, room temperature), bond 
wash, CD3 antibody incubation (Santa-Cruz, Dallas, USA; cat no. sc-20047, 60 min), 
polymer incubation (15 min), bond wash, dH2O rinse, 3,3′-Diaminobenzidine staining 
(DAB; 10 min) and haematoxylin counterstaining (5 min), bond wash. Sections were 
then dehydrated and mounted with DPX mountant. 
Whole section 
Sections were imaged by slide scanner (x20 magnification) and quantified 
automatically using ImageJ. Whole section images were duplicated and one copy 
converted to binary. This binary imaged was used to create a region of interest 
encompassing the entire section, which was then applied to the original image. The 
‘Measure’ function was then used to generate a readout of stain intensity. 
Hotspots 
1 section/tumour was scanned at 100x magnification and the two most intense regions 
of signal identified and imaged (this was performed by a blinded observer). Images 
were thresholded and percentage stain area measured on ImageJ. Data presented are 
the average of the two hotspots per tumour.   
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 Picrosirius-red staining 
 Staining 
Picrosirius red staining was performed by Debbie Mauchline (Shared University 
Research Facilities).  Working solutions of Direct red (0.1%) and Fast green (0.1%) 
were combined in equal parts and added to picric acid (1:9 ratio for a working 
solution). This solution was then filtered and stored at room temperature in the dark. 
Slides were dewaxed and rehydrated then rinsed in tap water. Slides were incubated in 
the PSR solution (2 hours at room temperature) in a covered box to reduce light 
exposure. After incubation, slides were rinsed in tap water and very briefly rinsed in 
100% ethanol (<5s). Slides were then allowed to dry before mounting with DPX 
mountant.  
 Quantification 
Slide scanner images were obtained and quantified automatically using ImageJ.   
 Second Harmonic Generation imaging 
 Image acquisition 
To visualise Type-I collagen specifically, Second Harmonic Generation (SHG) 
microscopy was performed by Dr Martin Lee on WT-SCC tumours (N=6/group), 
Panc043 tumours (N=3/group) and SCC-B6-1 tumours (Day 28 N=6/group, Day 41 
N=3/group). A tunable pump laser (720–990 nm, 7 ps, 80 MHz repetition rate) and a 
spatially overlapped second beam, termed the Stokes laser (1064, nm, 5–6 ps and 
80 MHz repetition rate), were both provided by a picoEmerald (APE) laser. The pump 
laser used 50 mW power (measured at the objective) and was tuned to 816.8 nm. The 
Stokes laser used 20 mW power (measured at the objective). This laser was inserted 
into an Olympus FV1000 microscope coupled with an Olympus XLPL25XWMP N.A. 
1.05 objective lens. The objective lens used a short-pass 690 nm dichroic mirror 
(Olympus). A series of filters (FF552-Di02, FF483/639-Di01 and FF420/40) were 
used to filter the Second Harmonic Generation signal.  
 Image analysis 
SHG images were quantified automatically using Image J. 
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2.3.5 Unsuccessful immunohistochemistry 
 Identification of fibroblasts - Vimentin  
 Staining 
In an attempt to quantify fibroblasts, WT-SCC tumours from control and UE2316-
diet-fed mice (N=6/group) were stained with vimentin. Vimentin staining was 
performed using the general methods described in Section 2.3.3.4 using the antibodies 
described in Table 2.4.  
Antibody Dilution Catalogue # 
Vimentin (primary) 1/100 5741 (Cell Signalling 
Technology, Danvers, 
USA) 
Goat anti-Rabbit IgG, 
Alexa Fluor 488 
(secondary) 
1/1000 A-11034 (Molecular 
Probes) 
Table 2.4 – Antibodies used for vimentin staining. Antibodies diluted in 200µL 1% goat 
serum/PBS.  
Unfortunately, this stain proved ineffective, as although it produced a strong 
cytoplasmic stain, it was expressed almost ubiquitously across the tumour (see Figure 























Figure 2.1 - Vimentin positive cells in WT-SCC tumours. Adding secondary antibody to 
tumours in the absence of primary antibody resulted in no immunoreactivity (A), while 
addition of the primary vimentin antibody produced a strong cytoplasmic stain (green) in most 
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 11β-HSD1 staining 
Early attempts to optimise staining for 11β-HSD1 using the protocol described in 
Section 2.3.3.4 proved ineffective, with positive signal masked by excessive 
background. An alternative method was optimised on the BOND automated staining 
system by Lyndsey Boswell and emulated at the bench using an adapted protocol by 
combining both an Immpress HRP Anti-Goat Ig (Peroxidase) Polymer detection kit 
(Vector Labs) and tyramide signal amplification. Slides were dewaxed, rehydrated, 
antigen retrieved and permeabalised as described in Section 2.3.3.4 (with TBS used 
instead of PBS to reflect BOND staining conditions). Blocking was performed using 
2.5% horse serum (30 min) before incubation with 11β-HSD1 antibody (developed in-
house by Dr Scott Webster, sheep-raised anti-rodent/human, diluted 1/200 in TBS + 
1% BSA) for 1 hour at room temperature. Slides were then incubated with goat 
Immpress polymer (30 min) followed by Cy-3 conjugated tyramide (10 min 1/50 
dilution, Perkin-Elmer) and counterstained with DAPI (1/1000 in distilled water). 
Slides were washed thoroughly with TBS between incubations, and with distilled 
water before mounting with aqueous mountant (Fluoromount-G, Southern Biotech) 
for imaging on an LSM710 confocal microscope (Zeiss). 
The 11β-HSD1 staining protocol was used to stain liver tissue from wild-type FVB/N 
and 11β-HSD1 knockout (Del1) mice, and tumour tissue from wild-type FVB/N mice. 
Unfortunately, imaging on the LSM710 microscope showed that non-specific binding 
was apparent in the tissue of the knockout animals (Figure 2.2), confirming that this 
protocol was ineffective. 11β-HSD1 immunostaining was subsequently abandoned in 

























Figure 2.2 – 11β-HSD1 immunofluorescent staining. 11β-HSD1 staining was performed on 
tumour tissue from wild-type (WT) FVB/N mice (top), and liver tissue from wild-type FVB/N 
mice (middle) and 11β-HSD1 knockout (Del1) mice (bottom). Whilst primary antibody-
negative controls did not show immunoreactivity, binding was apparent in all antibody-
positive tissues, including in the knockout animals. Tissues imaged at 400x magnification, 
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2.3.6 Real-time qPCR 
 RNA extraction 
Cell lines were grown to >70% confluence in a 6-well plate (Corning) and lysed for 2 
minutes using 600µL Qiazol (Qiagen, Manchester, UK). A cell scraper was used to 
ensure cells were detached before Qiazol was transfered to 1.5mL Eppendorf tubes. 
For tissues (except sponges, described below), 30mg of frozen tissue was homogenised 
in 600µL of Qiazol reagent in a 1.5mL Eppendorf tube using a tissue homogeniser 
(T10 Basic, IKA, Staufen, Germany) and allowed to settle at room temperature for 5 
minutes. 120µL of chloroform was added to samples which were vortexed and allowed 
to settle (2 min). Samples were subjected to centrifugation (12000 RCF x 15 min at 
4°C) and the resultant aqueous phase mixed with an equal volume of 70% ethanol. All 
subsequent on-column steps were performed as per the RNeasy manufacturer protocol. 
RNA concentration and integrity were assessed using the Nanodrop 1000 (Thermo-
Fisher Scientific).  
 RNA extraction from subcutaneous sponge tissue 
Sponges required an alternative extraction protocol due to their fibrous nature. Tissues 
were thoroughly homogenised in 700μl of Qiazol (2 min disruption followed by 
splitting of sample across two Eppendorf tubes, addition of a further 350μl of Qiazol 
and a further 1 min disruption). Samples were incubated at room temperature (5 min) 
before 200μl chloroform was added. They were then mixed by vortex and incubated 
at room temperature (2 min) before being spun (12000 x g, 15 min, 4°) and the aqueous 
phases for the same samples combined and added to an equal volume of 70% ethanol. 
Where the aqueous phase was insufficient, a further 200μl Qiazol was added and 
samples re-spun. All subsequent on-column steps were performed as per RNeasy 
protocol. 
 cDNA generation 
cDNA was generated from RNA using the QuantiTect Reverse Transcription Kit 
(Qiagen) as per manufacturer’s protocol. For the PCR reaction, samples were 
incubated at 42° for 15 minutes followed by 95° for 3 minutes in a Thermal cycler 
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(Techne-Cole-Palmer, Staffordshire, UK). A H2O control (H2O replacing RNA) and 
no-RT control (H2O replacing reverse transcriptase) were also prepared.  
 qPCR 
cDNA was diluted 1/40 in RNase-free water and a standard curve constructed by 
pooling 2μL of each sample and serially diluting. In triplicate on a 384-well plate, 2μL 
of sample was combined with 5µL of Lightcyler 480 Probes Master mastermix 
(Roche), primers (0.1μl/sample Forward and Reverse), probe (0.1μl/sample) and 
RNase-free water to make up to 10μL total volume. Plates were spun (420 RCF x 2 
min on LCM-3000 plate centrifuge (Grant Instruments, Royston, UK) before analysis 
on the Light Cycler 480 (Roche). Samples were run for 50 cycles (10s at 95° and 30s 
at 60°).  
Primer sequences and UPL probes are detailed in Table 2.5. All data were normalised 
to the average of two housekeeping genes (GAPDH and TBP) (Figure 2.3A and 2.3B 
and Figure 2.4) with the exception of one experiment which was normalised to 
GAPDH only (Figure 2.3C).  
Gene/accession number Sequence UPL 
Gapdh (glyceraldehyde 3-phosphate 
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Vegfr2 (vascular endothelial growth factor receptor 
2) - NM_010612.2 
acaagcatacgggcttgttt 
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Tnfrsf21 (tumor necrosis factor receptor superfamily 
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Table 2.5 – Details of primers and UPL probes used for qPCR. Forward (upper row) and 
































Figure 2.3 – Averaged housekeeping gene expression. GAPDH and TBP were selected and 
averaged to give housekeeping gene concentrations to which other gene expression could be 
normalised. A and B) No differences were seen between treatment groups within SCC tumour 
types, however higher expression was seen in SCC tumour cells. C) No differences were seen 
between treatment groups within Panc043 tumour types, and Panc043 cell expression did not 


















Figure 2.4 – Averaged housekeeping genes. GAPDH and TBP were selected and averaged 
to give housekeeping gene concentrations to which other gene expression could be normalised. 











To measure corticosterone in murine plasma, a corticosterone ELISA kit (Enzo Life 
Sciences) was used as per manufacturer’s instructions. Plates were read using a 
microplate reader (OPTImax; 405-580nm, 22.1°C).  
2.3.8 Enzyme activity assays 
 Protein assay 
Tissue samples were homogenised in homogenisation buffer (Section 2.1.2) and 
diluted (1/20). A BioRad protein DC assay (BioRad, Hemel-Hempsted, UK) was 
performed as per manufacturer’s instructions to determine protein concentration. 
Homogenates were stored undiluted at -80°C until needed. 
 Dehydrogenase activity assay for tissue homogenate 
Samples were prepared in duplicate and kept on ice. Samples were diluted in C buffer 
(Section 2.1.2) to the required concentration in a 250µL final volume, but made up to 
190µL in C buffer. For the final assay, 10µL 3H-B (250nM), 50µL NADP+ (2mM; 
Cambridge Bioscience) and 190µL sample were added to 12x75mm borosilicate glass 
culture tubes, which were covered with parafilm and incubated in a shaking water bath 
(37°C) (three controls were run at each time-point: a protein-free control; a co-factor 
free control; and a protein/co-factor free control; with buffer used in lieu). After 
incubation, samples were placed on ice, mixed with 1mL ethyl acetate by vortex and 
allowed to settle. The top layer was transferred by glass pipette to a Chromacol vial 
(Thermo-Fisher) and condensed under nitrogen gas at 60°C. Samples were re-
suspended in 600µL mobile phase (65% water, 15% acetonitrile, 25% methanol) and 
sealed. Based on optimisation experiments, protein concentration and incubation time 
differed between WT-SCC (0.5mg/mL, 90 min), Panc043 (0.5mg/mL, 24 hours) and 
SCC-B6-1 (0.125mg/mL, 90 min) tumour homogenates. The following controls were 
also prepared in duplicate: Buffer + B (buffer replacing protein and co-factor), no 
protein (buffer replacing protein) and no cofactor (buffer replacing cofactor). 
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 Reductase activity assay for intact tissue 
 Intact tissue incubation 
Whole liver and aorta were excised from mice killed by cervical dislocation. Liver was 
cut into small pieces and weighed (10-20mg). Aortae were weighed then sectioned 
into four rings (~3mm length). 4 pieces were cut from liver using sterile dissection 
equipment and weighed (5-20mg). Single liver pieces and whole aortae (four rings) 
were placed in wells of a 12 well plate in 1mL treatment media and incubated for 24 
hours (5% CO2, 37°C). Treatments were applied to each mouse in duplicate. UE2316-
treated liver pieces (N=6) were cultured in 1mL DMEM-F12 medium containing 
12.5nM 3H-cortisone and1µM cold cortisone and 300nM UE2316. Control liver pieces 
(N=6) were cultured in the above medium with vehicle added in lieu of UE2316. All 
wells had a final DMSO concentration of 0.3%. The following controls were also 
prepared: blank media; treatment control (+ treatment, no tissue); standard control 
(+0.5µl substrate in 1mL media). Media was aspirated after incubation and stored in 
7mL glass bijous (samples could be frozen at this point for later extraction). All 
samples were run in duplicate. 
 Extraction 
Samples were passed through Sep-Pak C-18 cartridges (Waters, Elstree, UK); Sep-
Paks were inserted into 20-position extraction manifold chamber (Waters) and a 5mL 
syringe used to prime columns with 5mL methanol, followed by 5mL HPLC-grade 
H2O. Samples (1mL) were added to the column, washed with 5mL HPLC-grade H2O 
and eluted with 2mL methanol for collection into 13 x 75mL tubes. These samples 
were dried down (N2, 60°C), resuspended in 200µL HPLC-grade H2O and ethyl 
acetate extraction performed (10:1, vortex sample with 2mL ethyl acetate and remove 
upper phase to 12.x75mL tube) to remove phenol red contamination. Samples were 
dried down, resuspended in 600µL mobile phase (60% water, 40% methanol), 
transferred to chromacol vials, and sealed.  
 High-Performance Liquid Chromatography 
Samples were detected by HPLC with online scintillation counting. Set-up consisted 
of an autosampler (717 plus) maintained at 4°C, a mobile phase pump (pump600, 
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Berthold, Harpenden, UK), a column heater and a radioflow detector (LB509, 
Berthold) connected to a scintillation fluid pump (flow: 2ml/min). 
 Elution of steroids 
200μL of sample were injected into the HPLC system, equipped with a C-18 Sunfire 
symmetry column (15cm length, 4.6mm diameter, pore size μm; Water, Edinburgh, 
UK). A run time of 35 minutes (60:15:25 mobile phase, 1.5ml.min flow, 35°C column 
temperature) was required to detect 11-DHC (elution time: 15.8 min) and 
corticosterone (elution time: 23.4 min). Detected peaks had a width <2 minutes and 
were at least 3x higher than background. A run time of 35 minutes (60:40 mobile 
phase, 1.2mL/min flow, 34°C column temperature) was used to detect cortisone 
(elution time: 22.9 min) and cortisol (elution time: 28.7 min).  
 Quantitation 
Peaks were manually integrated and converted to % substrate and product formed. 
Amount of product formed (nmol) was then calculated from the known amount of 
substrate and data were expressed as the reaction velocity (product formed per unit 
incubation time per unit protein concentration; nmol/min/mg).   
2.3.9 Liquid chromatography tandem mass spectrometry 
Initially, optimisation of a dual-extraction method for corticosteroids and UE2316 was 
attempted to conserve plasma. This approach proved problematic due to differences in 
the extraction efficiencies between compounds/solvents (superior recovery of steroids 
was achieved using chloroform, while UE2316 recovery was better with ethyl acetate). 
Thus separate extractions were performed for corticosteroids and UE2316.  
 Liquid-liquid extraction of corticosteroids from plasma samples 
A 12-point aqueous extracted standard curve was prepared in 100µL HPLC-grade H2O 
(0 - 50ng A/B) alongside plasma samples. 2.5ng internal standard (d4F) was added to 
all samples/standards and a double blank was prepared (no internal standard). 
Samples/standards were mixed with a 10x volume of chloroform, vortexed and 
allowed to settle. The upper solvent phase was transferred by glass pipette into a 3.5mL 
vial. Samples were concentrated under nitrogen gas at 60°C before resuspension in 
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70µL mobile phase (70:30 water/acetonitrile) and transfer to liquid chromatography 
(LC) vials (Waters).  
 Liquid-liquid extraction of UE2316 from plasma samples 
A 12-point aqueous-extracted standard curve was prepared in 150µL human plasma 
(0 - 500ng UE2316) alongside plasma samples. 2.5ng internal standard (UE2341) was 
added to all samples/standards and a double blank was prepared (no internal standard). 
Samples/standards were mixed with a 10x volume of ethyl acetate, vortexed and 
allowed to settle. The upper solvent phase was transferred by glass pipette into a 3.5mL 
vial. Samples concentrated under nitrogen gas at 60°C before resuspension in 70µL 
mobile phase (70:30 water/acetonitrile) and transfer to LC vials (Waters).  
 Liquid-liquid extraction of UE2316 and corticosteroids from liver 
and tumour samples 
 Tissue homogenisation 
200-400mg liver tissue (weights recorded) or tumour tissue (whole tumour, ~30-
50mg) was homogenised in 1mL Krebs buffer (Section 2.1.2) in 1.5mL Eppendorf 
tubes using a tissue homogeniser. Tissue was homogenised at full speed for 20s, 
allowed to settle, then homogenised for a further 10s to ensure complete tissue 
disruption. The homogeniser was cleaned with ethanol and 2 x distilled H2O rinses 
between samples. 10µL of a 250ng/mL UE2341/d4f internal standard combined stock 
was added to samples.  
 Tissue extraction 
Samples were spun by centrifuge (15 min x 16,100 x g, 4°C) and supernatant (approx. 
1mL) removed to a 13 x 100mm vial. A 5x volume of ethyl acetate was added and 
samples vortexed for 20s. Samples were then spun by centrifuge (2 min x 1000 x g, 
4°C) and the top (clear) layer transferred to a new 13 x 100mm vial by glass pipette 
(this step was performed twice). Samples were condensed under nitrogen gas at 60°C 
and resuspended in 2mL 30% methanol/H2O. These were then passed through Sep-
Pak C18 cartridges (5mL methanol prime, 5mL water prime, 2mL sample, 5mL water 
wash, elution with 2mL methanol), collected into 13 x 100 mL vials and condensed 
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under nitrogen gas at 60°C. Samples were then resuspended in 100µL of mobile phase 
(70:30 water:acetonitrile). 
A 10 point standard curve was prepared and extracted as described above in 1mL 
Krebs in the absence of tissue.  
 Optimisation of tissue extraction 
The method for extracting corticosteroids and UE2316 from tissue required 
optimisation to achieve clean samples with sufficient analyte detectability. 
Ethyl acetate extraction 
The optimal ratio of ethyl acetate to sample, and the number of ethyl acetate extractions 
required, were both determined by testing a range of ratios (3:1, 5:1 and 10:1 compared 
to unextracted analytes) and performing the extraction either once, twice or three 
times. Extractions were performed on 1mL H2O samples spiked with 10ng of 
A/B/UE216/2341/d4F, with samples in triplicate for each condition. Ethyl acetate 
extractions were performed and samples then condensed and resuspended in 100µL 
mobile phase (70:30 water:acetonitrile). Samples were measured as described in 
Section 2.3.8.4. As shown in Figure 2.5A, maximum recovery was achieved using a 
5:1 double extraction.   
Sep-Pak recovery 
Initial attempts to extract tissue without the addition of solid phase extraction resulted 
in cloudy samples with a fat-like contaminant. Solid phase extraction was thus 
considered as a clean-up step. To assess recovery with solid phase extraction, Sep paks 
were primed with 5mL methanol and 5mL H2O, followed by the addition of 5mL H2O 
spiked with 10ng A/B/UE2316/2341/d4F. Columns were washed with 5mL H2O wash, 
and samples eluted with 2mL methanol. Eluted samples were then condensed (nitrogen 
gas, 60°C) and resuspended in 100µL mobile phase (70:30 water:acetonitrile) and run 
alongside an unextracted preparation of 10ng A/B/2316/2341/d4F (run conditions as 
described in Section 2.3.8.4). Recovery was calculated by dividing extracted peak area 
by unextracted peak area. Solid phase extraction resulted in reduced recovery of all 
analytes, though all were still well within the limits of detection (Figure 2.5B). 
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Extraction recovery and matrix recovery 
To determine the relative contribution of the extraction process and the tissue matrix 
to signal loss, the recovery after solid phase extraction was calculated, as well as the 
matrix suppression caused by the tissue itself. This was determined by preparing, in 
triplicate; pre-spiked livers; post-spiked livers; and unextracted standards. Livers were 
from FVB/N mice. 10ng of analyte mixture (A/B/UE2316/UE2341/d4F) in 10µL 
methanol) was spiked onto pre-spiked liver, and extractions performed as described in 
Sections 2.3.9.3.1-2 (internal standard was only added as part of the pre-spike 
mixture). Post-spiked livers had the analyte mixture added in 100µL mobile phase 
(70:30 water:acetonitrile) after the extraction process. Unextracted standards were 
10µL of the analyte mixture condensed (nitrogen gas, 60°C) and resuspended in 100µL 
mobile phase. Extraction recovery was calculated by dividing pre-spike peak area by 
post-spike peak area. Matrix recovery was calculated by dividing post-spike peak area 
by unextracted peak area. A/d4F/UE2316 showed similar extraction and matrix 
recovery, while B showed superior recovery compared to other analytes (Figure 2.5C). 
UE2341 showed 41% signal attenuation in the presence of matrix however as an 






























Figure 2.5 - Tissue extraction optimisation for mass spectrometry. A) Analyte recovery 
plateaus at a 5 to 1 double extraction, identifying this approach as optimal. B) Recovery of 
analytes in water after sep-pak extraction, as expressed as % of unextracted sample. C) 
Extraction and matrix recovery were acceptable for all analytes, though signal attenuation is 
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 Tandem mass spectrometry 
Mass spectrometry staff (Dr Natalie Homer, George Just and Dr Karen Sooy) operated 
the mass spectrometer and decided upon appropriate analytical parameters for all mass 
spectrometry experiments. The mass spectrometry system used was a Nexera LC-
30AD Ultra High-Performance Liquid Chromatograph (UHPLC) connected to a 
Nexera SIL-30 AC autosampler (Shimadzu, Kyoto, Japan). The mass spectrometer 
was a QTRAP 6500+ operated with an electrospray ionisation Turbo V source 
(SCIEX, Framingham, USA). 30µL sample was injected onto a C18-AR column (Ace 
Excel, 2μm, 150x2.1mm). Analytes were eluted under a gradient of 30% acetonitrile 
increasing to 90% over 9 minutes at a flow rate of 0.5mL/min at 40°C.  Column 
temperature was 40°C and sample temperature 10°C. Ionisation was achieved by 
positive ion electrospray, using a spray voltage of 5500 V, temperature of 700°C, 
curtain gas pressure of 40 psi, ion source gas 1 40psi, ion source gas 2 60psi and 
entrance potential 10. Analytes were measured by multiple reaction monitoring 
(declustering potential, collision energy, cell exit potential): corticosterone m/z 
347→121 (66, 69, 8V); 11-DHC m/z 345→121 (51, 133, 8V); UE2316 m/z 389→177 
(100, 39, 15V); UE2341 (internal standard) m/z 356→177 (85, 37.5, 17V); D4F 
(internal standard) m/z 367→121 (121, 25, 20V). Peaks area ratios were compared 
with corresponding standards.  
2.3.10 Genotyping of Del1 animals 
Genomic DNA isolation was performed using a GeneJET genomic DNA purification 
kit (Thermofisher) as per manufacturer’s instructions.  
Primers (100µM stocks, Table 2.6) were combined in equal proportions to make a 
primermix solution. A mastermix solution was prepared (12.5µL biomix red (Bioline, 
London, UK) + 8.5µL dH2O per sample). 3μL primermix solution was added to 1μlL 
DNA/sample in a 0.2mL tube. Samples were transferred to a thermal cycler for initial 
denaturation (5 min x 95°C). 21µL mastermix was then added to each sample to give 
a total reaction volume of 25µl. Samples underwent 30 cycles (1 min x 95°C, 1 min x 
61°C, 2 min x 72°C) and a final extension step (10 min x 72°C). Samples were then 
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run on an agarose gel (1% agarose in TAE buffer, 120V, 45 min) and imaged on a UV 
transilluminator. 
Primer code Sequence (5’-3’) 
Yuri2oligo4 CAC TGC ATT CTA GTT GTG GTT TGT CC 
Ex1-3F1 TTC TTC GTG TGT CCT ACA GG 
Ex1-3R1 CCC GCC TTG ACA ATA AAT TG 
Table 2.6 - Genotyping primers.  
2.3.11 Aortic ring assay 
 Tissue collection 
8-12 week old female mice were culled (exposure to increasing concentration of CO2) 
and the thoracic aorta dissected out and trimmed of adipose tissue and branching 
vessels. Mice were pinned out and fur washed with ethanol. The thoracic cavity was 
opened and the lungs and oesophagus removed using dissection scissors and forceps. 
The aorta was severed proximal to the diaphragm and 0.5mL Opti-MEM (Thermo) 
was injected into the heart to flush blood out of the aorta. The aorta was then removed 
by applying gentle tension to the vessel and cutting through the perivascular fat and 
connective tissue with micro scissors and fine tip forceps. Isolated aortae were 
transferred to opti-MEM and trimmed of perivascular fat and smaller branching 
vessels, then sectioned into 18 rings (1mm length) using micro scissors and fine tip 
forceps. 
 Tissue culture 
Aortic rings were cultured in 96-well plates, prepared as follows; rat tail collagen 
(EMD Millipore, Massachusetts, USA) was diluted to 1mg/mL in Opti-MEM and pH 
adjusted using 10µl/mL 1N NaOH to give a pink colour. Collagen was stored on ice 
throughout the process. 50µL of collagen was added to wells and aortic rings 
embedded using forceps (this was performed quickly to prevent premature 
polymerisation of collagen). Rings were orientated so that the vessel lumen was 
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parallel to the bottom of the well. Plates were incubated for one hour at 37°C to allow 
collagen to set, after which 150µL of media was added. Treatments were added to 
rings in 150µl of Opti-MEM supplemented with 2% FCS (days 0-3), 0.5U/mL heparin 
and 5ng/mL VEGF. Media were changed on days 3 and 5 and vessels were imaged 
and quantified on day 7. An equal concentration of ethanol/DMSO was present in all 
wells (0.3%). 
 Vessel quantification 
Vessels were counted manually using the 10x objective lens on a culture microscope 
(Olympus CK40, Olympus, Southend-on-Sea, UK) on day 7, using the method 
described by Nicosia & Ottinetti (1990). For the 11-DHC curve in Section 4.2.1, 
vessels counts from day 6/7 were pooled as equipment failure necessitated early 
conclusion of the study, however growth was sufficiently healthy to allow for this. 
2.3.12 Optimisation of the aortic ring assay 
In order to confirm the ideal experimental conditions under which to measure the 
effects of glucocorticoids and UE2316 on ex vivo angiogenesis, the standard lab 
protocol was optimised.  
 Tissue collection 
Aortic rings were harvested from C57BL6/J mice (female, aged 10-12 weeks). For 
optimisation studies, a single mouse was used for each study. 
 Tissue culture 
 Basal media conditions optimisation 
Rings were cultured as described in Section 2.3.10.2, with treatments (Table 2.7) 
added to rings in 150µL opti-MEM. Exposures were performed in triplicate. Media 
were added at day 0, and changed on days 3, 5 and 7. Vessel counts were performed 
on days 5, 7 and 10. 
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Condition Day 0-3 Day 4-7 
FCS + VEGF 2% FCS + 5ng/mL VEGF 5ng/mL VEGF 
FCS only 2% FCS 2% FCS 
VEGF only 5ng/mL VEGF 5ng/mL VEGF 
Blank  - - 
Table 2.7 - Media conditions for aortic ring assay optimisation. Exposures were replicated 
in triplicate. 150μL of media were added to each well. Media were added at day 0 and changed 
on days 3, 5 and 7. Vessels were quantified on days 5, 7 and 10.  
2% FCS + 5ng/mL VEGF caused sustained vessel growth that continued to day 10. 
Removal of VEGF from media led to a peak vessel count at day 7, after which vessels 
began to regress. 5ng/mL VEGF or opti-MEM alone led to poor growth with vessels 
beginning to regress after day 5 (Figure 2.6). Comparison of vessel counts performed 
at day 7 suggests that 2% FCS + 5ng/mL VEGF stimulate the most vessel growth (62.7 
± 22 vessels), leading to selection of these conditions for future experiments. Day 7 



























Figure 2.6 - Aortic ring assay optimisation. A) Aortic rings respond differently to different 
basal media conditions. Foetal Calf Serum (FCS) was used only between days 0-3 while VEGF 
was maintained throughout. Stimulation with both VEGF and FCS caused enhanced growth 
that was sustained for 10+ days (i), while stimulation with FCS alone led to a growth peak at 
day 7 (ii). VEGF (iii) and opti-MEM (iv) alone led to poor growth with vessel growth peaking 
at day 5 before regression. Images taken at day 7. B) Day 7 counts indicate that 2% FCS + 
5ng/mL VEGF is the optimum basal media for the investigation. N=1, treatments in triplicate. 
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 Effect of heparin on vessel growth 
The presence of heparin is reportedly required to facilitate the angiostatic effects of 
glucocorticoids (Folkman et al., 1983). In preliminary experiments (not shown), 
higher concentrations of heparin (60U/mL) were found to inhibit vessel growth. Thus 
the present optimisation experiment was performed to determine the optimal 
concentration of heparin required. Rings were cultured as described in Section 
2.3.10.2, with treatments (Table 2.8) added to rings in 150µL opti-MEM media + 2% 
FCS (days 0-3) and 5ng/mL VEGF. Exposures were performed in triplicate. Media 
was added at day 0, and changed on days 3 and 5. Vessels were counted on day 7 only. 
 Heparin optimisation study 
Condition Vehicle/Corticosterone Heparin 
(U/mL) 
Vehicle 0.3% ethanol - 
Vehicle + low heparin 0.3% ethanol 1 
Vehicle + high heparin 0.3% ethanol 10 
Corticosterone 300nM corticosterone - 
Corticosterone + low heparin 300nM corticosterone 1 
Corticosterone + high heparin 300nM corticosterone 10 
Table 2.8 - Media conditions for heparin optimisation. Exposures were performed in 
triplicate. 150μL of media + 2% FCS (days 0-3) + 5ng/mL VEGF were added to each well. 
Media were added at day 0 and changed on days 3 and 5. Vessels were quantified on day 7.  
Aortic rings were cultured in the presence of vehicle or 300nM corticosterone, in 
media containing 0-10U/mL heparin (Figure 2.7). Increasing heparin concentration 
reduced vessel number. Adding 1U/mL heparin to aortic rings reduced vessel number 
in all rings by day 7 and amplified the reduction in vessels in the presence of 
corticosterone. Increasing the heparin concentration to 10U/mL caused severe 
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angiostasis in all ring to the degree that the angiostatic effects of corticosterone were 
slightly masked (61% decrease). Thus, a low concentration of heparin (0.5U/mL) was 










Figure 2.7 - Optimising heparin conditions for glucocorticoid aortic ring assays. A high 
concentration of heparin in aortic ring medium reduced the number of vessel outgrowths at 
Day 7, while removing heparin altogether appears to reduce the degree of corticosterone-
mediated angiostasis. 1U/mL causes a lesser degree of growth inhibition while still facilitating 
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2.3.13 Cell growth analysis  
 Manual cell counts 
Cells were seeded into 6-well plates at a density of 30,000 cells per well (number 
determined by preliminary experiment), topped up with 2mL media and left to adhere 
over 12 hours. Once cells were adhered, media was replaced with treatment media 
(vehicle control and UE2316 at 37.5nM, 75nM, 150nM, 300nM and 600nM). All 
treatments were in duplicate and each well contained an equal concentration of DMSO 
(0.6%). After 48 hours cells were trypsinised and pelleted by centrifugation (1000rpm 
x 5min) then resupended in 1mL media for counting. Counts were performed by 
haemocytometer - all data were expressed as % of control.  
 Live cell imaging and alamarBlue assay 
100µL cells in standard media (charcoal stripped FCS was used in these experiments, 
Section 2.3.1.1) were seeded into 96-well plates (Bio-Greiner) and left for 16 hours to 
adhere before media was replaced with 100µL of treatment media. Cells were seeded 
at a density of 10000 cells/mL (SCC-B6-1 and Panc-043) or 5000 cells per well (WT-
SCC). All treatments were in sextuplet and all wells contained an equal concentration 
of ethanol/DMSO (0.6%) as vehicle controls for corticosteroids and UE2316 
respectively. Plates were imaged over the subsequent 72 hours (1 image per three 
hours) using the Incucyte ZOOM Live-cell analysis system (Essen BioScience) and a 
threshold applied to provide a measure of confluence (Segmentation 0.4, cutoff 
400µm). After 72 hours, samples were incubated with 10µl of alamarBlue cell viability 
dye (Thermo-Fisher) for 3 hours and read by plate reader (Envision Multilabel, Perkin 
Elmer; filter settings of 560EX nm/590EM. Room temperature) to provide a secondary 
measure of viable cell number.  
2.3.14 Systemic corticosterone manipulation 
 Cell injection 
WT-SCC cells were prepared and injected subcutaneously into both flanks of FVB/N 
mice. Treatments began on the same day as tumour implantation and the final 
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injections were delivered 24 hours before the cull. Injection volume did not exceed 
0.3mL.  
 Tumour development 
Tumours were allowed to develop over the subsequent 14 days during which they were 
measured by callipers every 2-3 days. Measurements were blinded where possible by 
masking of cage labels and randomisation of cages by a second individual. Mice and 
diet were weighed and mice checked for any unexpected signs of ill health every 2-3 
days.  
 Tissue collection 
At the end of the experiment, mice were culled by cervical dislocation and tissues 
harvested. Blood was collected rapidly from the thoracic cavity using a syringe without 
a needle and stored in anti-coagulant EDTA-treated tubes (Sarstedt). Plasma was 
separated from whole blood by centrifugation (2000 RCF x 10 min at 4°C) for storage 
at -20°C. Tumours were weighed upon removal and halved (one half was snap frozen 
in liquid nitrogen for storage at -80°C, the other half was fixed in formalin for 24 hours 
before transfer to 70% ethanol before wax processing). All other required tissues were 
removed and snap frozen in liquid nitrogen before storage at -80°C. 
2.3.15 RNA-sequencing 
RNA was sequenced using a combination of paired and single-end RNA-sequencing 
by GATC Biotech (Constance, Germany).  
Bioinformatics analysis was kindly performed by Dr Stuart Aitken. Raw data (fastq 
files) were processed using Tophat2 (Trapnell et al., 2009), which was used to map 
reads to the mouse mm10 reference genome. Mapped data (bam files) were then 
processed using Cuffdiff (Trapnell et al., 2012), which was used to analyse differential 
gene expression between groups. A Principle Component Analysis (PCA) was 
performed to assess variance between samples (both between and within groups). 
DEseq2 (Love et al., 2014) was used for the PCA. 
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Gene ontology analysis was performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.8, which uses a modified Fisher 
Exact test to determine whether the proportion of genes in a given list is significantly 
associated with a pathway compared to the murine genome. 
2.4 Data analysis and statistics 
All statistics were performed using Prism software v6/7 (Graphpad). Data are 
presented as mean ± S.E. Outliers were identified using a Grubbs test and excluded 
appropriately. All data sets were tested for normality using the Shapiro-Wilk or 
Kolmogorov-Smirnov tests (dependent on sample size) and analysed appropriately 
based on the result. Non-parametric data were transformed where possible to allow for 
the use of parametric tests. Where this was not possible, non-parametric tests were 
used. Repeated-measures data with 2 or more independent variables were compared 
using repeated measures 2-way ANOVA, with Tukey’s post-hoc test where 
appropriate.  Two independent samples were compared using the independent samples 
t-test (or Mann-Whitney U test where data had a non-parametric distribution). Three 
or more independent samples were compared using one-way anova with Tukey’s post-
hoc test. The Kruskal-Wallis test was used to compare 3 or more independent groups 
of non-parametric data, with Dunn’s post-hoc test used to make specific comparisons. 
N number refers to the number of animals per group in an experiment, with the 
exception of cell culture studies, in which N number refers to biological repeats on 
separate days using the same cell line.  A P value of <0.05 was considered significant, 
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3 11β-HSD1 inhibition and tumour growth 
3.1 Introduction 
11β-HSD1 catalyses the conversion of inert glucocorticoids (11-
dehydrocorticosterone, cortisone) and their active counterparts (corticosterone, 
cortisol) (Seckl and Walker, 2001). Selective 11β-HSD1 inhibitors have been 
developed to improve glycaemic control in diabetic patients (Anderson and Walker, 
2013) and to improve cognitive function (Sooy et al., 2015). In addition to their 
beneficial effects on glucose homeostasis and cognition, 11β-HSD1 inhibition and 
deletion has been shown to increase angiogenesis, an effect that promotes wound 
healing and recovery after induced myocardial infarction in rodents (Small et al., 2005; 
McSweeney et al., 2010). 
The mechanisms behind this proangiogenic effect remain largely unknown. 
McSweeney et al. (2010) showed that increased recruitment of pro-reparative 
macrophages preceded enhanced angiogenesis, while Logie et al. (2010) found that 
glucocorticoids induced cytoskeletal changes and increased thrombospondin 1 (TSP-
1) expression in cultured endothelial cells. Although promotion of angiogenesis can 
be beneficial, there is a concern that 11β-HSD1 inhibitors could promote pathological 
angiogenesis such as that seen in tumour growth and proliferative diabetic retinopathy 
(PDR).  
Investigation of the retina in mice with systemic 11β-HSD1 inhibition/global deletion 
did not find evidence of enhanced pathological neovascularisation (Davidson et al., 
2017), suggesting that it is unlikely to exacerbate PDR. 11β-HSD1 was not present in 
the retinal vessels, which may explain the lack of effect seen in this model. This does 
not mean, however, that inhibiting 11β-HSD1 would not increase angiogenesis in other 
conditions. There is very little in the literature examining the role of 11β-HSD1 
specifically in tumours. Liu et al. (2016) report that overexpression of the enzyme in 
hepatocellular carcinoma decreased metastasis, angiogenesis and tumour size in mice 
via reduced glycolysis, suggesting that increased generation of active glucocorticoids 
could reduce tumour growth. The present studies used an established murine model of 
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subcutaneous solid tumour growth in conjunction with UE2316, a novel small 
molecule inhibitor of murine 11β-HSD1 developed at the University of Edinburgh 
(Sooy et al., 2015), to investigate this risk. 
The tumour cell lines used for these experiments have distinct genetic origins which 
may influence their response to 11β-HSD1 inhibition. Both SCC cell lines used were 
generated by using a two-stage DMBA/TPA chemical carcinogenesis protocol 
(McLean et al., 2004). This protocol primarily targets the Hras1 gene as an initiating 
mutation, predominantly in keratinocyte stem cells, while the promotion phase leads 
to trisomies of chromosomes 6 and 7 and mutations in the Trp53 gene in mutated cells 
(Abel et al., 2009). Of note, genetic background powerfully influences susceptibility 
to skin carcinogenesis; FVB/N mice are more sensitive than C57BL6/J mice to the 
chemical induction of SCC (Hennings et al., 1993). The PDAC cell line used in these 
experiments is derived from the KPC mouse, a transgenic model with targeted 
mutations in the Kras and Trp53 genes leading to the development of invasive PDAC 
(Hingorani et al., 2005). Prediciting the influence of tumour cell genetics on 11β-
HSD1 sensitivity is challenging given the lack of previous studies examining Ras 
mutations in the context of glucocorticoid exposure. The anti-angiogenic effects of 
glucocorticoids are mediated via the GR (Small et al., 2005), and glucocorticoids cause 
a reduction in VEGF (Yano et al., 2006) and an increase in the anti-angiogenic 
glycoprotein TSP-1 (Logie et al., 2010), thus these factors are likely to be of relevance 
to 11β-HSD1 inhibition. The expression of the glucocorticoid receptor (GR) and 
mineralocorticoid receptor (MR) and the two 11β-HSD isozymes in tumours may 
confer varying degrees of sensitivity; high levels of both 11β-HSD1 and GR have been 
reported in squamous cell carcinomas (SCCs) (Azher et al., 2016), identifying them as 
a tumour type potentially ‘at risk’ from 11β-HSD1 inhibition. 
Hypotheses 
The work described in this chapter addressed the hypotheses that: 
- 11β-HSD1 inhibition/deletion will increase vessel density in, and the growth of, 
subcutaneous murine tumours  
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- Tumours with higher levels of 11β-HSD1 and GR will be more responsive to 11β-
HSD1 inhibition than those with low levels of 11β-HSD1 and GR, showing a more 
rapid increase in size  
Objectives 
The specific aims of this work were: 
(1) To determine whether inhibition/deletion of 11β-HSD1 increased:  
(i) the size of subcutaneous tumours in mice 
(ii) vascular density within murine tumours 
(iii) mRNA levels of pro-angiogenic factors within murine tumours 
(2) To determine whether expression of GR and 11β-HSD1 in tumours predicts 
sensitivity to 11β-HSD1 inhibition 















3.2.1 11β-HSD1 inhibition enhances WT-SCC tumour growth 
To investigate the effect of 11β-HSD1 inhibition on WT-SCC tumour growth, mice 
were injected with WT-SCC cells and fed either control or UE2316-RM1 diet. In the 
first of two experimental repeats, WT-SCC cells were injected into FVB/N mice 
(female, aged 10 weeks) fed either control or UE2316 diet (N=3/group). Tumours were 
grown for 16 days but began to regress after 11 days, resulting in poor quality tissue 
that could not be used for downstream analysis. Therefore, a second study was 
performed (N=6/group) using an identical protocol but with a pre-defined endpoint 
(day 11 after implantation). Data up to day 11 were pooled and reported as N=9/group 
(Figure 3.1) with all subsequent downstream analyses performed using tissue from the 
second study (N=6/group). WT-SCC tumours from UE2316-diet fed animals grew 
rapidly from day 4 onwards and reached a greater final volume (0.126 ± 0.029 cm3) 
than mice fed standard RM-1 diet (day 11, 0.050 ± 0.006cm3) (Figure 3.1A). UE2316- 
and control diet fed groups consumed similar quantities of diet (3.58 ± 0.21g RM-1 vs 
3.30 ± 0.20g UE2316-RM1) and did not differ in weight throughout the experiment 
(Figure 3.1B and C). The estimated dosage achieved in the present studies (based on 


























Figure 3.1 – The 11β-HSD1 inhibitor UE2316 enhanced squamous cell carcinoma 
tumour growth. A) Enhanced tumour growth was apparent from day 4 onwards in UE2316 
diet-fed mice injected with the squamous cell carcinoma cell line WT-SCC. B) Mice consumed 
both UE2316 and control diets in comparable quantities. C) Neither WT-SCC cell injection 
(day 5) nor UE2316-diet introduction affected mouse weight. N=9/group. ** P<0.01. Data 
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 11β-HSD1 inhibition does not increase vessel density in WT-SCC 
tumours 
To investigate the effect of 11β-HSD1 inhibition on vessels in tumours, experimental 
WT-SCC tumours were sectioned and stained for CD31/α-SMA-positive structures 
(Figure 3.2), which were quantified. Vessels staining positive for CD31 only were 
quantified separately to allow for the proportion of vessels lacking smooth muscle 
coverage to be quantified, providing an indication of vessel maturity. H+E section 










Figure 3.2 – Identification of vessels in WT-SCC tumours. A) Tumour tissue from WT-
SCC tumours; endothelial cells are stained green (CD31 visualised with Alexa-Fluor 488) and 
smooth muscle cells are stained red (α-SMA visualised with Cy3). Nuclei are stained blue 
(DAPI). Tumours had densely packed nuclei and vessels were typically distinct from one 
another rather than forming complex branching networks. 200x magnification. Scale bar 
50µm. B) CD31 was also visualised with diaminobenzidine (DAB) for Chalkley counts. 200x 
magnification. Scale bar 50µm.C) Haematoxylin and eosin-stained WT-SCC tumour tissue, 
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The number of blood vessels per field of view did not differ between control (28.6 ± 
1.3 vessels/mm2) and UE2316-treated tumours (30.0 ± 1.9 vessels/mm2) (Figure 3.3A). 
The proportion of vessels lacking smooth muscle coverage did not differ between 
control (47 ± 6%) and UE2316-treated tumours (51 ± 4%) (Figure 3.3B). Vessel 
number as determined by Chalkley counts did not differ between control (6.1 ± 0.5 
counts) and UE2316-treated (6.0 ± 0.6 counts) mice (Figure 3.3C). Vascular hotspots 
did not differ in vessel number between control (179.4 ± 10.8) and UE2316-treated 











Figure 3.3 – UE2316 does not affect vessel density in WT-SCC tumours. Vessels in WT-
SCC tumours from controls and UE2316-treated mice were quantified using multiple methods. 
A)  No difference was seen in manually quantified vessel density between groups. B) There 
were no differences in the proportion of vessels lacking smooth muscle coverage (CD31 only). 
Chalkley counts (C) and hotspot quantification (D) were used to confirm vessel density – no 
differences were identified with either approach. Columns show mean ± standard error. 1 
section/tumour, N=6 animals/group. Data compared by independent samples t-test for panels 
A/B/D, Mann-Whitney U test for Panel C. 
A B 
C D 
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 Vessel density is not a predictor of tumour volume in UE2316-
treated tumours 
To determine whether vessel number correlated with tumour size, total vessel number 
per tumour was extrapolated by multiplying vessel density by section area. Total vessel 
number did not differ between control (1577 ± 458 vessels/section) and UE2316-diet 
fed mice (2520 ± 615 vessels/section; Figure 3.4A) and did not correlate with tumour 












Figure 3.4 – Total vessel number per tumour does not differ significantly between control 
and UE2316-treated tumours and does not predict tumour volume. A) The total vessel 
number per tumour section (calculated by multiplying vessel density by section area) did not 
differ between control and UE2316-treated WT-SCC tumours. Columns represent mean ± 
standard error. N=6/group; data compared by independent samples t-test. B) No relationship 
was found between tumour volume and absolute vessel number in either group. 1 
section/tumour, N=5-6/group. Data compared by Spearman’s rank correlation.  
A 
B 
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3.2.2 11β-HSD1 inhibition does not affect vessel density 
during early tumour development 
To address the concern that an earlier period of enhanced angiogenesis may have been 
missed, a short-term WT-SCC tumour study was performed. WT-SCC cells were 
injected into female FVB/N mice (aged 8 weeks) and tumours taken at the first 
palpable point (day 4 after injection). Tumour size in the UE2316-treated group did 
not differ significantly from controls at the day 4 time point (Figure 3.5A). 
Representative images of control (Figure 3.5B) and UE2316-treated tumours (Figure 
3.5C) are shown. Tumours in this study were small enough to allow for complete 
manual quantification across the tissue section (no randomised fields of view used). 
Vessel density showed a trend towards being decreased in UE2316-treated tumours 
(P=0.1089) (Figure 3.5D), while the proportion of vessels lacking α-SMA coverage 
showed a strong trend towards being increased in UE2316-treated tumours (P=0.0526) 
(Figure 3.5E). Neither of these results reached significance; power calculations (80% 
power target) suggested that a sample size of 15/group would detect a difference of 





























 Figure 3.5 – The effect of UE2316 on early vessel density in WT-SCC tumours. A) WT-
SCC tumours grown for four days showed no difference in size after UE2316 treatment. 
Representative images of CD31 (green)/α-smooth muscle actin (SMA; red) co-stained control 
(C) and UE2316-treated (D) tumours are shown – diagonal white arrows = vessels lacking 
smooth muscle coverage, horizontal arrows = larger vessels with smooth muscle coverage. 
The number of vessels in UE2316-treated tumours showed a trend towards being reduced (D), 
while the number of vessels lacking smooth muscle coverage showed the opposite trend (E). 
1 section/tumour. N=4-6 animals/group; Data represent mean ± standard error and were 
compared by independent samples t-test.  
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3.2.3 Effect of 11β-HSD1 inhibition on Panc043 tumour size 
and vessel density 
 11β-HSD1 inhibition does not affect Panc043 tumour growth 
The effects of 11β-HSD1 inhibition in an alternative cell line, Panc043, was next 
investigated. Based on the observation that Panc043 cells formed tumours more 
rapidly than WT-SCC tumours (A Serrels, personal communication), 0.25 x 106 
cells/flank were initially injected into C57BL6/J mice (female, aged 10 weeks) fed 
either control or UE2316 diet (N=6/group), as rapid tumour growth risks ulceration. 
Palpable tumours formed by day 4 and grew at an exponential rate until day 15 when 
the experiment was ended due to tumour ulceration. Tumour growth was not affected 
by UE2316 (Figure 3.6A). Mouse weight remained stable throughout the study and 
did not differ between groups (Figure 3.6B). Tumours ulcerated before reaching their 
expected volume (based on previous observations in the lab group). As reducing cell 
number did not appear to prevent ulceration after two weeks, for future experiments it 



























Figure 3.6 – Initial Panc043 tumour growth curve (0.25 x 106 cells/flank). A) Pancreatic 
Ductal Adenocarcinoma (Panc043) tumours grew rapidly between days 4-15 but ulcerated at 
this point. Administration of UE2316 in the diet (approximately 25-30 mg/kg/mouse/day) did 
not affect the growth of Panc043 tumours. B) Tumour cell injection and UE2316-diet did not 
affect mouse weight (first weights taken one day before cell injection). N=3-6/group. Data 
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In the second study, Panc043 cells (1 x 106/flank) were injected into C56BL6/J mice 
(female, aged 10 weeks) fed either control or UE2316 diet (N=6/group). Tumours grew 
rapidly and achieved greater volumes than those produced in the initial experiment in 
a similar timeframe. No differences were seen in the growth dynamics or final (day 
14) volume of tumours growing in wild-type mice fed control diet (0.299 ± 0.035 cm3) 
or UE2316 diet (0.251 ± 0.044 cm3) (Figure 3.7A). Mice ate on average less UE2316-
diet per day (2.92 ± 0.16 g) than control RM1-diet (3.58 ± 0.12g, P<0.01, Figure 3.7B) 












Figure 3.7 – The 11β-HSD1 inhibitor UE2316 does not affect Panc043 tumour growth. 
A) Administration of UE2316 in diet did not affect the growth of subcutaneously implanted 
Pancreatic Ductal Adenocarcinoma (Panc043) tumours. B) Mice consumed slightly less 
UE2316-diet than control RM-1 diet. **P<0.01. Data compared by independent samples t-
test. C) Neither Panc043 cell injection (day 5) nor UE2316-diet affected mouse weight, despite 
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 11β-HSD1 deletion does not affect Panc043 tumour growth 
The growth of Panc043 tumours in mice globally deficient in 11β-HSD1 was 
investigated. Del1 mice (bred on a C57BL6/J background) are homozygous for a 
deletion of exon 3 of the hsd11b1 gene (see Zhang et al., (2017)). Genomic DNA 
isolation was performed on liver samples (WT vs Del1, N=6/group). Mice were 
genotyped and deletion of the 11β-HSD1 enzyme confirmed (Figure 3.8). Panc043 
cells were injected into wildtype C57Bl6/J mice (female, aged 11-13 weeks) fed either 
control or UE2316 diet, and into Del1 mice on control diet (N=6/group). No 
differences were seen in the growth dynamics or final (day 16) volume of Panc043 
tumours growing in wild-type mice fed control diet (0.623 ± 0.107 cm3), Del1 mice 
fed control diet (0.573 ± 0.071 cm3) or wild-type mice fed UE2316 diet (0.722 ± 0.122 
cm3) (Figure 3.9A). Tumour weights confirmed this finding (Figure 3.9B). Diet did 
not affect mouse weight but age-matched Del1 mice were found to be significantly 
heavier than wild-type controls (average weight across experiment - Del1 23.84 ± 
0.11g vs control 20.61 ± 0.1g; P<0.01), a difference apparent from the experimental 
onset and throughout the protocol (Figure 3.9C). No differences were seen in the 

























Figure 3.8 – Del1 mice lack 11β-HSD1. A) Genotyping demonstrated the deletion of the 11β-
HSD1 gene in Del1 animals. Primers flanking the wildtype (WT) allele produced a 255 base 
pair (bp) product, while primers flanking the hsd11b1 knockout allele produced a 363bp 
product. B) qPCR for 11β-HSD1 in liver from wild-type (WT) and Del1 (11β-HSD1 
knockout) mice confirmed genetic deletion of this enzyme. N=6/group; data are mean ± 
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Figure 3.9 – Panc043 tumour growth is unaffected by 11β-HSD1 inhibition or deletion.  
A) Panc043 cells, a pancreatic ductal adenocarcinoma cell line, grew rapidly over 16 days. 
Neither administration of an 11β-HSD1 inhibitor (UE2316) in the diet nor genetic deletion of 
11β-HSD1 affected tumour growth. B) Tumour weights at day 16 reflected this. N=6/group. 
P=0.20. Data represent mean ± standard error and were compared by one-way ANOVA. 
N=6/group. C) Del1 mice were heavier than control and UE2316 diet-fed mice despite age 
matching. * P<0.01. N=6/group. Data represent mean ± standard error and were compared by 
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 11β-HSD1 inhibition does not increase vessel density in Panc043 
tumours 
To determine whether 11β-HSD1 affected vessels in Panc043 tumours, experimental 
Panc043 tumours (H+E section shown in Figure 3.10A) were sectioned and stained 
for CD31/α-SMA-positive structures, which were considered vessels and quantified. 
CD31 Panc043 tumours contained a large number of cells with α-SMA 
immunoreactivity without associated CD31-positive structures, likely myofibroblasts 
(Figure 3.10B). The number of blood vessels per field of view did not differ between 
control (10 ± 1 vessels/mm2) and UE2316-treated tumours (10 ± 1 vessels/mm2) 
(Figure 3.10C). The proportion of vessels lacking smooth muscle coverage did not 






























Figure 3.10 – UE2316 does not affect vessel density in Panc043 tumours. A) Haematoxylin 
and eosin-stained section of control Panc043 tumour tissue. 100x magnification. Scale bar 
200µm. B) Panc043 tumour tissue with endothelial cells stained green (CD31 visualised with 
Alexa-Fluor 488) and smooth muscle cells stained red (α-SMA visualised with Cy3). Nuclei 
stained blue (DAPI). Solid white arrows = non-vascular α-SMA immunoreactivity, likely in 
cancer-associated fibroblasts. Dashed white arrow = vessel with clear smooth muscle coating. 
Panc043 tumours were less vascularised than WT-SCC tumours. 200x magnification. Scale 
bar 50µm. C) No difference was seen in manually quantified vessel density between tumours 
from control and UE2316-diet fed mice. D) There were no differences in the proportion of 
vessels lacking smooth muscle coverage (CD31 only). 1 section/tumour, N=6 animals/group. 
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3.2.4 Effect of 11β-HSD1 inhibition on SCC-B6-1 tumour size 
and vessel density 
 11β-HSD1 inhibition or deletion does not affect SCC-B6-1 tumour 
growth 
11β-HSD1 inhibition and deletion were investigated using a second SCC cell line 
syngeneic on a C57BL6/J background. SCC-B6-1 cells were injected into wildtype 
C57Bl6/J mice (female, aged 13-14 weeks) fed either control or UE2316 diet, and into 
Del1 mice globally lacking 11β-HSD1 (N=6/group). SCC-B6-1 cells implanted into 
C57BL6/J mice (1x106 cells/flank) grew more slowly than WT-SCC and Panc043 
cells, achieving comparable volumes to WT-SCC tumours after 37 days. No 
significant differences were seen in the growth dynamics or final (day 37) volume of 
SCC-B6-1 tumours growing in wild-type mice fed control diet (0.221 ± 0.037 cm3), 
Del1 mice fed control diet (0.246 ± 0.031 cm3) or wild-type mice fed UE2316-
containing diet (0.289 ± 0.049 cm3) (Figure 3.11A). A pattern of increased tumour 
growth in UE2316-treated mice began from day 24 but did not reach significance 
before the study was ended for reasons of tissue integrity. 3 mice per group were taken 
to 37 days but tumour tissue at this time-point was unsuitable for further analysis. 
Subsequently, 6 mice per group were culled at day 28 – the time point at which the 
initial tumours had begun to show a potential size effect in relation to treatment. 
Consistent with these data, tumour weights did not differ between groups (Figure 
3.11B). The type of diet given to mice did not affect their weight but Del1 mice were 
found to be significantly heavier than wild-type controls (average weight across 
experiment - Del1 23.76 ± 0.08g vs control 21.63 ± 0.07g; P<0.01), a difference 
apparent from the experimental onset and throughout (Figure 3.11C). No differences 





















Figure 3.11 – SCC-B6-1 tumour growth is not substantially affected by 11β-HSD1 
inhibition or deletion.  A) Squamous cell carcinoma cells (SCC-B6-1 cell line) produced 
tumours that grew more slowly than the other two tumour types (WT-SCC and Panc043) over 
4-6 weeks. Administration of UE2316 in the diet, or genetic deletion of 11β-HSD1 did not 
affect tumour growth. B) Tumour weights at day 28 reflect this lack of effect. C) Del1 mice 
were heavier than control and UE2316 diet-fed mice despite age matching. * P<0.05. Data 
represent mean ± standard error and were compared by repeated measures two-way ANOVA 
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 The effect of 11β-HSD1 inhibition on vessel density in SCC-B6-1 
tumours 
SCC-B6-1 tumours (H+E image shown in Figure 3.12A) were highly vascularised and 
contained interconnected vascular network with many branching points (Figure 


































Figure 3.12 – SCC-B6-1 tumour vessels are unaffected by 11β-HSD1 inhibition/deletion. 
A) Haematoxylin and eosin stained section of SCC-B6-1 tumour. 100x magnification. Scale 
bar = 200µm. B) Tumour tissue with endothelial cells stained green (CD31 visualised with 
Alexa-Fluor 488) and smooth muscle cells stained red (α-SMA visualised with Cy3). SCC-
B6-1 tumours contained vascular networks that were more interconnected and branching than 
those seen in WT-SCC and Panc043 tumours. 400x magnification. Scale bar 50µm. B) Manual 
vessel counts found no differences between tumours from control, UE2316-diet fed, or Del1 
mice. 1 section/tumour. N=6 animals/group. Data represent mean ± standard error and were 
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3.2.5 Tumour types have variable vascularity 
Pooling control and UE2316-treated tumour vessel density data and grouping by 
tumour type highlighted the significant (P<0.0001) differences in vessel density 
between WT-SCC (29.3 ± 1.1 vessels per field of view), Panc043 (10.0 ± 0.7 vessels 









Figure 3.13 – Vascular density differs between tumour types. Vessel density in tumours 
(control group) varied depending on the cell type used to induce tumour formation. WT-SCC 
had the highest vessel density, followed by SCC-B6-1 and then Panc043. N=12-17, P<0.0001. 




Chapter 3 - 11β-HSD1 inhibition and tumour growth 
145 
 
3.2.6 Effect of 11β-HSD1 inhibition on expression of 
angiogenic factor mRNA 
 11β-HSD1 inhibition does not affect mRNA levels of known 
angiogenic factors in WT-SCC tumours 
To further determine the influence of UE2316 on angiogenesis, mRNA levels of a 
selection of angiogenic factors were measured by RT-qPCR in control and UE2316-
treated tumours, (N=6/group) and cultured tumour cells (N=6/type). No differences 
were seen in VEGFa, VEGFR2, IL-6, HIF-1α or TSP-1 mRNA levels between control 
and UE2316-treated tumours (Figure 3.14). Cellular mRNA levels were lower than 
tumour levels for all genes. Glucocorticoids have previously been shown to inhibit 
VEGF signalling, to reduce IL-6 production, and to increase TSP-1 expression, while 
11β-HSD1 deletion has been shown to increase HIF-1α expression (Hori et al., 1996; 





























Figure 3.14 – Expression of angiogenic factors in WT-SCC tumours. Control and UE2316 
groups indicate WT-SCC tumours from the latter experiment described in section 3.2.1, cells 
are from the WT-SCC cell line (passage<20). Expression of angiogenic factors in tumour cells 
was measured to ascertain the possible contribution of host/donor tissues. All genes were 
normalised to TBP/GAPDH housekeeping genes. No differences were found between tumours 
from control or UE2316-treated mice in the levels of A) VEGFa; B) VEGFR2; C) IL-6; D) 
HIF-1α or E) TSP-1. Cellular expression of all genes was lower than in tumours, and VEGFR2 
(B) and IL-6 (C) were not detected in cultured cells. Data are mean ± standard error and tumour 
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 11β-HSD1 inhibition reduces HIF-1α mRNA levels in Panc043 
tumours. 
The same investigations were also carried out in Panc043 tumours. HIF-1α mRNA 
levels were lower (P<0.05) in UE2316-treated Panc043 tumours (1.65 ± 0.34, arbitrary 
units) than in control tumours (0.72 ± 0.17). No differences were detected in VEGFa, 
VEGFR2 or TSP-1 mRNA levels (Figure 3.15) and IL-6 was not detected in Panc043 































Figure 3.15 – Angiogenic factor expression in Panc043 tumours. Control and UE2316 
groups indicate Panc043 tumours from the second experiment described in section 3.2.3.1, 
cells are Panc043 cell line (passage<20). Expression of angiogenic factors in tumour cells was 
measured to ascertain the possible contribution of host/donor tissues. All genes were 
normalised to TBP/GAPDH housekeeping genes. No differences were found between tumours 
from control or UE2316-treated mice in the levels of A) VEGFa; B) VEGFR2; C) TSP-1. D) 
HIF-1α was reduced in Panc043 tumours treated with UE2316. * P<0.05. Cellular expression 
of all genes was lower than in tumours, and VEGFR2 (B) was not detected in cultured cells. 
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3.2.7 Glucocorticoid signalling in tumours 
 Glucocorticoid signalling profile differs between WT-SCC, 
Panc043 and SCC-B6-1 tumours 
The expression of key glucocorticoid receptors and metabolising enzymes was 
measured in tumours to provide an indication of their potential glucocorticoid 
sensitivity. GR, MR, 11β-HSD1 and 11β-HSD2 mRNA levels were measured in WT-
SCC and Panc043 tumours (control vs UE2316-treated, N=6/group) and SCC-B6-1 
tumours (control/UE2316-treated/Del1; N=6/group) and cells. GR was expressed in 
all tumour and cell types and was lower in UE2316-treated Panc043 tumours (1.47 ± 
032) compared to control tumours (0.51 ± 0.06). No change in GR expression was 
detected between control and UE2316-treated WT-SCC or SCC-B6-1 tumours. 
Cellular GR mRNA levels were lower than tumour levels (Figure 3.16). 
GR was more highly expressed (P<0.05) in WT-SCC tumours (1.52 ± 0.12) than in 
Panc043 (0.31 ± 0.06) and SCC-B6-1 tumours (0.29 ± 0.09) (Figure 3.17A). 11β-
HSD1 was more highly expressed (P<0.05) in SCC-B6-1 tumours (1.73 ± 0.42) than 
in WT-SCC (0.11 ± 0.02) and Panc043 tumours (0.0.022 ± 0.003) (Figure 3.17B). 
MR mRNA did not differ between Panc043 cells and tumours, and was not detected 
in other samples (Figure 3.18). 11β-HSD2 mRNA was not detected in any of the cells 
or tumour types.  
11β-HSD1 mRNA was detected in WT-SCC and SCC-B6-1 tumours, and was at the 
limit of detection for Panc043 tumours (cycles 34-36). 11β-HSD1 levels in WT-SCC 
tumours were lower in animals receiving UE2316 treatment compared to controls 
(0.69 ± 0.04 AU vs. 1.57 ± 0.28 AU, P<0.05; Figure 3.19A), and 11β-HSD1 levels in 
SCC-B6-1 tumours were unaffected by UE2316 treatment or genetic deletion of the 
enzyme in the host tissues (3.19B). Subcutaneous sponge implants (N=4, a kind gift 
from Dr Holly Stott) and control FVB/N liver (N=12) were also examined as a highly 
vascularised tissue and a tissue with high 11β-HSD1 expression respectively. 11β-
HSD1 levels were similar between WT-SCC tumours (0.156 ± 0.03) and 
subcutaneously implanted sponges (0.159 ± 0.06), whilst levels in liver were found to 
be 100-fold higher (15.02 ± 2.51) (Figure 3.20). 



















Figure 3.16 – GR mRNA levels in Panc043 tumours are reduced by UE2316 treatment. 
A) GR expression did not differ significantly between WT-SCC tumours from control and 
UE2316-treated mice. B) GR expression was lower in UE2316 treated Panc043 tumours 
compared with controls. * P<0.05. Data compared by independent samples t-test, N=6/group. 
C) GR expression did not differ between control and UE2316-treated SCC-B6-1 tumours, and 
SCC-B6-1 tumours grown in Del1 mice. Data compared by one-way ANOVA. N=6/group. 

























Figure 3.17 - GR and 11β-HSD1 mRNA in different tumour types. A) GR transcript levels 
were significantly greater in WT-SCC tumours compared to Panc043 and SCC-B6-1 tumours. 
B) 11β–HSD1 transcript levels were significantly greater in SCC-B6-1 tumours compared to 
WT-SCC and Panc043 tumours. * P<0.05. N=6/group. Data represent mean ± standard error 
and were compared by one-way ANOVA with Tukey’s post-hoc test.  
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Figure 3.18 - MR mRNA is only detectable in Panc043 tumours. MR mRNA did not differ 
between Panc043 tumours from control or UE2316-diet fed mice. MR levels were below the 
limit of detection in both SCC tumour types. N=6/group. Data represent mean ± standard error 






























Figure 3.19 – 11β-HSD1 mRNA is expressed in SCC tumours. A) 11β-HSD1 mRNA was 
lower in WT-SCC tumours from UE2316-diet fed mice vs control diet-fed mice. 11β-HSD1 
mRNA was not detected in WT-SCC cells in culture. * P<0.05, data compared by independent 
samples t-test. N=5-6/group. B) 11β-HSD1 expression in SCC-B6-1 tumours was not affected 
by UE2316 or 11β-HSD1 deletion (note the injected cells are not from 11-HSD1 deficient 
mice). 11β-HSD1 mRNA was not detected in SCC-B6-1 cells in culture. Data represent mean 
± standard error and were compared by one-way ANOVA, N=6/group. 
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Figure 3.20 - 11β-HSD1 mRNA levels are similar between WT-SCC tumour and 
subcutaneous sponge. mRNA levels of 11β-HSD1 were similar between WT-SCC tumours 
and subcutaneous sponges implanted into mice, while both had 100-fold lower levels than in 
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 11β-HSD1 activity differs between tumour types 
11β-HSD1 dehydrogenase activity was measured in control tumours (N=6/tumour 
type) to determine relative levels of enzyme activity between tumour types. Control 
liver from FVB/N animals acted as positive control tissue. 11β-HSD1 dehydrogenase 
activity in WT-SCC tumours was demonstrably lower than that in liver, with 
0.5mg/mL [protein] forming product more rapidly than 0.2mg/mL [protein] (Figure 
3.21A). A preliminary time course using WT-SCC tumours (0.5mg/mL [protein]) 
demonstrated that there was a linear relationship between incubation time and steroid 
conversion between 60 - 120 minutes, thus 90 minutes was selected as an appropriate 
time point for incubation. Similar experiments (data not shown) were used to optimise 
conditions for Panc043 and SCC-B6-1 tumours. When comparing 11β-HSD1 
dehydrogenase activity between tumour types, SCC-B6-1 tumours showed a 
considerably higher rate of product formation (1.798 ± 0.204 nmoles/min/mg) than 
both WT-SCC (0.291 ± 0.054 nmoles/min/mg) and Panc043 (0.038 ± 0.006 






























Figure 3.21 - 11β-HSD1 activity varies between tumour types. A) A preliminary time-
course experiment established that between 60 - 120 minutes, product conversion was linear, 
leading to the selection of a 90 minute incubation time at 0.5mg/mL [protein] as the conditions 
to measure WT-SCC activity. Liver was used as a positive assay control. Negative (protein-
free) controls were also run (not shown). B) Comparing enzyme activity between tumour 
types, SCC-B6-1 tumours had significantly greater 11β-HSD1 dehydrogenase activity than 
WT-SCC and Panc043 tumours. Experimental controls allowed for the subtraction of 
background signal. **** P<0.0001. N=6/group. Data represent mean ± standard error and were 
compared by one-way ANOVA with Tukey’s post-hoc.  
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3.2.8 UE2316 levels in tissues of experimental animals 
 UE2316 is detected in FVB/N and C57BL6/J plasma and liver 
To determine how much UE2316 delivered via diet had reached the tissues of mice, 
UE2316 levels were measured in the plasma and in the liver. Plasma from FVB/N 
mice fed control or UE2316-diet for 9 days (N=5/group) and C57BL6/J mice fed 
control or UE2316-diet for 19 days (N=5/group) were subject to liquid-liquid 
extraction. Liver and tumours were used from FVB/N mice (section 3.2.1.4.1) and 
C57BL6/J mice (section 3.2.1.4.2). UE2316 levels measured by LC-MS/MS were 
higher (P<0.05) in FVB/N mouse plasma (64.05 ± 30.45 ng/mL) than in C57BL6/J 
mouse plasma (5.60 ± 2.42 ng/mL) (Figure 3.22A). UE2316 was detectable in the liver 
of both C57BL6/J mice (130.7ng/g) and FVB/N mice (36.4 ng/g) (Figure 3.22B). 
UE2316 was not detected in tissues from animals receiving control diet from either 
strain. Both strains ate the same amount of UE2316-diet (Figure 3.22C). Tumour tissue 
was too small to allow LC-MS/MS analysis, thus it was not possible to measure 





























Figure 3.22 - UE2316 is detected in FVB and C57BL6/J mouse plasma and liver. A) LC-
MS/MS analysis of plasma from UE2316 diet-fed animals revealed higher levels in FVB/N 
mice compared to C57BL6/J mice. B) UE2316 was detected in liver tissue from both strains, 
while the drug was not detected in the liver of untreated animals. C) No strain difference was 
seen in the amount of UE2316 diet consumed. * P<0.05. N=5-6/group. Data represent mean ± 
standard error and were compared by Mann-Whitney U test for panels A/B and independent 








The studies presented in this chapter addressed the hypothesis that 11β-HSD1 
inhibition, or deletion, would decrease local tissue glucocorticoid levels and thus 
increase the vessel density and subsequent growth of subcutaneous murine tumours. It 
was further postulated that tumours with higher levels of 11β-HSD1 activity and GR 
expression would show a more pronounced growth increase in response to 11β-HSD1 
inhibition, due to their increased glucocorticoid sensitivity. The data presented support 
the notion that 11β-HSD1 inhibition can promote tumour growth, as WT-SCC tumours 
grew more rapidly and reached a larger volume in FVB/N mice fed a diet containing 
the 11β-HSD1 inhibitor UE2316 than in mice fed a control diet. Enhanced growth after 
11β-HSD1 inhibition or deletion was not seen in Panc043 tumours, or in the alternative 
SCC-B6-1 cell line, suggesting that the risk of enhanced tumour growth may be 
specific to certain tumour types. SCC-B6-1 tumours exhibited significantly greater 
levels of 11β-HSD1 activity than both WT-SCC and Panc043 tumours, suggesting that 
high levels of 11β-HSD1 activity are not predictive of increased growth after 
inhibition. However, WT-SCC tumours expressed higher levels of GR than either of 
the non-responsive tumour types, highlighting GR levels as potentially important when 
assessing sensitivity to 11β-HSD1 inhibition. Crucially, vessel density and angiogenic 
factor expression were unaltered by 11β-HSD1 inhibition in all tumour types 
suggesting that an alternative mechanism mediates enhanced growth.  
11β-HSD1 inhibition and tumour growth 
Subcutaneous injection of WT-SCC or Panc043 cells produced tumours that were 
large enough for subsequent analysis after 1-2 weeks. In contrast, SCC-B6-1 cells took 
5-6 weeks to produce tumour of comparable volumes. Previous studies making use of 
the WT-SCC cells report tumour volumes of 0.06-0.08cm3 after 20 days growth in vivo 
(Serrels et al., 2012), suggesting the present studies achieved volumes appropriate to 
the study duration. Panc043 and SCC-B6-1 tumours are as yet unpublished elsewhere; 
however volumes achieved were consistent with observations within the lab group (M. 
Muir, personal communication). 11β-HSD1 inhibition enhanced growth in WT-SCC 
tumours. This effect was observed across a total of 9 animals per group across two 
technical repeats. One limitation of the present study was a failure to weigh tumours 
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from the original WT-SCC study. This parameter was introduced for later studies and 
added a confirmatory second measurement of tumour growth. The change in tumour 
size, however, was of sufficient magnitude as to be visually obvious to a secondary 
observer (M. Muir); thus this limitation is of relatively minor importance. 
WT-SCC are syngeneic on an FVB/N background, while the Del1 mice are 
backcrossed to a C57BL6/J background, rendering the cells non-compatible with the 
knockout. Panc043 tumours are non-responsive to both inhibition and deletion. SCC-
B6-1 cells are an alternative SCC type syngeneic on a C57BL6/J background, but their 
characteristics differ from WT-SCC in some key respects. The appearance of the WT-
SCC cells was spindle-shaped, whereas the SCC-B6-1 cells were cobblestone-like. 
Spindle-cell carcinomas are a more advanced and highly malignant variant of SCC 
which become more refractile, invasive and chemotactic (Klein-Santzo et al., 1989; 
Buchman et al., 1991). This aggressive variant has been termed ‘Class B’ SCC while 
the more typical SCC is termed ‘Class A’ (Wong et al., 2013). Thus the morphology 
of WT-SCC is indicative of them having undergone the epithelial-mesenchymal-
transition after their original generation by DMBA/TPA chemical carcinogenesis and 
gained a more aggressive and invasive ‘Class B’ phenotype (Usami et al., 2008; Huang 
and Balmain, 2014). The growth of SCC-B6-1 cells was considerably less aggressive, 
more typical of the ‘Class A’ phenotype. Tumours took around 2-3 times longer to 
reach sizes comparable to WT-SCC, by which point the tissue integrity was 
compromised and hindered histological preparation.  
The growth-enhancing effect of 11β-HSD1 inhibition could not be replicated using the 
Del1 mice in the present studies. No significant differences in tumour growth were 
detected between groups in the SCC-B6-1 studies, although a trend towards increased 
tumour size following UE2316 administration was apparent between days 28-37; an 
effect absent in tumours generated in Del1 mice. Power was a likely limitation in this 
study, but the aforementioned degradation of tumour tissue at later stages limited the 
usefulness of this experiment and informed the decision to impose a 28 day limit on 
the length of the study, at which point tumours were intact and could be examined 
histologically.  Given the discrepancy in SCC-B6-1 tumour growth after 11β-HSD1 
inhibition compared to deletion, it would be useful to repeat the study with the addition 
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of a UE2316-treated Del1 mouse group. The use of the inhibitor in global 11β-HSD1 
knockout mice would ensure that enzyme activity was absent in both host and donor 
cell types, as well as addressing any concerns regarding off-target effects. 
The only previous study to directly manipulate 11β-HSD1 expression in a solid tumour 
model demonstrated that 11β-HSD1 overexpression reduced the growth of HCC 
tumours in Balb/C nude mice (Liu et al., 2016). Overexpression of 11β-HSD1 in this 
model caused a similarly pronounced alteration in growth which was apparent from a 
very similar timepoint (3-5 days after cell injection). These and the present findings 
together support a role for 11β-HSD1 and local glucocorticoid metabolism in 
regulating tumour growth from an early stage, although important differences between 
the studies suggest alternative mechanisms may be involved. Different carcinomas 
were examined in these studies (HCC and SCC), though notably both are derived from 
tissues in which 11β-HSD1 is known to play a regulatory role (liver and skin) 
(Tiganuscu et al., 2011; 2013; Terao et al., 2011; 2014; Itoi et al., 2013; Kuo et al., 
2015). The use of Balb/C nude, rather than FVB/N, mice also removes the potential 
influence of the immune system on tumour growth in the study of Liu et al.. The use 
of a murine tumour cell line able to grow in mice with a functional immune system is 
a considerable strength of the present studies, as 11β-HSD1 deletion reduces T-cell 
infiltration in some inflammatory models (Wamil et al., 2011; Luo et al., 2012; Kipari 
et al. 2013) and is likely to influence the tumour microenvironment (Kim et al., 2007). 
Most importantly, Liu et al. (2016) saw a significant reduction in tumour angiogenesis 
(CD31/CD34 staining), attributed to reduced glycolysis, in tumours overexpressing 
11β-HSD1 compared to controls. This effect was notably absent from the present 
study, thus the mechanisms responsible in the HCC model of Liu et al. and in the 
present study models are likely different. 
11β-HSD1 inhibition and angiogenesis 
Contrary to the hypothesis, both vessel density and the proportion of vessels with 
smooth muscle coverage were unaltered by 11β-HSD1 inhibition. Small et al. (2005) 
were the first to demonstrate that deletion of 11β-HSD1 could promote angiogenesis 
in vivo.  In their studies, 11β-HSD1 KO mice had a greater angiogenic response than 
their wild-type litter mates across three separate models; subcutaneous sponge 
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implantation, chronic coronary artery ligation and dermal wound healing. Vessel 
density in both sponge and dermal wounds was quantified by Chalkley count, an 
established methodology for use in tumours (Hansen et al., 2000). Chalkley counts 
were one of three different vessel quantification methods used in the present studies, 
all of which demonstrated no difference between groups. As well as Chalkley counts, 
quantification of vessels from both random fields of view and from pre-selected 
vascular hotspots showed no difference in vessel density after 11β-HSD1 inhibition, 
demonstrating the robust nature of the observation.  
Vessel density has previously proven to be a valid measure of tumour angiogenesis. 
Yano et al. (2006) found that exposing mice to 1µg dexamethasone thrice weekly 
reduced prostate cancer-derived subcutaneous tumour size and vessel density, 
quantified using very similar methodology to that used in the present study. Of note, 
vessel counts in the prostate cancer tumours were considerably lower (30-50 vessels 
per 0.74mm2) than counts in WT-SCC tumours (150-200 vessels per 0.74mm2). While 
this may reflect a difference in quantification criteria, more likely it suggests that the 
WT-SCC tumours are a highly vascularised tumour type. Potentially, this may render 
them less sensitive to angiogenic manipulations, as the sheer magnitude of the 
angiogenic response could overwhelm any potential influence of altered 
glucocorticoid levels. This is further supported by the more pronounced difference in 
vessel density seen in WT-SCC tumours removed at day four compared with those 
removed at day 11; it is possible that the day four timepoint precedes an intensely pro-
angiogenic phase. As this observation did not reach significance, further investigation 
would be required before conclusions can be drawn. In the present project, alternative 
lines of investigation were pursued based on results presented in later chapters. Yano 
et al., (2006) also saw a decrease in VEGF-A mRNA levels corresponding to their 
reduced vessel density data; in the present study VEGF-A and VEGFR-2 were both 
unaffected by 11β-HSD1 inhibition, which does not support the original hypothesis.  
The main pathological models in which Small et al. (2005) saw enhanced angiogenesis 
were coronary artery ligation and dermal wound healing. Enhanced angiogenesis and 
recovery post-myocardial infarction has since been demonstrated a number of times, 
using both 11β-HSD1 knockout mice (McSweeney et al., 2010; White et al., 2015; 
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Mylonas et al. 2017) and the 11β-HSD1 inhibitor UE2316 (McGregor et al., 2014). 
The reparative response to myocardial infarction is characterised by enhanced 
neutrophil and macrophage recruitment into the myocardium, a response that is 
enhanced by 11β-HSD1 inhibition (McSweeney et al., 2010; Mylonas et al., 2017). 
11β-HSD1 deficiency also increases acute inflammation in models of arthritis, 
peritonitis and pleurisy (Coutinho et al., 2012; 2016). This effect is not seen across all 
disease models; in adipose tissue and atherosclerotic plaques from 11β-HSD1 KO 
animals, inflammatory and immune cell infiltration is attenuated (Wamil et al., 2011; 
Kipari et al., 2013). Arguably, the chronic, non-resolving inflammation and hypoxia 
seen in obese adipose tissue and atheroma is more similar to the tumour 
microenvironment than ischaemic myocardium, thus mechanistically these models 
may be of more relevance. Furthermore, angiogenesis after induced myocardial 
infarction in rodents is a beneficial process and distinct from the aberrant non-
resolving hypoxia-driven angiogenesis seen in tumours (Carmeliet, 2003, Chung and 
Ferrara, 2011).   
Panc043 tumours were significantly less vascularised than WT-SCC tumours, an 
observation in keeping with the literature. Olive et al. (2009) report that pancreatic 
ductal adenocarcinoma (PDAC) specimens are hypovascularised and hypothesise that 
their vascular architecture limits the perfusion and drug delivery into PDAC. 
Importantly, the KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ (KPC) mouse model 
used by Olive et al. (2009) to produce their murine PDAC tumours is the same used 
to generate the Panc043 cells used in the present study, making these findings highly 
comparable. PDAC has also been reported to be hypovascularised by groups using 
contrast-enhanced ultrasound to examine tumour perfusion (Sofuni et al., 2005; 
Sakamoto et al., 2008) and PDAC does not respond to the anti-angiogenic drug 
bevacizumab (Van Cutsem et al., 2009), further demonstrating that these tumours are 
relatively nonangiogenic or that their development is not dependent on angiogenesis. 
PDAC is also characterised by an abundant desmoplastic stroma comprising mainly 
α-smooth muscle actin-positive cancer-associated fibroblasts (CAFs) (Özdemir et al., 
2014; Öhlund et al., 2017), associated with excessive extracellular matrix (ECM) 
deposition and increased interstitial fluid pressure which are thought to further inhibit 
drug delivery (Provenzano et al., 2012; Whatcott et al., 2012). Thus it is possible that 
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poor perfusion led to compromised delivery of UE2316 into tumours. The present 
study is limited by the failure to quantify intra-tumour UE2316 levels; insufficient 
tissue was available to produce a robust result. While reduced perfusion could explain 
the lack of Panc043 response to UE2316-treament, it cannot explain the lack of 
response seen in the Del1 mice, suggesting that sensitivity to 11β-HSD1 manipulation 
is governed by more than just tissue architecture. However, tissue perfusion remains 
an important consideration as acute enzymatic inhibition may affect tumour growth 
differently to chronic deletion of 11β-HSD1. 
The surprising observation that Del1 mice were significantly heavier than the 
commercially purchased C57BL6/J mice that formed the control and UE2316 groups, 
despite age-matching, is difficult to explain. Although not the result of an experimental 
manipulation (weights differed from the beginning of the study), the difference was 
apparent across all experiments using the Del1 mice. No differences in the amount of 
diet consumed by Del1 mice were seen, thus the effect cannot be explained by 
increased feeding. The previous 11β-HSD1 knockout mice generated in-house did not 
differ in weight from their wild type litter mates (Kotelevtsev et al., 1997). The current 
knockout, Del1, has been back-crossed to the C57BL/6OlaHSD substrain (available 
from the Jackson Laboratory), the same substrain as the commercially purchased mice 
used in these experiments. Increased body weight is more perplexing still in light of 
reports that 11β-HSD1 deletion protects against, whereas overexpression promotes, 
obesity (Stimson and Walker, 2007; Morton et al., 2008; Harno et al., 2013). The 
difference is thus most likely to have arisen as a result of different housing conditions 
between in-house lines and commercial lines. The importance of mouse substrain has 
recently been highlighted as a consideration commonly neglected by researchers 
(Fontaine and Davis, 2016). Ideally littermate controls would be used for comparison 
in studies such as this, however as the available Del1 colony was entirely homozygous 
mutants, age-matched controls of an identical-substrain were selected as the most 
suitable option. 
11β-HSD1 inhibition and angiogenic factor expression 
The absence of an effect on vessel number in tumours led to the examination of 
angiogenic factor expression in tumours, to confirm that a more subtle effect had not 
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been overlooked. SCC-B6-1 were not included in these studies as the considerable 
differences seen between WT-SCC and SCC-B6-1 tumour growth limited the 
usefulness of this comparison. Panc043 tumours were analysed and presented as a non-
responsive comparison to the WT-SCC tumours. No differences were seen in 
expression of VEGFA, VEGFR2 or TSP-1 in WT-SCC or Panc043 tumours. VEGFA 
and VEGFR2 are central to the process of endothelial cell migration, and are pre-
requisites for the coordinated Notch-DLL4 signalling that dictates stalk and tip cell 
identity (Carmeliet and Jain, 2011). Glucocorticoid-mediated alterations in 
angiogenesis are often reflected in VEGF mRNA levels (Nauck et al., 1998; Gille et 
al., 2001; Pufe et al., 2003; Wen et al., 2003; Yano et al., 2006; Michailidou et al., 
2012), though a change in VEGF transcript does not always accompany changes in 
angiogenesis. Hasan et al. (2000) found glucocorticoids were able to promote 
haemangioma regression without an accompanying reduction in VEGF. Logie et al., 
(2010) also saw no effect of cortisol on VEGFA or VEGFR2 transcript expression in 
HUVECs, though they did observe a significant increase in the anti-angiogenic 
glycoprotein TSP-1. Reduced TSP-1 expression and increased 11β-HSD2 signalling 
were also seen in women with heavy menstrual bleeding (Rae et al., 2009), suggesting 
this protein may play a mechanistic role in the regulation of angiogenesis by 
glucocorticoids. 11β-HSD1 knockout mice show increased angiogenesis in models of 
MI and inflammatory arthritis without an accompanying increase in VEGFA mRNA 
(McSweeney et al., 2010; Zhang et al., 2017), leading to the proposition that enhanced 
angiogenesis after 11β-HSD1 deletion is mediated by tissue resident macrophages 
downstream of VEGF (Zhang et al., 2017).  
HIF-1α expression in WT-SCC tumours was unaltered by administration of UE2316, 
whereas in Panc043 tumours its expression was reduced by UE2316 treatment. This 
suggests that, despite not affecting tumour growth, 11β-HSD1 inhibition may still be 
exerting an effect on the tumour microenvironment. Whether this effect is systemic or 
mediated within the tumour cannot be determined by the present data. The finding that 
HIF-1α was decreased by UE2316 in Panc043 tumours is at odds with the reduction 
in HIF-1α and VEGF protein seen in 11β-HSD1 overexpressing HCC tumours (Liu et 
al., 2016), and, without an associated change in angiogenesis cannot be attributed to 
reduced hypoxia within the tumour. In keeping with the present observation, 
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Michalidou et al. (2012) observed decreased HIF-1α expression in adipose tissue from 
11β-HSD1 knockout mice, likely the result of reduced tissue hypoxia and 
inflammation. The lack of impact that UE2316 had on Panc043 tumour size suggests 
that these observations are not of major relevance to tumour progression, but they 
highlight the myriad influences glucocorticoid manipulation may have on tumour 
biology. Given the role of HIF-1α in promoting metastasis (Masoud and Li, 2015), 
such findings may warrant further investigation.  
IL-6 is a pro-angiogenic inflammatory cytokine (Gopinathan et al., 2015). In 
keratinocytes it is regulated by glucocorticoids in a biphasic manner, whereby 
physiological stress level of cortisol elevate its expression while pharmacological 
levels suppress it (Bernabé et al., 2011). The angiostatic effects of glucocorticoids have 
been linked to reduced production of IL-6 in vivo (Hori et al., 1996; Hasan et al., 
2000). Given that high IL-6 levels are predictive of poor prognosis in squamous cell 
carcinoma (Duffy et al., 2008) and are seen to be regulated by glucocorticoids in 
glucocorticoid-sensitive cancers (such as prostate; Nishimura et al., 2001), it was 
investigated as a potential mechanistic factor; however IL-6 levels did not differ 
between WT-SCC tumours and transcript could not be detected in Panc043 tumours. 
Glucocorticoid sensitivity of different tumour types 
A research question for this chapter was whether the glucocorticoid profile of a tumour 
(11β-HSD1/2, GR and MR levels) was predictive of tumour sensitivity to 11β-HSD1 
inhibition. Findings suggest that GR levels may be important, as WT-SCC tumours 
expressed significantly more GR than either of the other tumour types. The absence of 
MR transcript from WT-SCC tumours strongly suggests that GR is of more 
mechanistic importance (notwithstanding the possibility of a systemic mechanism 
mediated outwith the tumour). The present findings are in agreement with other studies 
that report SCC express particularly high levels of GR (Budunova et al., 1997; 
Spiegelman et al., 1997) and lack MR (Suzuki et al., 2000), though data from this 
chapter did not examine receptor function. As GR levels are a key determinant of tissue 
sensitivity to glucocorticoid action (Vanderbilt et al., 1987; Lin and Wang, 2016), this 
suggests that SCC may be a glucocorticoid-sensitive tumour type. GR expression in 
Panc043 tumours, but not in SCC tumours, was reduced by UE2316 treatment, 
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additional evidence that 11β-HSD1 inhibition may be altering this tumour type in a 
manner that does not affect growth. This finding is unexpected; 11β-HSD1 inhibition 
would be expected to decrease tumour glucocorticoid levels, and glucocorticoids 
downregulate GR mRNA expression in many tissues including tumours (Rosewicz et 
al., 1988; Vedeckis et al., 1989; Budunova et al., 1997; Freeman et al., 2004); notable 
exceptions include some lymphoid cell lines (Eisen et al., 1988). Thus this finding is 
difficult to interpret without further investigation.  
The relevance of absolute enzyme levels is unclear; SCC-B6-1 tumour type expressed 
large amounts of 11β-HSD1 mRNA and a high degree of activity compared to WT-
SCC tumour, but did not respond to 11β-HSD1 inhibition. The cell types expressing 
11β-HSD1 within tumours remain to be identified. Understanding cell-specific 
distribution of this enzyme may clarify the apparent paradox of a tumour with high 
11β-HSD1 activity not responding to 11β-HSD1 inhibition. The present data suggest 
that 11β-HSD1 expression in SCC-B6-1 tumour cells is induced after they are injected 
into animals, as the Del1-grown tumours had transcript present, despite the gene being 
deleted in host tissues. Induction of 11β-HSD1 expression may be a consequence of 
exposure to inflammatory cytokines (Chapman et al., 2013a). The same could 
theoretically have occurred in the other tumour types, but it is possible that enzyme 
expression in tumour cells is less important than expression within 
immune/inflammatory or fibroblast cell populations. The concept that 11β-HSD1 
expression is important in a specific subset of cells would somewhat negate the 
relevance of absolute 11β-HSD1 levels in tumours. From the present data the 
conclusion is that tumour GR expression within tumours may be predictive of 
sensitivity to 11β-HSD1 expression, whereas expression of overall tumour 11β-HSD1 
is not predictive.  
A large number of cancerous tissues express less 11β-HSD1 and more 11β-HSD2 than 
healthy controls (Takahashi et al., 1998; Bland et al., 1999; Coulter et al., 1999; 
Cooper et al., 2000; Gingras and Margolin, 2000; Pácha et al., 2002; Dovio et al., 2009; 
Liu et al., 2016) and several reports suggest this switch enhances cell proliferation 
(Hundertmark et al., 1997; Koyama and Krozowski, 2001; Woitge et al., 2001; 
Koyama et al., 2001; Rabbitt et al., 2002). This would suggest that targeting 11β-HSD1 
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would promote tumour growth. SCC are an exception in that 11β-HSD1 remains 
detectable while 11β-HSD2 is undetectable (Suzuki et al., 2000; Gronau et al., 2002; 
Cirillo et al., 2012; Terao et al., 2013). The present findings are in agreement with the 
literature; 11β-HSD1 was detected in both SCC tumour types at a higher level than in 
Panc043 tumours (in which 11β-HSD1 levels were at the limit of detection). 11β-
HSD2 was undetectable in all tumour types.  
11β-HSD1 mRNA levels were reduced by UE2316 in WT-SCC tumours but not in 
SCC-B6-1 tumours, another potential contributor to the enhanced response seen in 
WT-SCC tumours. Dexamethasone increases 11β-HSD1 expression in adipose tissue 
(Balachandran et al., 2008), thus the opposite process may be occurring in tumours, 
whereby decreased binding of active glucocorticoids to GR reduces 11β-HSD1 
expression. The reverse is often true in biology though, with reduced signalling leading 
to compensatory increased expression of pathway components. Alternatively, the 
decrease in whole tumour 11β-HSD1 transcript after UE2316 treatment may reflect a 
change in the relative proportion of 11β-HSD1-positive cell types; data from the 
current chapter show that vascular cell proportions are not altered by UE2316 and 
suggest that WT-SCC contribute no or negligible 11β-HSD1 content, thus 
inflammatory/immune cells and fibroblasts are candidate populations. As 11β-HSD1 
expression is also increased by inflammatory stimuli (Sun and Myatt, 2003; Ignatova 
et al., 2009; Ahasan et al., 2012), reduced 11β-HSD1 expression after UE2316 
treatment may also suggest reduced intra-tumour pro-inflammatory signalling. 11β-
HSD1 is reduced in conditions that stimulate proliferation of keratinocytes (Terao et 
al., 2013) so reduced enzyme expression may actually be a consequence of enhanced 
tumour growth. 
Attempts to localise 11β-HSD1 histologically were, unfortunately, unproductive due 
to problems with the immunohistochemistry technique, specifically, non-specific 
binding of the 11β-HSD1 antibody in tissues from knockout animals. 11β-HSD1 
immunostaining was subsequently abandoned in favour of enzyme transcript and 
activity measurements, which were reproducible but offered no insight into cellular 
localisation. No 11β-HSD1 transcript was detected in cultured tumour cells. Key sites 
of 11β-HSD1 expression in the tumour microenvironment are the vasculature (Walker 
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et al., 1991; Dover et al., 2007), immune and inflammatory cells (Thieringer et al., 
2001; Gilmour et al., 2006), and fibroblasts (Lee et al., 2013; Tiganescu et al., 2013; 
Terao et al., 2014). Experimental evidence reported in this chapter showed that, 
whereas 11β-HSD1 expression was low in WT-SCC tumours compared to liver, its 
expression was very similar in subcutaneous sponge tissue taken from mice 7 days 
after implantation. Implanted sponges are infiltrated by host vessels, inflammatory 
cells and stromal cells. Implanted tumour cells form tumours which are similarly 
populated by host tissues, thus this observation may suggest similar 11β-HSD1-
expressing cell populations within WT-SCC tumours. The importance of stromal cells 
as 11β-HSD1-expressing cells in tumours warrants further investigation, as despite 
reports (and qualitative observations from the present study) that PDAC express high 
levels of stromal CAFs (Özdemir et al., 2014; Öhlund et al., 2017), Panc043 tumours 
had negligible 11β-HSD1 activity, suggesting that stromal cells in these tumours do 
not express large amounts of 11β-HSD1. This would most readily be achieved by 
fluorescence associated cell sorting of tumour cells.  
Delivery of UE2316 
For the in vivo experiments described in this thesis, UE2316 was delivered via a 
custom-made RM-1 diet (McGregor et al., 2014; Sooy et al., 2015). Diet-based 
delivery was selected to avoid the stress associated with other delivery routes 
(injection/gavage/mini-pump) which could affect circulating glucocorticoids. Mice 
were given access to diet ad-libitum but tissues were also taken as close to 8am as 
possible so as to capture nadir baseline corticosterone levels. A previous study using 
the drug-diet delivered an efficacious calculated dosage of 30mg/kg/mouse/day (Sooy 
et al., 2015). The estimated dosage achieved in the present studies (based on diet 
consumed per cage per 2-3 days) was 25-30mg/kg/mouse/day, a dose seen to be 
efficacious in previous studies. UE2316 levels in C57BL6/J mouse plasma were in a 
similar region to previous measurements that used mini-pump administration of 
UE2316 (Wheelan et al., 2015). Cobice et al. (2013; 2017) have shown that whole 
brain levels of UE2316 in C57BL6/J mice given 20-25 mg/kg orally (via gavage) fall 
rapidly from 300-500 ng/g after 1-2 hours to around 50 ng/g after 4-6 hours, 
demonstrating the fast clearance of the drug. This may explain why plasma UE2316 
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levels were significantly lower in C57BL6/J animals than in FVB/N animals despite 
both strains consuming very similar amounts of drug-diet. Liver levels of UE2316 
were variable in C57BL6/J mice (50-200 ng/g) and lower but more consistent in 
FVB/N mice (25-50 ng/g). The time at which mice had last eaten may have affected 
measured levels and could explain this discrepancy between strains and variability 
within groups, however strain-specific differences in pharmacokinetics cannot be 
discounted. 
In conclusion, data from this chapter provide evidence that 11β-HSD1 inhibition can 
promote growth in some models of subcutaneous tumour formation. The sensitivity of 
tumours formed following injection of WT-SCC may be due to their high GR 
expression, but high expression of 11β-HSD1 itself is less predictive of a growth 
response to 11β-HSD1 inhibition. Contrary to the research hypothesis, the mechanism 
responsible for increased growth does not appear to be increased angiogenesis. 
UE2316 promotes angiogenesis in a mouse model of myocardial infarction (McGregor 
et al. 2014) but recent evidence suggests that it does not affect angiogenesis in a mouse 
model of hindlimb ischaemia (J. Wu, personal communication), thus its effects on 
angiogenesis appear to be context-dependent. No studies have previously examined 
the effect of a selective 11β-HSD1 inhibitor on an ex vivo model of angiogenesis, with 
previous studies using the non-selective 11β-HSD inhibitor carbenoxolone (Small et 
al., 2005). If the tumour vasculature is unaffected by 11β-HSD1 inhibition, what is the 
mechanism? Before examining the different components of the tumour 
microenvironment, it will be important to directly assess the effect of UE2316 and 
glucocorticoids on tumour cell proliferation in vitro. 
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4 11β-HSD1 inhibition, angiogenesis and 
tumour cell division 
4.1 Introduction 
In the previous chapter, UE2316 increased the growth of WT-SCC tumours but did 
not affect vessel density or molecular markers of angiogenesis. 11β-HSD1 inhibition 
has previously been shown to increase angiogenesis in other contexts, including in vivo 
after induced myocardial infarction (Small et al., 2005; McSweeney et al., 2010; 
McGregor et al., 2014; White et al., 2015) and ex vivo in the aortic ring assay using 
the non-selective 11β-HSD inhibitor carbenoxolone and genetic deletion (Small et al., 
2005). In tumours, sources are limited but Liu et al. (2016) report that over-expression 
of 11β-HSD1 in hepatocellular carcinoma decreased tumour angiogenesis and size. 
Thus, the lack of angiogenic effect observed in the present study was unexpected. 
UE2316 is a selective murine 11β-HSD1 inhibitor. The ex vivo angiogenic effects of 
the 11β-HSD1-selective inhibitor UE2316 have never been studied before, with 
previous studies using the non-selective 11β-HSD inhibitor carbenoxolone. Small et 
al., (2005) used the aortic ring assay to show that while 11-dehydrocorticosterone (11-
DHC) and corticosterone were angiostatic, inhibition using carbenoxolone, or genetic 
deletion of 11β-HSD1, prevented the angiostatic effects of 11-DHC. These findings 
suggest that local activation of glucocorticoids promotes angiostasis, however the 
effects of acute selective 11β-HSD1 inhibition must be determined. 
If the enhanced growth effect observed in squamous cell carcinoma (SCC) tumours is 
not the result of increased angiogenesis, a direct effect on tumour cell proliferation 
may be responsible. The syngeneic murine solid tumour model generates subcutaneous 
tumours comprised of donor tumour cells and a tumour microenvironment comprised 
of invading host cells (predominantly immune, inflammatory and vascular cells). 
Reports concerning the effects of glucocorticoids on cancer cell lines, including 
squamous cell carcinoma, are conflicting. The inhibitory effects of glucocorticoids on 
cell proliferation are well-reported (Azher et al., 2016) but in many solid tumours 
glucocorticoids induce resistance to chemotherapeutics and promote cell proliferation 
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(Zhang et al., 2007; Lin and Wang, 2016). The proliferation of healthy keratinocytes 
is inhibited by locally regenerated glucocorticoids (Terao et al., 2011), though the 
story in tumour cells is often complicated by increased resistance to glucocorticoid 
mediated apoptosis (Schlossmacher et al., 2011). Furthermore, corticosteroids have 
been shown to both increase (Bernabé et al., 2011; Cirillo et al., 2017) and inhibit 
proliferation (Hofmann et al., 1995) in SCC. Whilst the working hypothesis for these 
studies predicts the involvement of host cells, an off-target effect of UE2316 on tumour 
cell growth also cannot be ruled out. 
Hypotheses 
The work described in this chapter addressed the hypotheses that: 
- The 11β-HSD1 inhibitor UE2316 influences angiogenesis and tumour cell 
proliferation in ex vivo and in vitro models of these intra-tumour processes 
- 11β-HSD1 inhibition/deletion prevents conversion of 11-DHC to corticosterone, thus 
preventing 11-DHC-mediated angiostasis in the aortic ring assay 
- Physiological concentrations of glucocorticoids inhibit SCC cell proliferation 
Objectives 
The specific aims of this work were: 
(1) To determine whether 11-DHC and corticosterone exert angiostatic effects on 
aortic rings from FVB/N and C57BL6/J mice ex vivo. 
(2) To determine whether UE2316 selectively inhibits 11-DHC mediated-angiostasis 
(3) To determine whether deletion of 11β-HSD1 selectively inhibits 11-DHC 
mediated-angiostasis  
(4) To confirm the inhibitory effect of UE2316 on 11β-HSD1 in intact tissue 
(5) To determine whether UE2316 promotes the proliferation of WT-SCC, Panc043 
and SCC-B6-1 cells 
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(6) To determine whether physiological concentrations of corticosterone inhibit the 




















4.2.1 The effects of 11β-HSD1 inhibition and deletion on aortic 
ring vessel growth 
 Angiostasis is inhibited by 100-300nM 11-DHC 
Before examining the effects of 11β-HSD1 inhibition on aortic rings, an initial 
experiment was performed to determine an assay appropriate glucocorticoid 
concentration for inhibiting angiogenesis. A preliminary 11-DHC concentration-
response curve was performed, showing that 100 - 300nM 11-DHC significantly 
reduced vessel number. Aortic rings were harvested from wild-type (WT) C57BL6/J 
mice (female, aged 10-12 weeks). Experiments included five treatment conditions: 
vehicle (0.3% ethanol/DMSO); 11-DHC (10nM, 30nM, 100nM, 300nM) - N=10 for 
all conditions bar 10nM, for which N=8. 300nM was selected for use in future 
experiments (Figure 4.1). This experiment was performed by Eileen Miller, with data 







Figure 4.1 – 11-DHC concentration-response curve for ex vivo angiogenesis. Aortic rings 
from wild type C57BL6/J mice were cultured for one week in the presence of varying 
concentrations of the inactive glucocorticoid 11-dehydrocorticosterone (11-DHC). 300nM 
caused a marked reduction in vessel number, while 100nM induced mild angiostasis. Lower 
concentrations had no significant effect. Note that vessel counts are pooled for days 6/7. N=8-
10. * P<0.01, **** P<0.0001 vs. control. Data represent mean ± standard error and were 
compared by one-way ANOVA with Dunnett’s post-hoc test. 
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 UE2316 did not rescue steroid-mediated angiostasis and reduced 
outgrowths from aortic rings  
 C57BL6/J mice 
To determine whether UE2316 could prevent corticosteroid-mediated angiostasis, 
aortic rings from C57BL6/J (female, aged 10-12 weeks, N=8) were cultured in the 
presence of either vehicle, 300nM 11-DHC or 300nM corticosterone, with or without 
300nM UE2316 (Figure 4.2A). Vehicle-treated rings produced 72 ± 14 vessels at day 
7 (N=8). Addition of UE2316 alone reduced the number of outgrowths on day 7 (31 ± 
7 vessels, P<0.01). 11-DHC (20 ± 4 vessels, P<0.0001) and corticosterone (9 ± 2 
vessels, P<0.001) were both angiostatic and UE2316 did not prevent this angiostasis.  
 FVB mice 
To confirm findings in C57BL6/J mice in the FVB/N mice, aortic rings from FVB/N 
mice (female, aged 10-12 weeks, N=6 mice) were cultured in the presence of either 
vehicle (0.3% ethanol/DMSO), 300nM 11-DHC or 300nM corticosterone, with or 
without 300nM UE2316 (Figure 4.2B). Vehicle-treated rings produced 23 ± 5 vessels 
at day 7 (N=6), fewer than the counts seen in C57BL6/J aortic rings. Addition of 
UE2316 alone had no effect (23 ± 6 vessels). 11-DHC (1.2 ± 0.8 vessels, P<0.05) and 



























Figure 4.2 - UE2316 did not prevent glucocorticoid-mediated angiostasis. A) In vessels 
from C57Bl6/J mice, 300nM of the 11β-HSD1 inhibitor UE2316 reduced new vessel 
outgrowths. 300nM 11-dehydrocorticosterone (11-DHC) or corticosterone potently inhibited 
angiogenesis, and UE2316 did not affect this inhibition. N=8, data compared by one-way 
ANOVA with Dunnett’s post-hoc test. B) In vessels from FVB mice, the angiostatic effect of 
UE2316 alone was not apparent. However, UE2316 did not prevent glucocorticoid-mediated 
angiostasis. Aortic rings from FVB mice showed less vessel growth than C57Bl6/J. * P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001. N=6. Data represent mean ± standard error and were 
compared by Kruskal-Wallis test with Dunn’s post-hoc test.  
B 
A 
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 Del1 mice were protected from the angiostatic effect of 11-DHC 
To determine whether 11β-HSD1 deletion could prevent glucocorticoid-mediated 
angiostasis, aortic rings from WT C57BL6/J mice (female, 10-12 weeks, N=6) and 
Del1 mice (homozygous for disruption of hsd11b1 gene, female, 10-12 weeks, N=4) 
were cultured in the presence of either vehicle (0.3% ethanol/DMSO), 300nM 11-DHC 
or 300nM corticosterone (Figure 4.3). Vehicle-treated rings from WT (41 ± 8 vessels) 
and Del1 mice (74 ± 29 vessels) produced vessels by day 7, with Del mice producing 
1.8-fold more vessels than WT mice (non-significant). In WT mice, 11-DHC (10 ± 2 
vessels) and corticosterone (10 ± 3 vessels) both caused angiostasis (P<0.01). In Del1 
mice, only corticosterone was angiostatic (10 ± 5 vessels, P<0.01) while 11-DHC had 
no effect on vessel growth (68 ± 9 vessels). Thus, the lack of 11β-HSD1 in Del1 mice 
prevents the activation of glucocorticoids and their angiostatic effects, an effect not 
seen using UE2316. 
























Figure 4.3 - Genetic ablation of 11β-HSD1 prevented 11-DHC-mediated angiostasis. 
Aortic rings from wildtype mice showed a significant reduction in angiogenesis in the presence 
of 300nM 11-dehydrocorticosterone (11-DHC) compared to Del1 mice in the presence of 
300nM 11-dehydrocorticosterone. 300nM corticosterone inhibited angiogenesis in aortae from 
both wild-type and Del1 mice. ** P<0.01. Data represent mean ± standard error and were 
compared by one-way ANOVA with Dunnett’s post-hoc test. N=6 wild type C57BL6/J mice, 






















Figure 4.4 - UE2316 is antiangiogenic and did not rescue 11DHC-mediated angiostasis 
in the same fashion as 11β-HSD1 KO. Representative images of aortic rings from wild-type 
and Del1 (11β-HSD1 knockout) animals, treated with glucocorticoids and the 11β-HSD1 
inhibitor UE2316. Vehicle-treated rings grow similarly in both wild-type and Del1 animals 
(top and bottom left), while UE2316 causes a moderate reduction in vessel number (middle 
left). 11-dehydrocorticosterone (11-DHC) and corticosterone potently inhibit angiogenesis in 
all rings apart from Del1 animals (bottom middle). The addition of UE2316 does not prevent 
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4.2.2 Effect of UE2316 on 11β-HSD1 activity in intact liver 
To confirm the inhibitory effect of UE2316 on 11β-HSD1 activity, an enzyme activity 
assay was performed using liver from C57BL6/J mice (N=6). 300nM UE2316 
inhibited the reduction of 3H-cortisol to 3H-cortisone by 11β-HSD1 in intact liver by 
45% (P<0.0001), demonstrating the inhibition of 11β-HSD1 reductase activity (Figure 
4.5). Cortisol and cortisone were used as an alternative to 11-DHC and corticosterone 
in this assay, as they can be commercially purchased as purified steroids, whereas in-
house generation of 3H-11-DHC results in the detection of other interfering breakdown 
products during HPLC analysis. Furthermore, 11-DHC/corticosterone and 








Figure 4.5 - UE2316 inhibits 11β-HSD1 reductase activity in intact tissue. Liver pieces 
incubated with 3H-cortisone and 300nM of the 11β-HSD1 inhibitor UE2316 were unable to 
generate as much cortisol over 24 hours as control liver incubated in the absence of UE2316, 
demonstrating the inhibitory action of the drug. N=6/group, **** P<0.0001. Data represent 
mean ± standard error and were compared by independent samples t-test. 
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4.2.3 Effects of UE2316 and glucocorticoids on tumour cells 
 Manual cell counts 
To determine the effects of UE2316 on WT-SCC and Panc043 cell proliferation, 
manual cell counts were performed on cells exposed to the compound for 48 hours. 
Manual cell counting found no significant effect of UE2316 on absolute cell number 
across a range of UE2316 concentrations (Figure 4.6). This was true for both cell types 









Figure 4.6 – Manual cell counts after exposure of WT-SCC and Panc043 to UE2316. 
Quantification of cell number found no differences across the UE2316 (11β-HSD1 inhibitor) 
concentration curve after 48 hours. N=3-4 technical repeats, treatments in duplicate. Data 
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 Automated cell confluency analysis 
Cells were also imaged using the Incucyte ZOOM live cell imaging system to 
investigate the effects of UE2316 and glucocorticoids on tumour cell growth and 
morphology (Figure 4.7). The pro-apoptotic compound staurosporine (STS; 300nM) 
was added as a positive assay control. 
 UE2316  
Cell confluence increased steadily over 72 hours. WT-SCC grew more quickly than 
SCC-B6-1 and Panc043 cells, with both the latter cell lines only reaching 
approximately 35% of WT-SCC total confluence by 72 hours. Treatments were as 
follows: vehicle (0.6% ethanol/DMSO); 25nM UE2316; 75nM UE2316; 150nM 
UE2316; or 300nM UE2316. Addition of increasing concentrations of UE2316 had no 
effect on the growth of WT-SCC or SCC-B6-1 cells over 72 hours (Figure 4.8A/C), 
but 150nM and 300nM UE2316 produced a small but significant inhibition of Panc043 
growth (P<0.01, Figure 4.8B). The cytotoxic staurosporine (STS) prevented growth in 
all cell types. 
Viable cell number after 72 hours was assessed using an alamarBlue assay. UE2316 






Figure 4.7 - Tumour cells imaged on the Incucyte Zoom live cell imaging system. WT-
SCC cells (A) have a spindle-like morphology, while Panc043 (B) and SCC-B6-1 cells (C) 
have a cobblestone-like morphology. Scale bar = 300µm. 
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Figure 4.8 - UE2316 selectively reduced Panc043 cell confluence. The confluence of WT-
SCC cells (A) and SCC-B6-1 cells (C) imaged over 72 hours using the Incucyte was unaffected 
by the 11β-HSD1 inhibitor UE2316, however 150nM and 300nM UE2316 caused a small but 
significant reduction in Panc043 confluence (B). 300nM STS was included in all experiments 
as a positive assay control (cytotoxic effects). ** P<0.01. N=5 (technical repeats, treatments 
in sextuplet). Data represent mean ± standard error and were compared by 2-way ANOVA 































Figure 4.9 - Viable cell number was unaffected by UE2316. Cell viability, as determined 
by the alamarBlue assay, was unaffected by the addition of the 11β-HSD1 inhibitor UE2316 
to WT-SCC (A), Panc043 (B) and SCC-B6-1 cells (C). N=4 (technical repeats, treatments in 
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 Corticosterone  
Treatments (in sextuplet) were added as follows: vehicle (0.6% ethanol/DMSO); 
37.5nM corticosterone; 75nM corticosterone; 150nM corticosterone; or 300nM 
corticosterone. Addition of increasing concentrations of corticosterone had no effect 
on the growth of WT-SCC or SCC-B6-1 cells over 72 hours (4.10A/C), but 75nM and 
600nM corticosterone produced a small but significant inhibition of Panc043 growth 
(P<0.05 and P<0.01, respectively, Figure 4.10B). 300nM STS was potently cytotoxic 
and prevented growth in all cell types. 
Viable cell number after 72 hours was assessed using an alamarBlue assay. 
Corticosterone was not found to affect cell viability in any cell type at any 

































Figure 4.10 – Corticosterone selectively reduces Panc043 cell confluence. The confluence 
of WT-SCC cells (A) and SCC-B6-1 cells (C) imaged over 72 hours using the Incucyte was 
unaffected by corticosterone. In contrast, 75nM and 600nM corticosterone caused a small but 
significant reduction in Panc043 confluence (B). 300nM STS was included in all experiments 
as a positive assay control (cytotoxic effects). * P<0.05, ** P<0.01. N=5 (technical repeats, 
treatments in sextuplet). Data represent mean ± standard error compared by 2-way ANOVA 































Figure 4.11 - Viable cell number is unaffected by corticosterone. Cell viability, as 
determined by the alamarBlue assay, was unaffected the addition of corticosterone to WT-
SCC (A), Panc043 (B) and SCC-B6-1 cells (C). N=4 (technical repeats, treatments in 











The experiments presented in this chapter addressed the hypothesis that either 11β-
HSD1 inhibition (with UE2316) or deletion of 11β-HSD1 would prevent the inhibition 
of angiogenesis induced by the addition of 11-DHC to the aortic ring assay. Such 
effects were demonstrated by Small et al., (2005) using a previous 11β-HSD1 
knockout mouse model as well as the non-selective 11β-HSD inhibitor carbenoxolone. 
The effectiveness of UE2316 as an 11β-HSD1 inhibitor was confirmed in liver. 
Finally, studies were performed to investigate the effects of UE2316 and 
glucocorticoids on tumour cell proliferation. All three of the experimental tumour cell 
lines were shown to express negligible 11β-HSD1 transcript, and UE2316 previously 
has shown no off-target effects during selectivity screening (Yau et al., 2015) thus no 
off-target effects were anticipated. The literature on glucocorticoids and tumour cell 
proliferation is complex and, thus, outcomes were more uncertain. The data in this 
chapter are in agreement with previous findings (Small et al., 2005) in terms of the 
angiostatic effects of glucocorticoids and the pro-angiogenic effect of 11β-HSD1 
deletion; angiogenesis in aortae from Del1 mice was unaffected by the addition of 11-
DHC but powerfully inhibited by corticosterone. UE2316 on the other hand did not 
prevent 11-DHC-mediated angiostasis, and furthermore the drug itself exerted 
angiostatic effects in the absence of corticosteroids. These findings are unexpected, as 
studies of reductase activity in liver tissue using identical concentrations of UE2316 
found the drug to reduce conversion of inactive to active glucocorticoids by 50%, 
demonstrating its efficacy ex vivo.  Furthermore, neither UE2316 nor physiologically-
relevant levels of glucocorticoids were seen to affect SCC tumour cell proliferation in 
vitro, indicating that the in vivo effect observed is likely mediated by an alternative 
cell type.  
Aortic ring studies 
Achieving a balance between substrate and inhibitor concentrations was challenging, 
as low levels of 11-DHC failed to produce significant angiostasis whereas high 
concentrations risk displacing the inhibitor. An initial experiment exposing aortic rings 
to increasing concentrations demonstrated that 300nM 11-DHC was an appropriate 
concentration to achieve a pronounced angiostatic response. Small et al. (2005) saw a 
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similar degree of angiostasis using 300nM and 600nM 11-DHC, and chose to proceed 
with 600nM glucocorticoids for their inhibitor experiments. Importantly, both the 
studies in this chapter and those of Small et al. (2005) made use of concentrations far 
closer to those relevant physiologically, as opposed to the pharmacological doses used 
by Folkman et al. (1983) and others (Hori et al., 1996; Hasan et al., 2000). Both 11-
DHC and corticosterone were angiostatic at 300nM, adding further evidence that 
endogenous glucocorticoids can regulate angiogenesis. Only corticosterone, and not 
11-DHC, was able to induce angiostasis in aortae from Del1 mice, emulating the 
findings of Small et al. (2005) and demonstrating that it is the conversion of 11-DHC 
to corticosterone by 11β-HSD1 that produces the angiostatic effect.  
Unexpectedly, UE2316 did not prevent 11-DHC-mediated angiostasis, despite the 
previous finding (Small et al., 2005) that carbenoxolone prevented 11-DHC-mediated 
angiostasis, albeit to a lesser degree than enzyme deletion. This led to questions 
surrounding the effectiveness of the inhibitor under these culture conditions. UE2316 
has an IC50 of 162nM in vitro (Sooy et al., 2010), thus 300nM UE2316 was intended 
to completely inhibit 11β-HSD1. However, results from the reductase assay performed 
in cultured liver tissue demonstrated 300nM UE2316 successfully reduced conversion 
of inactive glucocorticoids by around 50%. Similar findings have been reported in the 
brain (Wheelan et al., 2015). The reductase assay performed in mouse liver tissue was 
intended to address the question of compound effectiveness in intact tissue ex vivo. 
Unfortunately, attempts to optimise this assay for use with aortic tissue failed as tissue 
volumes were too low to detect activity. Nevertheless, it remains possible that residual 
conversion of 11-DHC to corticosterone may still have been sufficient to induce 
angiostasis in the aortae treated with both 11-DHC and UE2316. Given the unexpected 
finding that UE2316 did not prevent 11-DHC-mediated angiostasis, a useful future 
study would be to expose aortic rings to a UE2316 concentration curve – this would 
remove the risk of misinterpreting data from single concentration studies. 
The above argument still cannot explain one of the most surprising findings from this 
study; UE2316 itself exerts moderate angiostatic effects in the absence of 
glucocorticoids. Assay sensitivity is one potential explanation for this finding. Efforts 
were taken to minimise the levels of heparin in culture medium, as although Folkman 
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et al. (1983) demonstrated the requirement for heparin in promoting the angiostatic 
effects of glucocorticoids, its addition did appear to have a detrimental effect on 
growth and could have contributed to assay sensitivity. Findings in the Del1 mice, 
however, suggest that the assay was correctly optimised, as addition of 11-DHC here 
had no effect on growth despite the presence of heparin. If UE2316 does induce anti-
angiogenic effects then this warrants further investigation, though data in this chapter 
only allow for speculation. The present experiments would have benefited from the 
addition of a UE2316-treatment group in the Del1 aortae to test for an off-target effect; 
this experiment has since been performed by others in the group using an identical 
protocol; the anti-angiogenic effect of UE2316 did not occur in mice lacking 11β-
HSD1, only in wild-type C57BL6/J aortae (E. Miller and J. Wu, unpublished). These 
data, in combination with previous reports that UE2316 does not have significant off-
target activities (Yau et al., 2015), suggest a previously unreported 11β-HSD1-
dependent inhibition of angiogenesis which is glucocorticoid-independent. 
Accurate interpretation of these data requires a consideration of the model. The aortic 
ring assay allows the angiogenic process to be examined in the absence of the paracrine 
effects of surrounding tissues and the effect of circulating leukocytes (Baker et al., 
2011). Unlike cell-based assays of angiogenesis, the aortic ring assay uses intact tissue 
explants that have not undergone modification by serial passage under culture 
conditions (Aplin et al., 2008) and involves the development of fully lumenized 
endothelial tubes which recruit supporting mural cells in a manner far more 
representative of in vivo angiogenesis (Aplin et al., 2008; Baker et al., 2011). Small et 
al. (2005) originally interpreted their observations as evidence for the role of smooth 
muscle 11β-HSD1 in constraining the angiogenic response during vascular 
inflammation, on the grounds that the aortic ring assay lacks inflammatory cell 
involvement. Evidence has since emerged that renders this interpretation problematic. 
Several studies have demonstrated an important role for tissue-resident macrophages 
and dendritic cells in the adventitia of aortic explants (Aplin et al., 2006; Gelati et al., 
2008), suggesting that the innate immune system remains relevant in this model. 
Furthermore, White et al. (2015) did not see the same pro-angiogenic effects of 11β-
HSD1 deletion in the myocardium when the knockout was specifically targeted to 
smooth-muscle cells. This new information necessitates a reconsideration of the 
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potential mechanism at work, though this mechanism likely involves the 
glucocorticoid receptor (GR) rather than the mineralocorticoid receptor (MR) (Small 
et al., 2005).  
Based on the available evidence so far, other 11β-HSD1 expressing cell types of 
potential importance in this model are cells of the innate immune system (Thieringer 
et al., 2001; Freeman et al., 2005; Gilmour et al., 2006; Chapman et al. 2013b; 
Coutinho et al., 2016) and fibroblasts (Lee et al., 2013; Tiganescu et al., 2013; Terao 
et al., 2014). Endothelial cells express little or no 11β-HSD1 (Hadoke et al., 2001; 
Christy et al., 2003; Rae et al., 2009), although the paracrine influence of other cell 
types on endothelial cells cannot be excluded in light of the anti-angiogenic effects of 
glucocorticoids on HUVEC tube-like structure formation (Logie et al., 2010). 
Interestingly, the most recent studies examining the role of 11β-HSD1 in angiogenesis 
focus on fibroblasts (Mylonas et al., 2017) and macrophages (Zhang et al., 2017), 
respectively. An important future study will be to perform the aortic ring assay using 
the cell-specific 11β-HSD1 knockout animals. For now, it remains difficult to explain 
why 11β-HSD1 inhibition has the opposite effect on angiogenesis to 11β-HSD1 
deletion. The importance of chronic, as opposed to acute, loss of 11β-HSD1 activity 
may yet prove to be of importance.  
The aortic ring assays described above were performed in C57BL6/J mice (OlaHSD 
substrain), the strain in which Panc043 and SCC-B6-1 tumours were grown. 
Interestingly, SCC-B6-1 tumours did show a trend towards increased growth that was 
more pronounced in WT mice fed an 11β-HSD1 inhibitor than in the Del1 mice – this 
did not reach significance and thus should not be subject to over-interpretation, yet it 
adds to evidence suggesting that inhibition and deletion of the enzyme may operate 
via separate mechanisms. The same aortic ring experiments were performed using 
aortae from FVB mice, as this strain was used for WT-SCC tumour studies. While 
glucocorticoids were still powerfully angiostatic and UE2316 did not prevent 11-
DHC-mediated angiostasis, no anti-angiogenic effect of UE2316 alone was apparent 
in this model. While this may reflect a genuine strain-difference, more likely it reflects 
the poor angiogenic potential of FVB/N mice; control rings produced around 30% of 
the vessel outgrowth seen in control C57BL6/J mice, and their lack of suitability for 
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assays of angiogenesis has previously been described (Rohan et al., 2000; Zhu et al., 
2003; Kim et al., 2013). Thus, rather than resistance to UE2316-mediated angiostasis, 
outgrowths from these aortae may simply have grown too poorly under control 
conditions to allow accurate detection of moderate angiostatic effects. In terms of 
relating findings from the aortic ring assay back to the previous chapter’s conclusions, 
an effect of UE2316 on angiogenesis in the FVB mouse is distinctly absent, adding 
more weight to the theory that an alternative mechanism is responsible for enhanced 
tumour growth.  
Tumour cell proliferation studies 
The original research hypothesis of 11β-HSD1 causing enhanced angiogenesis and 
promoting tumour growth is not supported by the available evidence. The next 
potential mechanism to examine was a direct effect of either UE2316 or 
glucocorticoids on tumour cell proliferation. 11β-HSD1 is rarely expressed in highly-
proliferative tumour cell lines (Chapman et al., 2013b) and the cell lines in this chapter 
were no exception. Therefore, adding UE2316 to cells in culture was performed mainly 
to confirm the absence of an off-target effect. Three separate methods were used to 
assess cell growth. Simple cell counting allowed for a direct readout of cell number, 
while assessment with the incucyte allowed both high-throughput analysis and 
assessment of cell morphology. The alamarBlue assay provided a tertiary measure to 
confirm impact on cell viability. No effect of UE2316 on either WT-SCC or SCC-B6-
1 cells was seen across a wide range of concentrations (encompassing those detected 
in vivo in plasma in the previous chapter). A subtle but significant reduction in 
Panc043 confluence in the presence of 150-300nM UE2316 was apparent, though this 
was not pronounced enough to reach significance in the alamarBlue assay of cell 
viability and did not appear to alter tumour growth in the previous chapter.  
Attention was, thus, turned to glucocorticoids, the effects of which are varied when 
applied to tumour cells. In androgen-sensitive cancers (breast and prostate), 
glucocorticoids can suppress tumour cell proliferation, but in many carcinomas 
glucocorticoids inhibit the apoptotic effects of chemotherapeutics and promote tumour 
cell proliferation via upregulation of survival factors (reviewed by Lin and Wang, 
2016). Many of these studies used high concentrations of dexamethasone, a highly 
Chapter 4 – Effects of the 11β-HSD1 inhibitor UE2316 
194 
 
potent synthetic glucocorticoid which is selective for the GR. While this was relevant 
to these studies (which were concerned with the use of therapeutic glucocorticoids in 
conjunction with chemotherapy), the present work is related to manipulation of 
endogenous glucocorticoids and thus made use of physiologically relevant 
concentrations of corticosterone (Kotelevtsev et al., 1997; Harris et al., 2001; Yau et 
al., 2007; Benedetti et al., 2012; Gong et al., 2015), the naturally occurring murine 
glucocorticoid. Synthetic glucocorticoids bind the GR with much higher affinity than 
naturally-occurring corticosteroids (Hollenburg et al., 1985), making direct 
comparison of studies difficult. Ishiguro et al. (2014), for example, found that, while 
dexamethasone (and several other glucocorticoids) promoted bladder cancer cell 
growth, corticosterone exhibited only marginal effects. Thus it is perhaps unsurprising 
that corticosterone was not seen to drastically affect tumour cell proliferation in the 
present study. 
Panc043 cells again appeared to be slightly sensitive to corticosterone exposure, 
although this was not concentration-dependent and the effect was absent from 
alamarBlue analysis. Zhang et al. (2006a; 2007) report resistance to the cytotoxic 
effects of chemotherapeutics after exposing numerous pancreatic ductal 
adenocarcinoma cells to dexamethasone, but inhibition of proliferation has also been 
reported in pancreatic ductal adenocarcinoma cells (Gower et al., 1994).  Evidence 
from Panc043 tumour growth in vivo (Section 3.2.6.2) did suggest that tumours were 
affected by 11β-HSD1 inhibition (altered GR and HIF-1α signalling); however, this 
did not alter tumour growth. It is likely, therefore, that the observed mild in vitro 
effects of glucocorticoids are negligible in the in vivo situation in which the tumour 
microenvironment and systemic factors are at play. Similar effects have previously 
been reported; Shpilberg et al. (2015) found that although corticosterone inhibited cell 
cycle progression in breast cancer cells in vitro, co-incubation with conditioned media 
from adipose tissue overrode this effect. Alternatively, and in light of the effects of 
UE2316 on Panc043 confluence, it may be that these cells undergo slight 
morphological changes when stressed by the addition of a treatment in vitro (which 
could affect confluence data). 
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The absence of a glucocorticoid-mediated effect in either SCC cell line strongly 
suggests that direct proliferative effects on tumour cells are not the mechanism by 
which 11β-HSD1 inhibition promotes tumour growth. This finding is not necessarily 
surprising. A previous study exposing SCC cell lines to glucocorticoids was 
inconclusive; while exposure to cortisol did promote proliferation in two separate SCC 
lines, in one line only pharmacological concentrations (1µM) induced this affect, but 
in the other growth was only enhanced by low physiological concentrations (10nM) 
(Bernabé et al., 2011). Furthermore, a recent study exposing SCC cell lines to 
glucocorticoids only found increased invasiveness in one of three cell lines (Cirillo et 
al., 2017) and of particular note, the more aggressive cell line was non-responsive. The 
absence of an in vitro tumour cell effect implicates other aspects of the tumour 
microenvironment in the enhanced growth of WT-SCC tumours. Previous studies have 
also found that although dexamethasone decreased the growth of tumour xenografts in 
vivo, exposing the cancerous cells to dexamethasone in vitro had no effect (Crowley 
et al., 1988; Yano et al., 2006). Determining which component of the WT-SCC tumour 
microenvironment is sensitive to local glucocorticoid manipulation will be key in 
determining the risk posed by 11β-HSD1 inhibitors.  
In conclusion, closer examination of angiogenesis and tumour cell proliferation has 
not revealed a clear mechanism of action for UE2316 in promoting WT-SCC tumour 
growth. As predicted, active glucocorticoids proved angiostatic ex vivo and aortae 
from mice lacking the 11β-HSD1 enzyme were protected from angiostasis after 
exposure to exogenous 11-DHC. UE2316, however, did not have the expected effect; 
despite preventing conversion of 11-DHC to corticosterone in liver ex vivo, the 
inhibitor failed to prevent 11-DHC-mediated angiostasis and instead caused moderate 
angiostasis in the aortic ring assay. Neither UE2316 nor glucocorticoids had drastic 
effects on tumour cell proliferation, suggesting that direct effects on cell proliferation 
are unlikely to be responsible for the increased growth seen in UE2316-treated WT-
SCC tumours in vivo. These findings suggest that UE2316 may be interacting with an 
alternative component of the tumour microenvironment to influence tumour growth. 
The recent literature points towards immune and inflammatory cells, as well as 
fibroblasts. The priority now will be to investigate the wider influence of UE2316 on 
the tumour microenvironment in vivo. 
Chapter 4 – Effects of the 11β-HSD1 inhibitor UE2316 
196 
 












Mechanism of enhanced WT-SCC tumour 








Chapter 5 – Mechanism of enhanced tumour growth 
198 
 
5 Mechanism of enhanced WT-SCC tumour 
growth after 11β-HSD1 inhibition 
5.1 Introduction 
In chapter 3, inhibition of 11β-HSD1 with UE2316 was shown to promote the growth 
of WT-SCC tumours. In the previous chapter, it was demonstrated that UE2316 did 
not mimic the effect of 11β-HSD1 deletion on angiogenesis ex vivo, despite its ability 
to inhibit 11β-HSD1 activity in intact tissue. Similarly, neither UE2316 nor 
physiologically-relevant concentrations of corticosterone directly influenced the 
proliferative capacity of tumour cells. Key questions remains unanswered – by what 
mechanism does UE2316 promote WT-SCC tumour growth and why is a response 
apparent in only one of the three tumour types examined?  
Strain-specific differences in the response to UE2316 may influence tumour sensitivity 
to 11β-HSD1 inhibition. 11β-HSD1 inhibition/deletion decreases tissue-specific 
glucocorticoid concentrations but the available evidence suggests that 11β-HSD1 
inhibitors, including UE2316, do not affect plasma glucocorticoid levels in pre-clinical 
models or clinical trials (Hermanowski-Vosatka et al., 2005; Harno and White, 2010; 
Sooy et al., 2010; Coutinho et al., 2016). Furthermore, while conflicting evidence 
exists surrounding plasma glucocorticoid levels in 11β-HSD1 knockout (KO) animals 
(Kotelevtsev et al., 1997; Harris et al., 2001), C57BL6/J mice appear to be largely 
resistant to alterations in HPA axis function (Carter et al., 2009; Harno and White, 
2010). This is of great clinical advantage as systemic manipulation of glucocorticoids 
in humans risks Addisonian crisis or Cushing’s syndrome. To the author’s knowledge, 
no studies have previously used 11β-HSD1 inhibitors in FVB/N mice, thus it remains 
possible that circulating glucocorticoids in this strain may be affected by UE2316. 
Tumour type itself is also likely to affect the response to UE2316. The sensitivity and 
response of tumours to glucocorticoids is highly variable between cancer types, with 
higher glucocorticoid receptor (GR) expression predictive of greater sensitivity to 
changing glucocorticoid concentrations (Lin & Wang, 2016). Expression of 11β-
HSD1 is often reduced in cancerous tissues compared to their healthy equivalents, and 
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this can enhance tumour growth (Azher et al., 2016; Liu et al., 2016). Of particular 
note are studies indicating a role for 11β-HSD1 in constraining the progression of 
squamous cell carcinoma (SCC) (Terao et al., 2011; 2013; 2014) and increased GR 
expression in SCC compared to normal skin (Budunova et al., 1997). These reports 
suggest that SCC are a candidate tumour type for glucocorticoid sensitivity and thus 
may be at particular risk from 11β-HSD1 inhibitors.  
As well as tumour cells and vascular cell types, a variety of immune and inflammatory 
cells and extracellular matrix producing fibroblasts form the tumour 
microenvironment (Hanahan and Weinberg, 2011). Over the past 15 years, mounting 
evidence has highlighted the importance of considering the microenvironment when 
assessing how best to effectively target cancers. Collagen deposition, for example, may 
be of relevance in skin cancer (Azher et al., 2016), with remodelling of the 
extracellular matrix a common component of malignancy (Hompland et al., 2008). 
11β-HSD1 amplifies local glucocorticoid concentrations which consequently 
influences collagen fibril organisation. In aging skin, inhibition of 11β-HSD1 
increases collagen density and improves dermal integrity and wound healing 
(Tiganescu et al., 2013). In adipose tissue, the opposite is true; 11β-HSD1 KO mice 
show reduced fibrosis (Michailidou et al., 2012). Several methodologies now exist for 
quantifying collagen in histological sections; as well as conventional picrosirius red 
staining, techniques like second-harmonic generation imaging allow for label-free 
high resolution imaging of the fibrillar network in tumours (Hompland et al., 2008). 
Inflammatory and immune cell types can have powerful effects on tumour progression. 
The anti-inflammatory and immunosuppressive effects of glucocorticoids are 
therefore likely to be very relevant when targeting tumour 11β-HSD1. Reducing the 
regeneration of local glucocorticoids may predict a less constrained inflammatory 
response and has been suggested as a mechanism in myocardial infarction 
(McSweeney et al., 2010). Yet the opposite effect has been reported in other 
inflammatory contexts such as the vasculature (Luo et al., 2012) and adipose tissue 
(Peng et al., 2016), thus a pro-inflammatory effect of 11β-HSD1 inhibition cannot be 
assumed. Locally regenerated glucocorticoids produced by SCC cells are able to 
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inhibit the proliferation of anti-tumour CD8+ T-cells (Cirillo et al., 2017), thus anti-
tumour immunity may also be affected by 11β-HSD1 inhibitors.   
Hypotheses 
The work described in this chapter is intended to address the hypotheses that: 
- 11β-HSD1 inhibition/deletion does not affect systemic glucocorticoid levels 
- UE2316-responsive WT-SCC tumour growth will increase in response to reduced 
circulating glucocorticoids 
- 11β-HSD1 inhibition alters the tumour microenvironment in a manner that promotes 
tumour growth 
Objectives 
The specific aims of this work were: 
(1) To confirm the effects of 11βHSD1 inhibition/deletion on circulating 
glucocorticoids in FVB/N and C57BL6/J mice  
(2) To investigate whether reduced glucocorticoid exposure increases WT-SCC 
tumour growth in vivo, and whether glucocorticoid replacement reverses this effect 
(3) To use RNA-sequencing to examine the impact of UE2316 on the WT-SCC 
transcriptome 
(4) To determine the impact of 11β-HSD1 inhibition on aspects of the 
immune/inflammatory cell population and non-cellular fibrillar network of the tumour 
microenvironment 




5.2.1 Plasma corticosterone was decreased in UE2316-treated 
FVB/N mice 
 ELISA 
To compare plasma corticosterone concentrations between UE2316-diet fed FVB/N 
mice and control diet-fed FVB/N mice, blood was sampled from female FVB/N mice 
fed UE2316 or RM-1 diet for 14 days and plasma for analysis by ELISA. FVB/N mice 
fed UE2316 diet had lower levels of corticosterone than mice fed RM-1 control diet 








Figure 5.1 - Plasma corticosterone was decreased in UE2316 treated FVB/N mice bearing 
WT-SCC tumours. Mice fed UE2316-diet showed significantly reduced plasma 
corticosterone levels compared to mice fed control diet. Symbols represent individual animals. 









To confirm the findings of the ELISA, 11-dehydrocorticosterone (11-DHC) and 
corticosterone were measured in the plasma of FVB/N mice (WT-SCC tumours) and 
C57Bl6/J mice (Panc043 tumours) by LC-MS/MS. A combination of low plasma yield 
and technical issues leading to loss of samples necessitated the pooling of FVB/N 
plasma samples from two experiments in order to achieve sufficient sample volume. 
FVB/N mice fed UE2316- (n=4) or control diet (n=3) for 9 days were pooled with 
FVB/N mice fed UE2316 (n=4) or control diet (n=6) for 16 days to give a total sample 
size of N=7-10/group. All mice underwent identical treatment (implantation of 
subcutaneous WT-SCC tumours after 5 days on diet), with the only difference being 
the length of time tumours were left to develop (4 vs 11 days). C57BL6/J plasma was 
from the second study described in Section 3.2.3.1 (Panc043 tumours grown for 16 
days) and from the 41 day SCC-B6-1 study described in Section 3.2.4.1.   
11-DHC levels did not differ between RM-1 and UE2316 diet-fed FVB/N or 
C57BL6/J mice, but were significantly elevated in Del1 mice compared to RM-1 diet 
fed wild-type (WT) C57BL6/J controls (49.73 ± 20.95 nmol/L vs. 5.83 ± 1.63 nmol/L, 
P<0.05, Figure 5.2A). 
Corticosterone levels were reduced in UE2316 diet-fed FVB/N mice compared to RM-
1 diet-fed FVB/N mice (56.4 ± 14.8 nmol/L vs. 328.9 ± 84.4 nmol/L, P<0.01, Figure 
5.2B). Corticosterone levels in C57BL6/J mice were unaffected by both UE2316 and 
Del1 phenotype. 
Glucocorticoids were also measured in the plasma of C57Bl6/J mice implanted with 























Figure 5.2 – Effects of 11β-HSD1 inhibition or deletion on systemic glucocorticoid levels. 
A) The 11β-HSD1 inhibitor UE2316 did not significantly alter plasma 11-
dehydrocorticosterone (11-DHC) concentrations in either C57BL6/J or FVB/N mice, whereas 
genetic ablation of 11β-HSD1 (Del1) increased 11-DHC concentrations. * P<0.05. Data 
represent mean ± standard error and were compared by one-way ANOVA with Dunnett’s post-
hoc test. B) UE2316 treatment reduced circulating corticosterone in FVB/N animals only, 
whereas corticosterone concentrations in C57Bl6/J animals were unaffected by inhibitor or 
Del1 genotype. **=P<0.01. Data represent mean ± standard error and were compared by 
independent sample t-test. 
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Figure 5.3 – Corticosteroid concentrations in the plasma of C57Bl6/J animals implanted 
with SCC-B6-1 tumours are not consistently affected by 11β-HSD1 deletion or inhibition. 
Neither the Del1 genotype nor the 11β-HSD1 inhibitor UE2316 altered plasma corticosterone 
levels in C57BL6/J animals implanted with the squamous cell carcinoma cell line SCC-B6-1. 
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5.2.2 Tumour-bearing does not affect circulating 
glucocorticoids 
Plasma glucocorticoids were compared between tumour and non-tumour bearing 
animals to assess whether the presence of a subcutaneous tumour affected circulating 
glucocorticoids in mice. While 11-DHC was below the limit of detection in FVB/N 
plasma in this experiment, no differences in 11-DHC were found between tumour-
bearing and control C57BL6/J mice (Figure 5.4A), and no differences in corticosterone 
































Figure 5.4 - Tumour bearing did not consistently affect circulating glucocorticoids. A) 
Plasma 11-dehydrocorticosterone (11-DHC) concentrations in C57Bl6/J mice were not 
significantly altered by pancreatic ductal adenocarcinoma (Panc043) tumour bearing. B) 
Plasma corticosterone concentrations were not significantly affected by tumour bearing in both 
FVB/N mice with WT-SCC tumours and C57Bl6/J mice with Panc043 tumours. N=3-8. Data 
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5.2.3 UE2316 treatment increases the 11-DHC to 
corticosterone ratio in liver tissue in FVB/N mice 
To investigate whether UE2316 could alter tissue-specific glucocorticoid 
concentrations, 11-DHC and corticosterone were both measured by LCMS-MS in liver 
and tumour tissue from FVB/N mice (Section 3.2.1) and C57BL6/J mice (Section 
3.2.3.1). Although trends for increased levels of 11-DHC (Figure 5.5A) and decreased 
levels of corticosterone (Figure 5.5B) after UE2316 treatment were apparent in FVB/N 
liver, neither reached significance. Differences in C57BL6/J after UE2316 treatment 
were less pronounced. When levels were expressed as the ratio of 11-DHC to 
corticosterone (A:B ratio), FVB/N liver had a significantly (P<0.0001) higher 
proportion of 11-DHC to corticosterone in UE2316 treated mice (0.31 ± 0.03) 
compared to control mice (0.06 ± 0.01). In C57BL6/J mice, a strong trend towards an 
increased A:B ratio was apparent (P = 0.053) but this did not reach significance (Figure 



























Figure 5.5 – UE2316 increases ratio of 11-DHC to corticosterone in FVB/N liver. A) 11-
dehydrocorticosterone (11=-DHC; Kendall’s compound ‘A’) levels did not differ between 
livers from control and UE2316-treated C57BL6/J mice, but there was a trend towards 
increased 11-DHC in the livers from UE2316-treated FVB/N mice compared to controls. B) 
Corticosterone (Kendall’s compound ‘B’) levels did not differ in livers from control and 
UE2316-treated C57BL6/J mice, but there was a trend towards decreased corticosterone in the 
livers from UE2316-treated FVB/N mice compared to controls. C) The A:B ratio in livers from 
UE2316-treated C57BL6/J mice showed a strong trend towards being increased compared to 
controls. In FVB/N mice, this increase achieved significance. N=6/group. Data are mean ± 
standard error and were compared by independent samples t-test. 
A B 
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5.2.4 Systemic manipulation of glucocorticoids in vivo 
 Systemic manipulation of glucocorticoids did not affect WT-SCC 
tumour growth 
This study was performed on FVB/N mice (N=6/group) to determine whether altered 
circulating glucocorticoid levels influenced WT-SCC tumour growth. One group 
received daily intraperitoneal (i.p.) injections of saline (0.1mL/10g body weight), one 
group received daily i.p. injections of metyrapone (100mg/kg, prepared as described 
in Section 2.1.3.3) to inhibit adrenal 11-hydroxylase and hence glucocorticoid 
synthesis and a third group received daily i.p. metyrapone injections (100 mg/kg) and 
corticosterone in drinking water (25 µg/mL) to replace endogenous glucocorticoids. 
Neither metyrapone nor metyrapone with corticosterone replacement altered WT-SCC 
tumour growth (Figure 5.6A), final tumour weight (Figure 5.6B), or mouse weight 
(Figure 5.6C) when compared to tumours from control mice. Small but significant 
changes in some organ weights were observed between groups; heart weights were 
higher (117.4 ± 6.7 mg vs 96.7 ± 1.8 mg, P<0.05) and spleen weights decreased (111.3 
± 9.0 mg vs. 145.2 mg, P<0.05) in mice receiving glucocorticoid compared with 
vehicle-treated controls (Figure 5.7A and E). Kidney weights were slightly higher in 
metyrapone-treated mice compared with vehicle-treated controls (142.7 ± 3.4 mg vs. 
133.6 ± 0.97mg, P<0.05, Figure 5.7B). Adrenal and thymus weights were similar 

























Figure 5.6 – WT-SCC tumour growth was unaffected by metyrapone or metyrapone with 
corticosterone replacement.  A) 100mg/kg metyrapone (i.p.) daily did not affect squamous 
cell carcinoma (WT-SCC) tumour growth compared to vehicle (saline). Addition of 
corticosterone to drinking water (25µg/mL) alongside metyrapone treatment (100mg/kg, i.p.) 
to replace systemic glucocorticoids also had no effect on tumour growth. Data compared by 
repeated measures two-way ANOVA. B) Final (day 15) tumour weight was unaffected by 
either metyrapone or metyrapone with corticosterone. Data compared by one-way ANOVA. 
C) Mouse weight was unaffected by either metyrapone or metyrapone with corticosterone. 
























Figure 5.7 – Effects of metyrapone with/without corticosterone on glucocorticoid 
sensitive organ weights.  A) Heart weight was increased in the mice treated with metyrapone 
daily (100mg/kg, i.p.) and corticosterone (25µg/mL in drinking water). B) Kidney weight was 
increased in the mice treated with metyrapone daily. C) Adrenal and D) Thymus weights were 
unaffected by either treatment. E) Spleen weight was decreased in the mice treated with 
metyrapone and corticosterone. N=6/group. * P<0.05. Data are mean ± standard error and 
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 Effect of metyrapone and corticosterone replacement on plasma 
glucocorticoids  
The corticosterone synthesis inhibitor metyrapone did not significantly alter 
circulating 11-DHC levels in mice injected daily (100mg/kg). Mice injected with the 
same dose of metyrapone and given access to corticosterone in drinking water 
(25µg/mL) had elevated levels of circulating 11-DHC compared to metyrapone-
treated mice (10.95 ± 1.76 nmol/L vs. 3.40 ± 1.03 nmol/L, P<0.05, Figure 5.8A). 
Circulating corticosterone levels were not significantly affected by either metyrapone 








Figure 5.8 – Metyrapone was ineffective in inhibiting adrenal glucocorticoid synthesis.  
A) 11-dehydrocorticosterone (11-DHC) levels were increased in the metyrapone 
(100mg/kg/day) + corticosterone (25µg/mL in drinking water) group compared to the 
metyrapone (100mg/kg) group. *P<0.05. B) Corticosterone levels were not significantly 
altered by metyrapone or metyrapone + corticosterone. Glucocorticoid levels measured by 
liquid chromatography tandem-mass spectrometry. N=5-6/group. Data are mean ± standard 
error and were compared by one-way ANOVA with Tukey’s post-hoc test.  
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5.2.5 Cell proliferation in tumours 
 Slide scanner analysis  
To determine whether inhibition of 11β-HSD1 with UE2316 affected cell proliferation 
in vivo in tumours, proliferation marker Ki67 was quantified in WT-SCC tumours from 
control or UE2316 diet-fed wildtype mice and Panc043 and SCC-B6-1 tumours from 
control or UE2316 diet-fed wildtype mice or control diet-fed Del1 mice (N=6/group). 
ImageJ thresholding and quantification of whole tissue images from the slide scanner 
revealed no significant differences in Ki67 % area between tumours from control, 








Figure 5.9 – UE2316 and 11β-HSD1 deletion do not affect Ki67 % area in any of the three 
tumour types. ImageJ was used to threshold and quantify whole sections from each tumour 
type stained with the cell proliferation marker Ki67 and imaged on the slide scanner. Data are 
expressed as % stain area. Squamous cell carcinoma tumour (WT-SCC) data were compared 
by independent samples t-test, Panc043 and SCC-B6-1 tumour data were compared by one-
way ANOVA. N=6/group. Data are mean ± standard error. 
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 Hotspot quantification 
 WT-SCC 
As a secondary method of quantification, hotspots from Ki67-stained tumours were 
identified and quantified. Representative images from control (Figure 5.10A) and 
UE2316-treated tumours (Figure 5.10B) demonstrate the strong nuclear signal 
produced. Immunoreactivity was apparent across the tumour but concentrated in 
distinct proliferative hotspots. No difference in DAPI-positive nuclei per mm2 was 
seen between control and UE2316 WT-SCC tumours (Figure 5.10C), demonstrating 
an equal cell density between treatment groups. Quantification of Ki67-positive cell 
nuclei staining revealed a trend towards reduced proliferation in UE2316-treated 
tumours as compared to control tumours (16.64 ± 0.97 % vs 22.16 ± 2.64 %, P=0.077), 
though this did not reach significance (Figure 5.10D).   A power calculation suggests 
a sample size of 11/group would detect a difference of this magnitude with the given 



























Figure 5.10 - End-stage UE2316-treated WT-SCC tumours showed a trend towards 
reduced proliferation. Representative images of hotspots from Ki67-stained squamous cell 
carcinoma (WT-SCC) tumours from control (A) and UE2316 treated (B) mice are shown. 
Hotspots were typically near the periphery of the tumour. Scale bar = 50µm. C) Nuclear 
density between control and UE2316-treated tumours was unaltered. D) The proportion of 
cells staining positive for proliferation marker Ki67 showed a trend towards being reduced in 
tumours from UE2316-treated mice but this did not reach significance. N=6/group. Data 
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 Panc043 and SCC-B6-01 
Ki67 staining of Panc043 and SCC-B6-1 tumours showed no differences or trends 
between control tumours, UE2316-treated tumours and tumours from Del1 mice in 












Figure 5.11 – UE2316 and 11β-HSD1 deletion do not affect cell proliferation in end-stage 
Panc043 and SCC B6-1 tumours. Panc043 (A) and SCC-B6-1 (C) tumour nuclear density is 
unaffected by UE2316 treatment and 11β-HSD1 deletion (Del1 mice). The percentage of cells 
staining positive for Ki67 was also unaffected by either condition in both Panc043 (B) and 
SCC-B6-1 (D) tumours. N=6/group, data represent mean ± standard error and were compared 
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5.2.6 RNA-sequencing in WT-SCC tumours 
 Principal component analysis (PCA) 
To gain further insight into the mechanism behind the enhanced growth seen in WT-
SCC tumours after UE2316 treatment, RNA-sequencing was performed on WT-SCC 
samples (day 11 timepoint, Section 3.2.1). The average number of reads obtained from 
control samples was 45 million and from UE2316 samples was 42 million. Tophat2 
was used to map an average of 43 million control reads and 41 million UE2316 reads 
to the mouse mm10 reference genome. The average concordant pair alignment rate 
was 86% across the entire sample. 
Control samples are coded as CON1-6 and UE2316-treated tumours as T1-6. PCA 
showed that samples subjected to single-end sequencing rather than paired-end 
sequencing (CON4 and T5) were separated along the first principle component, likely 
a processing effect. PCA also showed a further UE2316-treated tumour (T4) to be an 
outlier (Figure 5.12A). Samples CON4/T4/T5 were therefore excluded from further 
analysis. Repeat PCA showed a split in the control samples along the first principle 
component CON1/2/3 vs CON5/6 (Figure 5.12B). Consequently, differential gene 
expression was assessed between samples CON1/2/3/5/6 vs. T1/2/3/6 but genes also 
found to be significantly different within the control group were excluded from Gene 


























Figure 5.12 - Principal component analysis of RNA-sequencing data. A) Principal 
Component Analysis (PCA) showed that samples sequenced using a single-end protocol 
(CON4/T5) were outliers, as was T4, necessitating their exclusion.  B)  Repeat PCA of the 
samples revealed a split within the control group. To maintain sample size rather than 
excluding further data, only genes shown to differ significantly between T1/2/3/6 and 
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 Gene Ontology Enrichment analysis 
Genes found to be differentially expressed between groups were fed into the Database 
for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 (Huang et al., 
2008). Whilst data presented here are derived using this tool, it is important to note 
that near identical results were achieved using similar GO databases, for example 
AmiGO (Carbon et al., 2009) accessed via the GO website using data from the GO 
consortium (Ashburner et al., 2000). Significantly relevant (P<0.05) biological 
processes are listed in Table 5.1. 
Genes associated with the inflammatory response, immune response and collagen 
fibril organisation (as identified by DAVID) and their relative expression in UE2316-
treated tumours (as identified by RNA-seq) are shown in Figures 5.13-5.15 
respectively. These particular processes were selected based on their q-values from 
GO analysis, and also their mechanistic relevance to the 11β-HSD1 inhibition 
literature – further investigations pertaining to these processes are described below. 
Process q-value 
Inflammatory response 2.76E-08 
Cellular response to interferon-beta 4.08E-07 
Positive regulation of gene expression 2.73E-04 
Immune response 6.21E-04 
Response to lipopolysaccharide 9.91E-04 
Positive regulation of cell migration 0.00134 
Chemokine-mediated signalling pathway 0.00375 
Cellular response to interferon-γ 0.003808 
Negative regulation of osteoblast differentiation 0.00345 




Collagen fibril organization 0.007565 
Defence response to virus 0.007221 
Positive regulation of apoptotic process 0.008123 
Circadian rhythm 0.00936 
Osteoblast differentiation 0.014029 
Negative regulation of cell migration 0.028646 
Cell adhesion 0.042488 
Ossification 0.042287 
Immune system process 0.047532 
Positive regulation of osteoblast differentiation 0.046155 
Defence response to protozoan 0.045956 
Table 5.1 - Gene ontology analysis of RNA-seq data demonstrates importance of immune 
response. Gene Ontology (GO) analysis was performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) v6.8. Significance is expressed using the p-
value corrected for multiple hypothesis testing using the Benjamini-Hochberg method (q-





















Figure 5.13 – ‘Inflammatory response’ genes identified by Gene Ontology analysis. These 
differentially expressed genes were identified as being related to the inflammatory response 
by Gene Ontology analysis. Note that mRNA coding for a large number of pro-inflammatory 
cytokines are reduced after UE2316 treatment, while cytokine receptors and toll-like receptor 
transcript is increased. N=4-5/group. A modified Fisher Exact test was used to determine 
whether the proportion of genes in a given list was significantly associated with a biological 




















Figure 5.14 – ‘Immune response’ genes identified by Gene Ontology analysis. These 
differentially expressed genes were identified as being related to the immune response by Gene 
Ontology analysis. Note that mRNA coding for a large number of pro-inflammatory cytokines 
are reduced after UE2316 treatment, while toll-like receptor and mast cell protease transcript 
is increased. N=4-5/group. A modified Fisher Exact test was used to determine whether the 
proportion of genes in a given list was significantly associated with a biological process 





















Figure 5.15 – ‘Collagen fibril organisation’ genes identified by Gene Ontology analysis. 
These differentially expressed genes were identified as being related to the inflammatory 
process by Gene Ontology analysis. N=4-5/group. A modified Fisher Exact test was used to 
determine whether the proportion of genes in a given list was significantly associated with a 
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5.2.7 Validation of RNA-sequencing by RT-qPCR 
A selection of key differentially expressed genes were assessed by RT-qPCR to 
determine the validity of the RNA-sequencing data. The genes of interest and their 
associated RNA-sequencing data are listed in Table 5.2. Validated genes with their 
expression reduced by UE2316 treatment were: Type 1 collagen (COL1A1); 
chemokine (C-X-C motif) ligand 9 (CXCL9); colony stimulating factor 1 (CSF1); 
platelet factor 4 (PF4); fas cell surface death receptor (FAS); signal transducer and 
activator of transcription 2 (STAT2); C-C motif chemokine ligand 11 (CCL11 );  nitric 
oxide synthase (inducible) (NOS2); arginase 1 (ARG1); and 11β-HSD1 (HSD11B1). 
Validated genes with their expression increased by UE2316 treatment were: tumour 
necrosis factor receptor superfamily, member 23 (TNFRSF23); integrin alpha-10 
(ITGA10) (P<0.05 control vs. UE2316; Figure 5.16A). To confirm the specificity of 
the RNA sequencing, genes from similar pathways not found to be significant by RNA 
sequencing were also compared between groups using RT-qPCR. Chemokine (C-X-C 
motif) ligand 2 (CXCL2) and interleukin-6 (IL6), both pro-inflammatory cytokines, 
were selected and found not to differ between control and UE2316-treated WT-SCC 
tumours (Figure 5.16A). 
Genes that could not be validated (non-significant) were: decorin (DCN); tumour 
necrosis factor receptor superfamily, member 9 (TNFRSF9, P=0.12); tumour necrosis 
factor receptor superfamily, member 21 (TNFRSF21); tumour necrosis factor (TNF, 
P=0.10); alpha smooth muscle actin (ACTA2); toll-like receptor 9 (TLR9, P=0.14); 
angiopoietin-like protein 2 (ANGPTL2); chondroitin sulfate proteoglycan 4 precursor 
















Enriched in UE2316 tumours 
Tlr9 5.92963 8.6073 0.537619 0.0112153 
Itga10 26.2958   51.8496 0.979502 0.00211442 
Dcn 538.249   722.191 0.424106 0.024116 
Angptl2 145.96   218.175 0.579917 0.00211442 
Cspg4 34.3593   53.7223 0.64482 0.00211442 
Reduced in UE2316 tumours 
Ccl24 3.08241 0.533999 -2.52915 0.00712227 
Wnt11 0.813976 0.286914 -1.50437 0.0399818 
Ccl17 6.82636 2.56146 -1.41415 0.0112153 
Ccl11 26.0511 9.93497 -1.39076 0.00211442 
Cxcl11 41.6018 20.7693 -1.0022 0.0230463 
Cxcl5 44.3702 22.6915 -0.967439 0.00211442 
Tnf 8.77976 4.80803 -0.868736 0.00211442 
Acod1 19.6915 11.3465 -0.795329 0.00211442 
Fas 12.934 7.59826 -0.767429 0.00211442 
Csf1 67.5942 41.5673 -0.701449 0.00211442 
Pf4 34.6935 23.2396 -0.578079 0.0356906 
Cxcl9 211.537 144.709 -0.547754 0.00211442 
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Cxcl12 47.8659 33.7732 -0.503119 0.00211442 
Cx3cl1 66.6268 48.2425 -0.465796 0.0124766 
Arg1 128.306 92.6027 -0.470468 0.00211442 
Stat2 46.327 34.9967 -0.404637 0.0112153 
Acta2 30.5468   9.32152 -1.71238 0.00211442 
Table 5.2 – Selected differentially expressed genes of interest. The listed differentially 
expressed genes play key roles in a range of the biological processes identified by Gene 
Ontology analysis and thus are likely to be important mediators of the effects of UE2316 in 
































Figure 5.16 – Validation of RNA-sequencing genes by RT-PCR. cDNA generated from 
WT-SCC tumours grow in control and UE2316-diet-fed mice was subjected to RT-qPCR to 
confirm the RNA-sequencing data. An array of key genes was examined. A) Genes confirmed 
to significantly differ (P<0.05) between groups include type I collagen, 11β-HSD1 and several 
cytokines related to immune and inflammatory processes. The box on the right highlights 
genes that did not differ between groups in either the RNA sequencing or RT-qPCR analysis. 
B) Some genes failed to match the RNA-sequencing data, though several still showed a trend 
towards the expected change. N=5-6/group. Data are mean ± standard error and were 
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5.2.8 CD3 immunoreactivity in WT-SCC tumour was not 
affected by UE2316 treatment 
To quantify infiltrating T-cells, WT-SCC tumours from control vs UE2316-diet-fed 
mice (N=5/group) were stained for CD3-positive cells. The antibody produced a stain 
which was concentrated at the periphery of the tumour, usually very pronounced at 
one border (Figure 5.17A/B). A higher magnification image is shown in Figure 5.17C. 
There was no significant difference in CD3-positive area in tumours from RM-1 and 
UE2316 diet-fed mice, assessed either across whole tissue sections (Figure 5.17E) or 
































Figure 5.17 – CD3-positive cell number in WT-SCC tumours was unaffected by 11β-
HSD1 inhibitor (UE2316) administration. Representative images of CD3-stained control 
(A) and UE2316-treated (B) squamous cell carcinoma (WT-SCC). DAB immunoreactivity 
shown in brown and haematoxylin-counterstained nuclei in blue. CD3 signal was usually 
strongest along one border of the tumour. C) 200x magnification image showing perinuclear 
cytoplasmic localisation of CD3 (red arrows). Scale bar = 50µm. Immunostaining found no 
difference in CD3-positive stain area between WT-SCC tumours from control and UE2316-
treated mice, assessed by either whole section analysis (D) or hotspot analysis (E). Data 
represent mean ± standard error and were compared by independent samples t-test, N=5/group.  
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5.2.9 F4/80 immunoreactivity in WT-SCC tumours was not 
affected by UE2316 treatment 
To quantify inflammatory cell content, WT-SCC tumours from control vs UE2316-
diet-fed mice (N=6/group) were stained for F4/80-positive cells. The antibody 
produced a cytoplasmic stain, present across the tumour but concentrated at the tumour 
periphery and in regions near the centre of the tumour. There was no significant 
difference in F4/80-positive area in tumours from RM-1 and UE2316 diet-fed mouse, 































Figure 5.18 - F4/80 positive cell number in WT-SCC tumours was unaffected by 11β-
HSD1 inhibitor (UE2316) administration. Representative images of squamous cell 
carcinoma (WT-SCC) tumours from control (A) and UE2316-treated (B) mice are shown, with 
DAB immunoreactivity shown in brown and haematoxylin-counterstained nuclei in blue. C) 
Immunostaining did not reveal a difference in F4/80-positive stain area between tumour from 
control and UE2316-treated mice. N=6/group. Data are mean ± standard error and were 
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5.2.10 Effects of UE2316 on fibrosis in tumours 
 UE2316 decreased type I collagen mRNA in WT-SCC 
tumours 
After the observation that Type I collagen mRNA was decreased in WT-SCC tumours 
from UE2316-diet fed mice compared to control-diet fed mice (RNA-sequencing), 
expression was also examined in Panc043 tumours, where it did not differ between 








Figure 5.19 - Col1a1 mRNA was decreased in WT-SCC tumours, but not Panc043 
tumour, by 11β-HSD1 inhibitor (UE2316) administration. A) Col1a1 mRNA expression 
was decreased in squamous cell carcinoma (WT-SCC) tumours from UE2316-treated mice 
compared to control mice, an effect that was not seen in Pancreatic Ductal Adenocarcinoma 
(Panc043) tumours (B). * P<0.01. N=5-6/group. Data are mean ± standard error and were 
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 Second Harmonic Generation imaging shows reduced type 
I collagen content in UE2316 WT-SCC tumours  
To determine whether tumour collagen deposition was altered at the protein level by 
11β-HSD1 inhibition, picrosirius red staining was performed to quantify collagen 
protein content in WT-SCC tumours from control and UE2316 diet-fed mice 
(N=6/group). Quantification of stain % area failed to detect a difference (Figure 5.20). 
To visualise Type-I collagen specifically, Second Harmonic Generation (SHG) 
microscopy was performed by Dr Martin Lee on WT-SCC tumours (N=6/group), 
Panc043 tumours (N=3/group) and SCC-B6-1 tumours (Day 28 N=6/group, Day 41 
N=3/group). Automatic quantification of % collagen area from SHG images revealed 
a reduced amount of type I collagen in tumours from mice fed UE2316-diet (9.78 ± 
0.84%) compared to tumours from mice fed normal diet (3.85 ± 0.56%, P<0.001, 





























Figure 5.20 - Total collagen content does not differ significantly between WT-SCC 
tumours from control and UE2316-treated mice. A) Picrosirius red (PSR) images showed 
total collagen content in squamous cell carcinoma (WT-SCC) tumours from control (A) and 
UE2316-treated (B) mice. Scale bar = 100µm. B) UE2316-treated tumours, showed an 
apparent trend toward decreased collagen deposition, though this did not reach significance. 
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Figure 5.21 – Type I collagen is reduced in WT-SCC tumours from UE2316- treated 
mice. Second Harmonic Generation imaging showed that type I collagen (white signal) is 
reduced in WT-SCC tumours from UE2316-treated mice (B) as compared to tumours from 
control mice (A). Scale bar = 100µm. B) Type I collagen was reduced in tumours from 
UE2316-treated mice. *** P<0.001. N=5/group. Data represent mean ± standard error and 
were compared by independent samples t-test.  
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 Second Harmonic Generation imaging shows increased 
type I collagen content in SCC-B6-1 tumours from UE2316-
treated, but not del1, mice 
SCC-B6-1 tumours grown in C57BL6/J mice fed either control or UE2316-diet, and 
Del1 animals, were also examined using SHG imaging to determine whether an effect 
on collagen was likely to relate to tumour growth. SCC-B6-1 tumours grown to day 
28 (N=6/group) were sectioned and imaged using SHG – tissue from tumours grown 
to day 41 was too degraded for useful analysis. Automatic quantification revealed 
higher levels of type I collagen in SCC-B6-1 tumours from UE2316-treated mice 
compared with tumours from age-matched control mice (2.92 ± 0.72% vs. 6.38 ± 
1.82%, P<0.01, Figure 5.22). The collagen content of SCC-B6-1 tumours from Del1 








Figure 5.22 – Levels of type I collagen in SCC-B6-1 tumours were increased by 11β-
HSD1 inhibition (UE2316) but not by 11β-HSD1 deletion (Del1). Type I collagen, 
automatically quantified from Second Harmonic Generation (SHG) images, was increased in 
SCC-B6-1 tumours from the day 28 time point from UE2316-treated mice. SCC-B6-1 tumours 
from Del1 mice did not differ from control tumours. ** = P<0.01. N=5-6/group. Data represent 
mean ± standard error and were compared by one way ANOVA with Dunnett’s post-hoc test. 
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 11β-HSD1 inhibition and deletion do not affect collagen 
content in Panc043 tumours 
Type I collagen content in Panc043 tumours did not differ between groups (Figure 
5.23). 
 
Figure 5.23 - Panc043 collagen type I is not affected by UE2316 or 11β-HSD1 deletion. 
A) Type I collagen, automatically quantified from SHG images, was not affected in either 
Pancreatic Ductal Adenocarcinoma (Panc043) tumours grown in UE2316-treated mice or 
those grown in Del1 mice compared to those grown in control mice. N=6/group. Data represent 











The experiments described in this chapter tested three hypotheses; that 11β-HSD1 
inhibition and deletion would not affect circulating glucocorticoid levels in mice; that 
UE2316-responsive WT-SCC tumour growth would increase in response to reduced 
circulating glucocorticoids; and that the enhanced WT-SCC growth seen after 11β-
HSD1 inhibition would be associated with altered signalling between cells of the 
tumour microenvironment, likely fibroblasts and/or immune/inflammatory cells. Data 
presented led to the rejection of the first hypothesis; while circulating glucocorticoids 
in C57BL6/J mice were unaffected by UE2316 treatment, FVB/N mice showed a 
significant decrease in circulating corticosterone, suggesting a potential systemic 
effect. Corticosterone levels did not differ between wild-type and Del1 mice, but 11-
DHC levels were increased in the transgenic animals. Attempts to determine whether 
UE2316-responsive WT-SCC tumour growth would increase in response to reduced 
circulating glucocorticoids were unfortunately unsuccessful, as the adrenal 
glucocorticoid synthesis inhibitor metyrapone failed to reduce systemic corticosterone 
levels in FVB/N mice. The second hypothesis thus remains unaddressed. RNA-
sequencing data supports the third hypothesis; GO analysis and subsequent qPCR 
highlighted changes in immune and inflammatory signalling pathways in UE2316-
treated WT-SCC tumours, although histological analysis did not reveal differences in 
the extent of either F4/80- or CD3-positive cells in these tumours compared to controls. 
Collagen fibril organisation was also identified by GO analysis as an altered process 
in UE2316-treated tumours, a finding that was validated by SHG imaging which 
detected a decrease in type I collagen in UE2316-treated WT-SCC tumours.  
In vivo glucocorticoids 
It was originally predicted that neither UE2316 treatment nor 11β-HSD1 deletion 
would affect circulating glucocorticoid levels in mice. When 11β-HSD1 inhibitors 
were initially recognised as a prospective treatment for type 2 diabetes, questions arose 
surrounding their safety with regards to HPA axis function. The concern was that the 
reduction in tissue-specific cortisol regeneration after 11β-HSD1 inhibition would 
reduce negative feedback to the HPA axis and result in increased cortisol release by 
the adrenals. However, data generated using preclinical mouse models has not shown 
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a significant effect on basal circulating corticosterone levels using the selective 11β-
HSD1 inhibitors compound 544 (Hermanowski-Vosatka et al., 2005), compound L-
750 (Luo et al., 2012) or UE2316 (Sooy et al., 2010; Coutinho et al., 2016) in 
C57BL6/J mice. A number of clinical trials have also reported no alteration in 
circulating glucocorticoids after treatment with 11β-HSD1 inhibitors (reviewed by 
Harno and White, 2010; Anderson and Walker, 2013), suggesting that compensatory 
activation of the HPA axis acts only to restore normal levels of plasma glucocorticoids 
in response to increased cortisol/corticosterone clearance.  
In agreement with the literature (Sooy et al., 2010; Coutinho et al., 2016), the present 
studies did not detect a significant difference in circulating corticosterone or 11-DHC 
after UE2316 administration in C57BL6/J mice. In FVB/N mice, however, UE2316 
induced a significant decrease in circulating corticosterone, which was detected via 
two separate assays. This unexpected finding suggests reduced HPA axis activity after 
11β-HSD1 inhibition. One possible explanation for this finding is that the HPA axis 
of FVB/N mice are particularly sensitive to disruption of 11β-HSD1, potentially due 
to the importance of the enzyme at central negative feedback sites. Evidence for this 
theory is limited as FVB/N mice, whilst ideal for use in tumour studies (Huang and 
Balmain, 2014), are rarely used for studies of HPA axis activity. FVB/N mice are 
mentioned in the literature as being particularly sensitive to glucocorticoid-induced 
bone loss (Thiele et al., 2014), and in work performed as part of this chapter showed 
immediate signs of temporary mild sedation and hyperphagia after receiving 
100mg/kg metyrapone, a dose not reported to cause such effects in other strains. 
Strain-specific differences in the response of the HPA axis to 11β-HSD1 deletion have 
previously been reported; Carter et al. (2009) and Kotelevtsev et al. (1997) both report 
increased corticosterone levels in 11β-HSD1 KO mice bred on a 129/MF1 background 
compared to wild-type animals; the present evidence suggests FVB/N mice may also 
be a sensitive strain, and calls into question the role of genetic variation in determining 
patient response to 11β-HSD1 inhibitors.  
An alternative explanation for the reduced circulating corticosterone in UE2316-
treated FVB/N mice concerns animal handling and corticosterone clearance; although 
every effort was made to capture nadir corticosterone levels, it is likely that handling 
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of animals resulted in induction of the stress response. As 11β-HSD1 inhibitor-fed 
mice will have developed more rapid corticosterone clearance, it may be that the 
reported reduction in corticosterone levels reflects a more rapid return to baseline 
levels in UE2316-treated animals. Indeed, Sarabdjitsingh et al. (2014) report that 
stressed UE2316-treated C57BL6/J mice have significantly reduced plasma 
corticosterone compared to vehicle-treated controls, supporting this theory. That being 
said, the same method of plasma collection was used in UE2316-treated C57BL6/J 
animals and Del1 animals in the present studies, neither of which showed altered 
corticosterone levels. Thus even if the finding is the result of rapid corticosterone 
clearance and animal handling, FVB/N mice still show enhanced sensitivity and this 
could potentially influence tumour sensitivity to 11β-HSD1 inhibition. The same 
argument becomes relevant in relation to the data on liver-specific glucocorticoid 
levels; in FVB/N liver, changes in all three parameters after UE2316 treatment (11-
DHC levels, corticosterone levels and 11-DHC:corticosterone ratio) were more 
pronounced than in C57BL6/J mice, suggesting an enhanced sensitivity of FVB/N 
mice to glucocorticoid manipulation. Importantly, these liver data also demonstrate the 
effectiveness of UE2316 in preventing conversion of 11-DHC to corticsterone in vivo. 
It is an unfortunate limitation of the study that levels could not be shown in tumours; 
very small quantities of tissue obtained from the tumour studies meant that LC-MS/MS 
could not achieve the sensitivity required to measure corticosterone and 11-DHC 
accurately. Attempts to use state-of-the-art mass spectrometry imaging methods also 
proved unsuccessful but have previously been effective in demonstrating the 
effectiveness of UE2316 in altering brain glucocorticoid levels (Cobice et al., 2013; 
2017). Further optimisation of these mass spectrometry methods will provide greater 
insight into tumour steroid intracrinology.  
Although not statistically significant, 11-DHC levels appear to be decreased by 
UE2316 treatment in both C57BL6/J and FVB/N animals. Given the relatively small 
sample size in this study, it is important to appreciate the possibility of a type 2 error. 
If UE2316 does indeed reduce circulating 11-DHC levels, it may be indicative of an 
off-target effect on adrenal glucocorticoid synthesis, which may also explain the 
reduced corticosterone levels in FVB/N plasma. Repetition of the study with an 
increased sample size would be required to fully address this possibility.  
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In Del1 animals, corticosterone levels were not seen to differ from those in wild-type 
animals, while 11-DHC levels were increased around 10-fold compared to wild-type 
controls. These are the first reported plasma glucocorticoid levels in the Del1 mouse, 
with previous papers from the group having made use of an older KO mouse which 
exhibited some residual enzyme expression. The present corticosterone findings are in 
keeping with several other studies which did not see an effect on corticosterone in KO 
animals on a C57BL6/J background (Kotelevtsev et al., 1997; Carter et al., 2005; 
Harno and White, 2010). 11-DHC levels are less frequently reported, although Harris 
et al. (2001) do report an increase in 11-DHC in the previous 11β-HSD1 KO mouse. 
These findings suggest that 11β-HSD1 deletion in the Del1 mouse prevents the 
conversion of 11-DHC to corticosterone, resulting in accumulation of 11-DHC. While 
this increase in 11-DHC is apparent in the plasma, the HPA axis appears to be able to 
compensate for the increased clearance of corticosterone, presumably by increased 
release of CRH and ACTH to stimulate enhanced adrenal glucocorticoid synthesis. 
A key hypothesis that the present chapter unfortunately was unable to address was that 
inhibiting adrenal glucocorticoid synthesis would enhance WT-SCC tumour growth, 
and this effect could be reversed by glucocorticoid replacement. This experiment, had 
it been successful, would have provided support for the inference that alterations in 
active glucocorticoid exposure were responsible for the enhanced growth phenotype 
displayed by WT-SCC tumours treated with UE2316. Insufficient inhibition of adrenal 
glucocorticoid synthesis is likely the main reason the experiment failed. 
Considerations of animal welfare necessitated a limit in the number of intraperitoneal 
injections that could be administered to mice. The initial plan had been to co-
administer metyrapone, an 11β-hydroxylase inhibitor, in combination with 
aminoglutethamide, a P450 enzyme inhibitor that prevents the conversion of 
cholesterol to pregnenolone. This dual administration would have offered more 
complete inhibition and prevented the accumulation of the precursor 
deoxycorticosterone which can occur with metyrapone alone. Unfortunately, a 
common solvent in which both drugs were soluble could not be found, leading to the 
decision to use metyrapone alone in these studies. While metyrapone may have caused 
subtle alterations in circulating 11-DHC levels, these did not reach statistical 
significance and, critically, corticosterone levels were not reduced by metyrapone. 
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Compensatory activation of the HPA axis appears to have been able to overcome the 
effects of metyrapone treatment alone, as the only significant difference in circulating 
glucocorticoids detected was an increase in plasma 11-DHC in the mice given 
metyrapone in combination with corticosterone replacement (potentially due to 
inhibition of 11β-HSD1 by metyrapone). If time allowed, a repeat of this study using 
surgical adrenalectomy (prohibited in these experiments by the terms of the Home 
Office Project Licence) would provide far more useful data; the data generated here 
are invalidated by the methodological limitations.   
Cell proliferation in tumours  
Ki67 staining of tumours revealed a small (~5%) decrease in proliferating cells in 
UE2316-treated WT-SCC tumours that fell slightly short of statistical significance 
(P=0.077), likely due to lack of power. Imaging parameters (gain/digital offset) for 
these experiments were optimised using negative experimental controls (secondary 
antibody only, no primary), with levels set below the threshold of background 
fluorescence. Strict optimisation of imaging parameters is important given that 
alteration of these parameters is subject to investigator bias and could influence the 
statistical outcome of image analysis. Given the trend observed in the data, it is 
necessary to note that alternative imaging parameters may have achieved true 
statistical significance.  
The relevance of this observation is unclear, as it was only apparent when examining 
proliferative hotspots and not the entire tumour section. Whilst the underpowered 
nature of the study limits the interpretation, this observation could suggest a decrease 
in the proliferation of a particular cell type in the tumour microenvironment, localised 
to certain regions of the tumour. Hotspots were typically found near the tumour border 
rather than the centre of the tumour, suggesting that infiltrating host cells (fibroblasts, 
immune cells, inflammatory cells) may have been more prevalent. Key future studies 
would involve the optimisation of co-stains for specific cell populations that could 
identify not only the proportion of proliferating cells, but also the type. Importantly, 
this effect was completely absent from the both the SCC-B6-1 and the Panc043 
tumours, indicating it could be of relevance to the enhanced growth phenotype 
observed in WT-SCC tumours. 
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Immune and inflammatory signalling in tumours 
RNA sequencing of WT-SCC tumours and subsequent GO analysis identified a 
number of prospective mechanistic pathways which may have contributed to the 
enhanced growth seen after 11β-HSD1 inhibition. Immune and inflammatory 
responses feature heavily in the GO analysis list of significantly altered biological 
processes. WT-SCC tumours from UE2316-treated mice showed reduced expression 
of a range of pro-inflammatory cytokine and chemokine genes, including members of 
the CCL, CXCL, CX3CL and TNF families, and CSF1. These changes were 
accompanied by an increase in the expression of several members of the TLR and 
TNFRSF families, and CSF1R, suggesting reduced pro-inflammatory ligand binding. 
Furthermore, expression of a number of interferon-γ (IFN-γ) inducible genes was 
reduced in tumours from UE2316-treated animals, including some CXCL chemokines, 
OAS2 and OASL2, members of the interferon inducible protein (IFI) family, 
lymphotoxin-alpha (LTA) and NOS2. As TLR activation can stimulate the production 
of IFNs, interleukins and TNF by myeloid and lymphoid cells (Chapman et al., 2013a), 
the evidence overwhelmingly points towards reduced inflammatory and immune cell 
signalling within tumours from UE2316-treated mice. Unfortunately, not all of the 
differentially expressed genes selected for validation achieved significance when 
compared by qPCR. Despite this, the majority of genes tested were validated and many 
of the changes appear to be specific to certain pathways, thus failure to validate all of 
the genes does not detract from the overwhelming evidence that intra-tumour immune 
and inflammatory signalling is significantly disrupted by UE2316. The reduced 
expression of CCL and CXCL chemokines would predict reduced migration of 
eosinophils, neutrophils and T-cells into tumours. The reduced expression of 11β-
HSD1 itself after UE2316 treatment is indicative of reduced immune/inflammatory 
cell infiltration and activation as the enzyme is expressed in macrophages and 
lymphocytes (Chapman et al. 2013b) and upregulated by immune cell activation, 
including TNF and IL1 stimulation (Hardy et al., 2006; Ahasan et al., 2012). 
The overriding message to emerge from the RNA sequencing data is that UE2316 
treatment leads to a dampening of the innate immune response in WT-SCC tumours. 
Determining the cell types responsible for this effect will be a focus of future work. 
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11β-HSD1 is expressed in the mast cells (Coutinho et al., 2013) and macrophages 
(Thieringer et al., 2001) that are responsible for the initial release of pro-inflammatory 
mediators during an immune response. Expression of chymase 2 (CMA2) and mast 
cell proteases (MCPT) 1, 2 and 4 were all increased in tumours from UE2316-treated 
mice, suggesting increased mast cell degranulation. Coutinho et al. (2013) 
demonstrated that 11β-HSD1 deficiency reduces the activation threshold of mast cells 
and increases the rate of piecemeal degranulation, a slower form of degranulation 
associated with chronic inflammation. The pro-inflammatory mediators released by 
mast cells recruit eosinophils and neutrophils to the site of inflammation, though a 
decrease in the expression of CXCL chemokines, Formyl Peptide Receptor 2 (FPR2), 
TNF and Platelet Factor 4 (PF4) all suggest reduced neutrophil recruitment. Blocking 
11β-HSD1 during acute inflammation results in more severe acute inflammation after 
myocardial infarct (McSweeney et al., 2010; White et al., 2015; Mylonas et al., 2017) 
and during pleural inflammation, arthritis and sterile peritonitis (Coutinho et al., 2012). 
The situation examined in these tumours, however, is not likely to represent the acute 
inflammatory phase, as transcript data are taken from tumours that have been 
developing over 11 days; thus conclusions cannot be drawn regarding the acute 
inflammation. As inflammation progresses towards resolution, mononuclear cells 
become the predominant cell type (Chapman et al., 2009). The failure of inflammation 
to resolve results in chronic inflammatory environments such as those seen in arthritis 
and atherosclerosis. In tumours from UE2316-treated mice, reduced expression of 
CCL chemokines, FPR2, CSF1, TNF, PLA2G7 and CD274 all suggest reduced 
macrophage infiltration and activity, and a dampened anti-tumour inflammatory 
response.  
11β-HSD1 inhibition and anti-tumour immunosurveillance 
The role of inflammation in tumour progression is controversial in that it can both 
promote tumour progression (via stimulation of angiogenesis for instance) but also 
inhibit tumour progression (via anti-tumour immunosurveillance). Manipulation of 
physiological glucocorticoids may well affect anti-tumour immunity; for example, in 
a model of colorectal cancer, generation of endogenous glucocorticoids prevented anti-
tumour immunity (Sidler et al., 2011) and physiological levels of corticosterone also 
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limit the effectiveness of immunotherapy in pancreatic cancer (Flint et al. 2016). 
Furthermore, Cirillo et al. (2017) recently demonstrated that glucocorticoids in 
conditioned media from SCC cells inhibited the proliferation of anti-tumour CD8+ T-
cells via binding at the GR (this effect was abolished by the addition of GR antagonist 
RU486). In the present model, 11β-HSD1 inhibition appears to decrease inflammation 
whilst enhancing tumour growth, raising the intriguing possibility that UE2316 
dampens the anti-tumour immune response. Transcriptomic data suggest a decrease in 
IFN-γ signalling in WT-SCC tumours from UE2316 treated mice. IFN-γ, released by 
NK cells and cytotoxic T-cells, is able to destroy tumour cells and prevent tumour 
progression as part of the ant-tumour immune response (Dighe et al., 1994; Kaplan et 
al., 1998; Shankaran et al., 2001; Girardi et al., 2001; Kim et al. 2007). Several further 
factors associated with anti-tumour immunity are altered in the present study. FAS has 
previously been shown to reduce the number of myeloid-derived suppressor cells 
MDSCs) in the tumour microenvironment (Sinha et al., 2011). These cells express KIT 
(Murdoch et al. 2008) so reduced FAS and increased KIT ligand (Murdoch et al., 
2008) in tumours from UE2316-treated mice could, therefore, result in increased 
MDSC number and activation in the tumour microenvironment. These MDSCs are 
known to suppress anti-tumour function of T-cells and NK cells and thus promote 
tumour progression (Sica and Bronte, 2007; Murdoch et al., 2008). The evidence is 
mixed though, as MDSCs are associated with increased ARG1 and NOS2 expression, 
both of which are in fact decreased in tumours from UE2316-treated mice (at least at 
the transcript level). The reduced expression of CXCL12 and CXCL5 in tumours from 
UE2316-treated mice would also be predicted to reduce MDSC infiltration. 
Glucocorticoids have previously been shown to increase the induction of MDSCs in 
mice (Varga et al., 2008), thus it may follow that 11β-HSD1 inhibition would reduce 
their migration into tumours. TNF and LTA have both previously been considered as 
effective promoters of a beneficial anti-tumour immune response in melanoma 
(Schrama et al., 2001; Drutskaya et al., 2010), thus their reduced expression supports 
the theory of reduced anti-tumour immunity. Factors known to negatively regulate T-
cell function, such as CBLB (Lutz-Nicoladoni et al., 2015), are also increased in 
tumours from UE2316-treated mice. Reduced CSF-1 in tumours treated with UE2316 
could also inhibit the differentiation of tumour suppressing dendritic cells (Menetrier-
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Caux et al., 1998). The complexity of immunosurveillance is increased in SCC by the 
interactions of the epimmunome (factors released by the epithelial tumour cells 
themselves rather than myeloid cells), and the fact that subtle alterations in one or two 
cytokines can cause a switch in the SCC inflammatory profile from a pro- to an anti-
tumour environment (Huang and Balmain, 2014). Glucocorticoids are known to affect 
the epimmunome (Stojadinovic et al., 2006; Sanchis et al., 2012; Itoi et al., 2013) and, 
likewise, SCC cells may produce endogenous glucocorticoids that prevent anti-tumour 
T-cell behaviour via a paracrine mechanism (Cirillo et al., 2017). In summary, 
deducing the exact cellular mechanisms at work will require more in-depth study at 
the protein and cellular level, but this work provides substantial evidence that factors 
relating to anti-tumour immunity are affected by 11β-HSD1 inhibition. Deducing the 
mechanisms and confirming intra-tumour glucocorticoid levels will prove vital in 
assessing the risk posed by these inhibitors in SCC. 
11β-HSD1 inhibition in chronic inflammatory conditions 
The notion that 11β-HSD1 inhibition may have differential effects based on whether 
inflammation is acute or chronic may be pivotal to understanding the effects of 
UE2316 in WT-SCC tumours. Obesity is a chronic inflammatory condition, and the 
way in which adipose tissue from models of obesity responds to 11β-HSD1 deletion 
shares some similarities with the response of WT-SCC tumours to UE2316. Wamil et 
al. (2011) studied the effects of 11β-HSD1 deletion in obesity and found that a number 
of similar cytokines (including members of the CCL, CXCL and TNF families) were 
decreased in adipose tissue from high-fat diet-fed 11β-HSD1 KO mice compared to 
wild-type controls. Furthermore, adipose tissue from 11β-HSD1 KO animals showed 
decreased CD8+ T-cell infiltration and macrophage infiltration. Michailidou et al. 
(2012) built upon the aforementioned work on 11β-HSD1 deficiency in obese mice 
and found increased angiogenesis in adipose tissue from 11β-HSD1 KO animals. The 
present study identified no such change. This could be due to the highly angiogenic 
nature of the tumour microenvironment, which potentially masked subtle changes in 
angiogenic factors. RNA-sequencing did identify a subtle increase in CSPG4 
expression in UE2316-treated tumours, which is known to be expressed in pericytes 
(Raza et al., 2010). Thus it may be that more detailed examination of tumour vessel 
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function would identify subtle differences. Alternatively, it may be that the changes in 
inflammatory and immune cell content, and the altered fibrosis, exerted a powerful 
influence on tumour cell proliferation and survival, and angiogenesis is less relevant 
in this model. The lack of differences seen in vessel smooth muscle cell coverage after 
UE2316 treatment supports the latter theory.   
Further similarities are seen in another chronic inflammatory context: atherosclerosis. 
11β-HSD1 deletion reduces macrophage and T-cell infiltration into plaques (Kipari et 
al., 2013). Several of the key gene expression changes seen in the present study have 
also been seen in atherosclerotic plaques after 11β-HSD1 inhibition (Luo et al., 2012), 
including reductions in interleukins, toll-like receptors, STAT family members, and 
several chemokines. Interestingly, when gene expression was profiled specifically 
within the vascular smooth muscle cell and macrophage populations from within 
whole aortic samples, reduced expression of pro-inflammatory mediators was still 
apparent in 11β-HSD1 deficient samples (Luo et al., 2012). This finding could perhaps 
imply that, as well as reduced inflammatory cell infiltration into tumours, these 
inflammatory cells may also be less active in the production of pro-inflammatory 
mediators.  
CXCL chemokines are induced by IFN-γ and TNF signalling which corresponds with 
the reduced TNF expression identified by RNA-seq (disappointingly qPCR did not 
validate TNF). CXCL signalling, as well as playing a role in tumour progression, has 
also been linked to atherosclerosis in which it does not promote neutrophil infiltration 
(as in acute inflammation) but rather exerts a beneficial effect by preventing 
macrophage foam cell accumulation in plaques (Rouselle et al., 2013). 11β-HSD1 
inhibition similarly prevents foam cell formation in vivo (Garcia et al., 2013). Several 
11β-HSD1 inhibitors, and genetic deletion of the enzyme, improve atherosclerosis by 
reducing plaque formation (reviewed in Hadoke et al., 2013). Garcia et al. (2013) 
examined gene expression in peritoneal macrophages from 11β-HSD1 KO mice and 
noted attenuation of the inflammatory state compared to wild-type macrophages, 
including reduced chemokine signalling. Release of TNF from 11β-HSD1 KO 
macrophages was reduced by 30% compared to control macrophages. Importantly, 
bone marrow transplantation studies demonstrated that it was the 11β-HSD1 
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deficiency in myeloid cells that was important in reducing plaque formation (Garcia 
et al., 2013; Kipari et al., 2013). This suggests that inflammatory cells may also be 
responsible for reduced TNF expression in tumours, and thus important in tumour 
progression. TLR expression was decreased in the study by Garcia et al. (2013), 
whereas in the present study, expression was increased and accompanied by a decrease 
in ACOD1 (a negative regulator of TLR expression). It is interesting to note the 
involvement of the TLRs in both studies, despite their opposing expression in the 
different models.  
Many of the observed effects of 11β-HSD1 inhibition (for example reduced 
interleukin, IFN, and TNF expression) mimic the reported anti-inflammatory and 
immunosuppressive effects of glucocorticoids (Sapolsky et al., 2000; Coutinho and 
Chapman, 2011), which occur as a result of binding at the GR (Cronstein et al., 1992; 
Cirillo et al., 2017). As 11β-HSD1 inhibition ought to reduce local glucocorticoid 
levels, this may seem counterintuitive. Yet there are several examples of 
physiologically relevant concentrations of glucocorticoids promoting, rather than 
reducing, inflammation. Barber et al. (1993) report that pre-treatment with 
glucocorticoids increased TNF-α and IL-6 release into the plasma of mice treated with 
lipopolysaccharide (LPS). Furthermore, low concentrations of corticosterone (500-
1000nM) enhanced T-cell growth in vitro (Weigers et al. 1993; 1994; 1995) and in 
vivo (Wiegers et al. 1993). This effect is thought to be mediated via activation of the 
MR in immune and inflammatory cells (Wiegers et al., 1993; Sapolsky et al. 2000) 
and the same mechanism has been proposed for anti-inflammatory effects of 11β-
HSD1 inhibition in atherosclerotic plaques (Luo et al., 2012). MR and GR are both 
expressed in macrophages (Barish et al., 2005; Lim et al., 2007), while only the 11β-
HSD1 (and not the 11β-HSD2) isozyme is expressed (Gilmour et al., 2006; Usher et 
al., 2010; Chapman et al., 2013a). Thus corticosterone binding at either receptor could 
be relevant to the effect seen in the present studies. MR antagonism also reduces pro-
inflammatory cytokine levels (including TNF) in obese adipose tissue (Guo et al., 
2008) and polarises macrophages towards an M2 phenotype whilst reducing fibrosis 
in models of cardiac hypertrophy and stroke (Usher et al., 2010; Frieler et al., 2011). 
While this evidence could explain why 11β-HSD1 inhibition exerts anti-inflammatory 
effects, MR was undetectable in WT-SCC tumours. Furthermore, Lim et al. (2007) 
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found that while low concentrations of corticosterone (100 pM) enhanced pro-
inflammatory cytokine production by macrophages, high concentrations (1µM) were 
potently anti-inflammatory (similar results were seen by Itoi et al. (2013) after 
exposing keratinocytes to glucocorticoids). Only deletion of GR abrogated the pro-
inflammatory response of macrophages to glucocorticoids, while MR deletion had 
little effect (Lim et al., 2007). GR blockade also prevented the anti-proliferative effect 
of tumour-derived glucocorticoids on T-cell proliferation in the study by Cirillo et al. 
(2017). Thus, GR likely remains the more important receptor in the solid tumour 
model. Studies using selective MR and GR inhibitors will be required to more 
comprehensively address this question. 
CD3 staining in the present study did not detect a difference between WT-SCC 
tumours from control and UE2316-treated mice However, CD3 is a general T cell 
marker and fluorescence associated cell sorting (FACS) is required to determine more 
subtle alterations in specific T-cell populations. The perinuclear localisation of CD3 
in many of the WT-SCC tumour cells may even suggest immature thymocytes 
(Swerdlow et al., 1988) in which CD3 has not yet been translocated to the cell surface; 
an avenue for future investigation. Likewise, F4/80 staining did not reveal a marked 
difference between treatment groups in our study, yet key markers of macrophage 
polarisation were altered (see below), suggesting a more subtle effect of 11β-HSD1 
inhibition on tumour inflammation, possibly on macrophage polarisation states. 
Accelerated switching of macrophages from an M1 to an M2 phenotype in 11β-HSD1 
deficient tissues is reported in the acute inflammatory context of myocardial infarction 
(McSweeney et al., 2010) but was not seen in vitro (Gilmour et al., 2006; Zhang et al., 
2007) or in adipose tissue in vivo (Wamil et al., 2006). Determining the polarisation 
state of macrophages from the RNA sequencing data is difficult due to conflicting 
expression of transcripts. UE2316 appears to have reduced IFN-γ signalling and TLR 
activation in WT-SCC tumours, and this would be predicted to polarise macrophages 
towards an M2 phenotype. Comparing the present RNA-seq data with previously 
published data on macrophage polarisation gene profiles (Martinez et al., 2006), a 
number of changes did suggest M2 polarisation (decreased expression of NOS2, 
CXCL9, OASL2, HSD11B1, FAS, TNF, CXCL11, and CCL11), yet several 
contradictory findings were also apparent (decreased expression of ARG1, platelet-
Chapter 5 – Mechanism of enhanced tumour growth 
250 
 
derived growth factor A (PDGF-A), macrophage scavenger receptor 1 (MSR1), LTA, 
CCL17 and CCL24). As transcripts from whole tumours were analysed, altered 
expression could reflect alternative cell populations infiltrating tumours, as opposed 
to change in polarisation state. A good case in point is the reduced 11β-HSD1 
expression seen in WT-SCC tumours after UE2316 treatment; M1 polarised 
macrophages increase their 11β-HSD1 expression while expression is unaffected by 
M2 polarisation (Chapman et al., 2013a), so this finding may indicate increased M2 
polarisation. However, this reduced expression may also reflect a reduced number of 
macrophages, dendritic cells, neutrophils, mast cells or activated T-cells in these 
tumours, as all of these cell types express 11β-HSD1 (Freeman et al., 2005; Zhang et 
al., 2005; Chapman et al., 2013a; Coutinho et al., 2016). Isolation of tumour-
associated macrophages by FACS and subsequent analysis is required if a more firm 
conclusion is to be reached.  
11β-HSD1 deficiency has also been studied in several non-cardiometabolic chronic 
inflammatory conditions, including peritonitis and arthritis. 11β-HSD1 deficient mice 
showed delayed clearance of apoptotic neutrophils (Gilmour et al., 2006), earlier onset 
and delayed resolution of inflammation in models of arthritis and sterile peritonitis 
(Coutinho et al. 2012). These effects are thought to be at least partially due to 11β-
HSD1 deletion in macrophages (Zhang et al., 2012), which promotes angiogenesis and 
contributes to pathology in arthritis (Jackson et al., 1997). By contrast, the selective 
11β-HSD1 inhibitor BVT-2733 improved symptoms of collagen-induced arthritis by 
reducing the expression of pro-inflammatory cytokines, including TNF, IL-1β and IL6, 
and reducing inflammatory cell infiltration into joints (Zhang et al., 2013). The 
beneficial effects of 11β-HSD1 inhibition in the synovium have been linked to reduced 
glucocorticoid action in synovial fibroblasts and osteoclasts (Hardy et al., 2012; 2013) 
resulting in a net reduction in damaging inflammation (Hardy et al., 2013). Thus there 
is a fascinating degree of crossover between these chronic inflammatory conditions 
and the findings in the solid tumour model; 11β-HSD1 in immune and inflammatory 
cells, and often fibroblasts, appears to be central to all of these models.  
11β-HSD1 inhibition, fibroblasts and the extracellular matrix 
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Thus far the present findings in solid tumours exhibit many similarities to chronic 
inflammatory cardiometabolic disorders; namely obesity and atherosclerosis. 
Mechanistically, fewer similarities are apparent between solid tumours and the acute 
inflammatory setting of the infarcted myocardium. That said, similar pathways do 
appear to be affected although apparently in the opposite direction depending on 
setting. Mylonas et al. (2017) recently showed that deletion of 11β-HSD1 from a 
subset of cardiac fibroblasts enriched for the enzyme results in the increased release of 
CXCL2 and 5, which subsequently recruit more neutrophils to the infarct and promote 
recovery. CXCL5 is reduced in WT-SCC tumours in which 11β-HSD1 has been 
inhibited. This discussion has thus far focussed on the role of immune and 
inflammatory cells in promoting tumour growth, yet cancer-associated fibroblasts 
(CAFs) and extracellular matrix (ECM) deposition can also heavily influence tumour 
progression.  
Mice in the present studies were given UE2316 for 5 days before tumour cells were 
injected, thus 11β-HSD1 inhibition and its associated effects on inflammation will 
have been present from the onset of tumour formation. Previously, depletion of 
macrophages before the point of injury has been shown to ameliorate fibrosis (Duffield 
et al., 2005). Duffield et al. (2005) used a model of liver injury to show that during the 
initial stages of inflammation, M2 macrophages dominate and maintain a resident 
population of myofibroblasts (which are mechanistically very similar to activated 
CAFs), which promote fibrosis. With decreasing levels of pro-inflammatory mediators 
(the recovery phase of inflammation), a subset of ECM-degrading macrophages 
becomes predominant (M1 phenotype). In the UE2316-treatment group in the WT-
SCC model, and in previous studies of 11β-HSD1-deficient adipose tissue 
(Michailidou et al., 2012), fibrosis and pro-inflammatory signalling are reduced; 
findings somewhat at odds with the expected effects of 11β-HSD1 inhibition on 
fibrosis. Yet in SCC-B6-1 tumours, the opposite effect was seen; UE2316 promoted 
fibrosis compared to tumours from control mice. Thus, this conclusion cannot be 
applied universally to the solid tumour microenvironment and likely depends on 
tumour type. Differences in the response of Class A and B SCC tumours to 
inflammation are well documented (Wong et al., 2013; Huang and Balmain, 2014), so 
it is perhaps not surprising that UE2316 exerts alternative effects in WT-SCC and 
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SCC-B6-1. Focus will remain on the WT-SCC tumours due to their altered growth 
phenotype.  
The reduced fibrosis seen in WT-SCC tumours was also found in obese adipose tissue 
from 11β-HSD1 KO animals, which showed decreased fibrosis and alpha-smooth 
muscle actin expression, suggesting reduced fibroblast numbers. In WT-SCC tumours, 
Type I collagen, detected using SHG imaging, was significantly reduced. This result 
is consistent with the reduced Col1a1 and Col1a2 expression and the increased matrix 
metalloprotease 11 expression reported in UE2316-treated tumours. Likewise, alpha-
smooth muscle actin was identified by RNA-seq as having reduced expression in 
tumours from UE2316-treated mice; though this finding could not be validated, 
making it difficult to conclude whether this reflects reduced fibroblast content.  
Although direct quantification of fibroblasts in WT-SCC was not performed in the 
present study, several factors suggest that CAF activation and possibly number is 
reduced by UE2316-treatment. Reduced fibrosis and reduced expression of COL1A1, 
COL1A2, COL14A1, stromal-cell derived factor 1 (SDF-1) and LOX are all 
suggestive of reduced fibroblast activity (Harper and Sainson. 2013; Fang et al., 2014). 
The possible reduced alpha-SMA (expressed by activated CAFs: Özdemir et al., 2014) 
in UE2316-treated tumours would also suggest reduced fibroblast number. CAFs can 
promote anti-tumour immune cell infiltration into tumours (Harper and Sainson, 2014; 
Özdemir et al. 2014), providing a link between the potentially dampened anti-tumour 
immune response seen in WT-SCC tumours treated with UE2316 and the reduced 
fibrosis observed.  Inflammatory cells are also able to recruit fibroblasts into SCC 
tumours (Coussens et al., 1999) and this enhanced recruitment can promote SCC 
growth suppression via the deposition of a fibrotic ECM that constrains tumour cell 
proliferation and invasiveness (Willhauck et al., 2006; Cretu and Brooks, 2007). 
Collagen itself is able to interact with the immune and inflammatory cells of the 
tumour microenvironment (Fang et al., 2014), and reducing collagen has been shown 
to predict poor prognosis in SCC (Baba et al., 2008). Whilst this is in keeping with 
observations from the present study, the decrease in fibrosis is unexpected given 
previous studies of 11β-HSD1 inhibition showing enhanced fibroblast proliferation 
and fibrosis in skin (Tiganesu et al., 2013; Terao et al., 2014) and given the inhibitory 
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effects of glucocorticoids on collagen deposition (Maragoudakis et al., 1989; Morgan 
et al., 2014). The tumour microenvironment is of course a very different situation from 
healthy skin and enhanced fibrosis was seen in obese adipose tissue (Michailidou et 
al., 2012), arguably a more similar chronic inflammatory environment. It is possible 
that 11β-HSD1 inhibition dampens the inflammatory response, leading to reduced 
activation and migration of pro-inflammatory CAFs (Erez et al., 2010) into the tumour 
which further dampens the anti-tumour immune response and leads to an 
underdeveloped ECM conducive to tumour growth. Disappointingly, attempts to 
quantify fibroblasts in this study were unsuccessful due to the expression of vimentin 
in SCC cells (Klein-Szanto et al., 1989; Huang and Balmain, 2014). 
In summary, inhibition of 11β-HSD1 in WT-SCC tumours dampens immune and 
inflammatory signalling within the tumour microenvironment, likely leading to the 
reduced activation of CAFs and the reduced deposition of type I collagen. These 
factors, in combination, promote WT-SCC growth. The effects of physiological 
glucocorticoid manipulation may relate to pro-inflammatory effects of MR, as well as 
GR, activation in inflammatory and immune cells. Future studies must focus on more 
detailed dissection of the tumour immune and inflammatory microenvironment using 
FACs, more detailed IHC studies to determine the exact cell types involved, and the 
use of selective receptor inhibitors to determine the relevant pathways.   
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6 Conclusions and future work 
6.1 Aims revisited 
The work presented in this thesis addressed the hypothesis that 11β-HSD1 inhibition 
promotes tumour angiogenesis and, consequently, enhances solid tumour growth. The 
need for this research arose from concerns surrounding the pro-angiogenic effects of 
reduced 11β-HSD1 activity, which are apparent in models of myocardial infarction 
(Small et al., 2005; McSweeney et al., 2010; McGregor et al., 2014; White et al., 2015; 
Mylonas et al., 2017), obesity (Michailidou et al., 2012), inflammatory arthritis 
(Zhang et al., 2017) and tumour growth (Liu et al., 2016). Increased tumour growth 
via enhanced angiogenesis would present a significant adverse effect of clinical 11β-
HSD1 inhibitors, which were originally designed to treat type II diabetes (Anderson 
and Walker, 2013) and have also shown promise in the treatment of Alzheimer’s 
disease (Webster et al., 2017). Given the findings of the present experiments, it is 
important to draw conclusions in relation to the primary research aims. 
The first research aim was to determine whether pharmacological inhibition or genetic 
ablation of 11β-HSD1 would promote tumour growth and angiogenesis in murine 
models of squamous cell carcinoma (SCC) and pancreatic ductal adenocarcinoma 
(PDAC). It was shown that only one of the tested SCC cell lines (WT-SCC) produced 
tumours that grew more quickly in response to 11β-HSD1 inhibition, while the other 
two cell lines examined (SCC-B6-1 and Panc043) grew normally, both in wild-type 
mice fed an 11β-HSD1 inhibitor and in Del1 mice genetically deficient for the enzyme. 
Unexpectedly, no evidence of increased angiogenesis in any tumour type was seen, 
strongly suggesting that an alternative mechanism was responsible for increased SCC 
growth. The second research aim was to determine the effects of pharmacological 11β-
HSD1 inhibition and exogenous glucocorticoids on ex vivo angiogenesis, and in vitro 
tumour cell growth. As has been seen previously (Small et al., 2005), active 
glucocorticoids were potently anti-angiogenic ex vivo. In the present experiments, only 
genetic deletion, not inhibition, of 11β-HSD1 was able to prevent this angiostasis. As 
neither glucocorticoids nor the 11β-HSD1 inhibitor UE2316 drastically affected 
tumour cell growth, attention was turned to other components of the tumour 
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microenvironment. The third and final research aim was to determine the effects of 
11β-HSD1 inhibition on the tumour microenvironment and to investigate mechanisms 
by which glucocorticoid manipulation might influence tumour growth. Inhibition of 
11β-HSD1 led to reduced expression of a range of pro-inflammatory cytokines and 
chemokines in WT-SCC tumours, suggesting a significant dampening of immune and 
inflammatory signalling in these tumours. Type I collagen deposition in WT-SCC 
tumours was also reduced by 11β-HSD1 inhibition; determining the degree to which 
altered immune signalling and collagen deposition are linked may provide an 
important mechanistic insight into the enhanced tumour growth.  
6.1.1 11β-HSD1 inhibition can promote squamous cell 
carcinoma growth 
One of the most important conclusions to be drawn from this work is that 11β-HSD1 
inhibitors can promote growth in some types of murine SCC. The finding that SCC in 
particular is sensitive to 11β-HSD1 inhibition is not entirely surprising, given the 
atypical expression of the 11β-HSDs in this cancer type. Upon progression to 
malignancy, healthy tissues typically show decreased 11β-HSD1 expression and 
increased 11β-HSD2 expression, a pathological ‘switch’ thought to promote tumour 
growth (Rabbitt et al., 2003b). This switch is absent in SCC, with many studies 
(including the present) detecting only the type 1 isozyme in SCC samples (Gronau et 
al., 2002; Terao et al., 2013), though low levels of 11β-HSD2 expression have been 
reported (Cirillo et al., 2017). This unusual 11β-HSD expression profile, combined 
with the known importance of 11β-HSD1 in skin homeostasis (Cirillo and Prime, 
2011), has led to an increased focus being placed on local glucocorticoid metabolism 
in SCC (reviewed by Azher et al., 2016).   
Incidences of skin cancer are increasing; healthcare data from the United States 
suggest that cases of non-melanoma skin cancers (including SCC) have doubled 
between 1994 and 2006 (Donaldson and Coldiron, 2011). Non-melanoma skin cancers 
are the most common cancer in the world, accounting for 80% of all skin cancers, with 
incidences outweighing all other cancers combined (Garcovich et al., 2017). SCC 
specifically is a disease of advanced age, with a mean age of 70 years at diagnosis and 
more than 80% of cases occurring in the elderly. Over the past three decades, incidence 
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of SCC in the elderly has increased dramatically due to cumulative ultraviolet-
exposure and an aging population (Leiter et al., 2014). Given the promise that 11β-
HSD1 inhibitors have shown in treating diseases of the elderly, such as type II diabetes 
(Anderson and Walker, 2013) and more recently Alzheimer’s disease (Sooy et al., 
2010; 2015; Yau et al., 2015; Webster et al., 2017), the prospect that they could 
promote SCC growth is concerning. A further concern is the evidence identifying 
chronic wounds (which are associated with type II diabetes) as a risk factor for SCC 
(Belbasis et al., 2016), though to date there is little evidence suggesting a direct 
association between diabetes and SCC. 11β-HSD1 activity is also increased in the skin 
of older individuals, potentially further increasing their sensitivity to 11β-HSD1 
inhibitors (Tiganescu et al., 2013). Thus, diligence is advisable when proceeding with 
clinical trials, with long-term monitoring of patients for SCC recommended.  
Further research to determine the mechanism responsible for enhanced SCC growth 
after 11β-HSD1 inhibition will hopefully provide answers to several key questions. 
How much of a threat do 11β-HSD1 inhibitors pose in promoting human SCC? 
The present experiments found increased tumour growth using a murine model of 
SCC, implanting cultured murine WT-SCC cells into female FVB/N mice. Female 
mice were used to allow for group housing as FVB/N males are prone to fighting when 
group housed (Thiele et al., 2014). The influence of the oestrus cycle was not 
examined in these studies, though previous studies in mice suggest that corticosterone 
levels are not drastically affected (Malisch et al., 2008; Gong et al., 2015). A murine 
cell line was selected for use in conjunction with an immunocompetent mouse strain 
to allow investigation surrounding the influence of the immune system on tumour 
growth. This is a significant strength in that it provides in vivo conditions more 
comparable to the clinical situation in which patients are unlikely to be 
immunodeficient. Yet the effects of 11β-HSD1 inhibition were only seen in one of the 
two SCC lines examined; SCC-B6-1 cells did not respond to inhibition or deletion of 
11β-HSD1 in C57BL6/J mice. This could be due to the different characteristics of the 
tumour type, but could also be due to strain-specific differences; plasma and liver 
glucocorticoid levels in FVB/N mice appeared to show increased sensitivity to 11β-
HSD1 inhibition compared to C57BL6/J mice. The reduction in circulating 
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corticosterone seen in UE2316-diet-fed FVB/N mice may suggest that these mice also 
had an increased net reduction in intratumour corticosterone levels compared to 
tumours grown in C57BL6/J mice, and this could explain the growth-enhancing effect 
of UE2316 on WT-SCC tumours that was not seen in SCC-B6-1 or Panc043 tumours. 
Until the influence of strain has been fully examined, it is difficult to draw firm 
conclusions regarding the degree of clinical risk. Genetic variation in glucocorticoid 
sensitivity is known to exist in humans, due in part to polymorphisms in the HSD11B1 
and GR genes (Edwards et al., 1988; Stewart et al., 1988; reviewed extensively by 
Quax et al., 2013). Older females are a group particularly associated with both 
increased glucocorticoid sensitivity (Heuser et al., 1994) and Alzheimer’s disease 
(Viña and Lloret, 2010), emphasising the need for particular vigilance when 
monitoring this prospective patient group.  
If it is the features of the tumour type that determine SCC sensitivity to 11β-HSD1, 
then this has important implications. 11β-HSD1 inhibition only promoted the growth 
of WT-SCC tumours, a tumour type displaying features characteristic of a ‘Class B’ 
SCC, including spindle-cell morphology, increased invasiveness and aggressive 
growth (Wong et al., 2013; Huang and Balmain, 2014). These tumours arise via an 
alternative pathway to classical ‘Class A’ SCCs, and are known to depend less on an 
inflammatory stimulus for their formation (Wong et al., 2013). If indeed Class B SCC 
is more sensitive to 11β-HSD1 inhibition, then measuring the impact of 11β-HSD1 
inhibition on number of metastases will be important (Wong et al. (2013) described a 
method for achieving this), as these tumours grow aggressively. Metastatic SCC has a 
10-year survival rate of less than 20% and metastasis vastly worsens prognosis.  
The question of whether host or donor 11β-HSD1 is more important in the tumour 
microenvironment remains unresolved. UE2316 will have inhibited 11β-HSD1 
activity in both host cells and donor tumour cells, while experiments in the Del1 mice 
will only have inhibited host 11β-HSD1. Given that 11β-HSD1 mRNA was detected 
in Del1-grown SCC-B6-1 tumours, the induction of 11β-HSD1 expression after 
injection of tumour cells cannot be ruled out. To address this problem, future studies 
must focus on generating SCC lines similar to WT-SCC (and responsive to UE2316) 
but syngeneic on a C57BL6/J background. This is difficult to achieve given the 
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increased sensitivity of the FVB/N strain to skin carcinogenesis (Hennings et al., 
1993). Additionally, the investigation of both classes of SCC in the FVB/N model 
would provide further insight into tumour-specific differences in sensitivity to 11β-
HSD1 inhibition. Ideally, the generation of an 11β-HSD1-deficient FVB/N line would 
allow comparison of acute inhibition and chronic deletion of 11β-HSD1. Developing 
such a model may pose less of a challenge given the advent of CRISPR/Cas9 gene-
editing technology. 
Are other tumour types at risk from 11β-HSD1 inhibition? 
Growth of PDAC tumours (Panc043) was unaffected by 11β-HSD1 deletion and 
inhibition, demonstrating that these inhibitors do not pose a universal risk to tumour 
growth. While it is unfeasible to consider examining every tumour type, it is important 
to use the present findings to anticipate which other tumour types may be sensitive to 
11β-HSD1 inhibition. Glucocorticoid therapy has shown some benefit in prostate 
(Yano et al., 2006; Sahu et al., 2013) and breast cancer (Karmakar et al., 2013; Lin 
and Wang, 2016). Colorectal cancer also shows an unusual system of local 
glucocorticoid regulation (Sidler et al., 2011; Cirillo et al., 2017), including increased 
11β-HSD1 expression compared to healthy tissue (Žbánková et al., 2004). These three 
cancers are candidate tumour types for future investigations. Azher et al. (2016) 
recently compiled a list of cancers exhibiting dysregulated glucocorticoid signalling, 
and found that small lung cell carcinoma commonly displays reduced glucocorticoid 
receptor (GR) expression or function. Given that the tumour responsive to 11β-HSD1 
inhibition in the present work displayed more GR than non-responsive tumour types, 
this may suggest that cancers expressing lower GR are less at risk. Blocking GR with 
RU486 or using cell-specific knockdown of GR in mice implanted with WT-SCC cells 
will be important for determining the importance of GR in regulating WT-SCC tumour 
growth.  
6.1.2 The anti-inflammatory effects of 11β-HSD1 inhibition in 
some solid tumours may promote their growth 
The original hypothesis for this thesis was that 11β-HSD1 inhibition would enhance 
angiogenesis and this would promote increased tumour growth. Yet, no evidence for 
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increased angiogenesis in tumours was found. Instead, RNA-sequencing data 
suggested that administration of UE2316 had reduced inflammatory and immune 
signalling in WT-SCC tumours. Second harmonic generation (SHG) imaging also 
demonstrated a significant reduction in type I collagen deposition in WT-SCC tumours 
from mice treated with UE2316. Although the present experiments have not 
established a causal relationship between these findings and the increased growth seen 
in UE2316-treated tumours, Gene Ontology (GO) analysis highlighted the relevance 
of these processes (7 of the top 10 significantly associated biological processes were 
related to immune and inflammatory cell signalling) – it appears that some of the most 
profound effects of 11β-HSD1 inhibition in SCC involve altered immune and 
inflammatory signalling. In light of the complex interplay between the immune and 
inflammatory cells, fibroblasts, and the extracellular matrix (ECM) of the tumour 
microenvironment, it is likely that the reduced immune and inflammatory signalling 
and altered ECM seen in tumours after UE2316 treatment are related. Indeed, 
determining the specific effects of 11β-HSD1 inhibition on the interaction between 
these components of the tumour microenvironment will be the first key step in 
identifying the mechanism of increased growth. 
Three firm conclusions can be drawn thus far. These are that WT-SCC tumours from 
mice treated with UE2316 show: reduced expression of pro-inflammatory cytokines 
and chemokines; reduced type I collagen deposition, and; increased growth. As 
discussed in chapter 5, many of the observations in the solid tumour model are similar 
to those seen after 11β-HSD1 inhibition or deletion in models of obesity (Wamil et al., 
2011; Michailidou et al., 2012), atherosclerosis (Luo et al., 2012; Garcia et al., 2013; 
Kiparie et al., 2013) and arthritis (Zhang et al., 2013). These chronically hypoxic and 
non-resolving pathological inflammatory situations are similar in many respects to the 
tumour microenvironment. It is very interesting to note that macrophages, T-cells and 
fibroblasts are all involved to some extent in each of these models. Other cell types do 
have an important role to play in these models (adipocytes in obesity for example, or 
osteocytes in arthritis). However, interaction with mesenchymal, lymphoid and 
myeloid cells is mechanistically integral to the effects of 11β-HSD1 deficiency in each 
situation. Even in models in which 11β-HSD1 deficiency promotes inflammation, the 
same applies; 11β-HSD1 inhibition (and thus reduced glucocorticoid binding at the 
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GR) in cardiac fibroblasts is thought to increase their expression of pro-inflammatory 
cytokines, promoting neutrophil recruitment, and subsequently improving recovery 
after myocardial infarction (Mylonas et al., 2017). Likewise, Zhang et al. (2017) 
recently demonstrated that 11β-HSD1 deficiency in macrophages specifically 
promotes inflammatory angiogenesis. Thus, it appears increasingly important to 
examine the role of 11β-HSD1 in these cell types if the full potential of 11β-HSD1 
inhibitors is to be realised, particularly in chronic inflammatory situations where 
inhibitors may be anti-inflammatory or immunosuppressive.  
Sapolsky et al. (2000) offer an interesting interpretation of the opposing effects 
glucocorticoids can exert upon inflammation and immunity. They propose that the 
immunosuppressive and anti-inflammatory effects caused by high ‘stressed’ 
glucocorticoid concentrations (or exploited clinically) are acting to constrain an 
anticipated inflammatory response (such as that seen during acute myocardial 
infarction), while basal levels of glucocorticoids may act permissively to promote 
inflammation at lower concentrations (Barber et al., 1993, Weigers et al., 1993; 1994; 
1995; Lim et al., 2007). Thus, in a chronic inflammatory situation, it can perhaps be 
argued that low level endogenous glucocorticoid production is permissive in allowing 
the low-level inflammation characteristic of tumours, atheroma, obesity or arthritis. 
Inhibiting the generation of these permissive glucocorticoids thus exerts anti-
inflammatory effects. 
By what mechanism does 11β-HSD1 inhibition promote tumour growth? 
The present work has not fully answered the question of mechanism, but has provided 
sufficient evidence to allow for the generation of a hypothesis. A proposed mechanism 
of enhanced growth in SCC is outlined in Figure 6.1. 11β-HSD1 inhibition in 
macrophages and fibroblasts dampens inflammatory signalling via reduced 
glucocorticoid binding at the GR, reducing reciprocal stimulation between these cell 
populations and decreasing the recruitment of anti-tumour cytotoxic T-cells and other 
tumour-suppressing cell types (natural killer cells, for example) (Coussens et al., 1999; 
Schrama et al., 2001; Drutskaya et al., 2010; Harper and Sainson, 2014; Özdemir et 
al. 2014). Furthermore, the reduced activation and/or recruitment of fibroblasts leads 
to impaired ECM deposition and thus removes the tumour-constraining influence of 
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the fibrotic scaffold (Willhauck et al., 2006; Cretu and Brooks, 2007). The reduced 
anti-tumour immunity and growth-restraining ECM deposition combine to promote 
rapid SCC growth. This model is overly simplistic in that it presents tumour cells as 
passive players, whereas in reality they are likely to be active participants in the 
inflammatory process. Given that pro-inflammatory cytokines can induce 11β-HSD1 
in cells (Chapman et al., 2013b), and 11β-HSD1 expression was seen in SCC-B6-1 
tumours implanted into Del1 mice, a possible role for tumour cell 11β-HSD1 cannot 
be excluded. A recent paper by Cirillo et al. (2017) concluded by postulating that 
cortisol generated by 11β-HSD1 in malignant keratinocytes could lead to tumour 
suppression via alterations to the fibroblast secretome, a hypothesis not dissimilar to 
that described here. Given the evidence available, this model seems a sensible starting 





























Figure 6.1 – Proposed mechanism of enhanced SCC tumour growth. 11β-HSD1 inhibition 
in macrophages and cancer-associated fibroblasts leads to reduced glucocorticoid (GC) 
binding at the glucocorticoid receptor (GR), resulting in reduced reciprocal pro-inflammatory 
signalling, and consequently leading to reduced anti-tumour T-cell recruitment to the tumour 
microenvironment. Reduced fibroblast recruitment/activation also reduces the deposition of 
tumour-constraining extracellular matrix (ECM) deposition. These factors combine to 
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Questions for the future 
The proposed mechanism presents several questions which must form the basis of 
future work.  
- Does 11β-HSD1 inhibition lead to reduced inflammatory and immune cell and 
fibroblast recruitment to the tumour microenvironment? 
Although RNA-sequencing and SHG data strongly suggest this may be the case, only 
by performing Fluorescence Associated Cell Sorting (FACS) and 
immunohistochemical staining can the true effects of 11β-HSD1 inhibition on the 
microenvironment be ascertained. 
- Which cells in the tumour express 11β-HSD1? 
Previous evidence points towards expression of 11β-HSD1 in macrophages, 
fibroblasts and vascular cell types. However, it will be important to determine whether 
tumour cells themselves also begin to express the enzyme once implanted into mice 
(possibly as a result of inflammatory cytokine exposure). This will require more 
elegant immunohistochemical techniques. Another approach may be to label 11β-
HSD1 with green fluorescent protein (GFP) and sort cells on the basis of GFP 
expression. Exposing cultured WT-SCC tumour cells to inflammatory cytokines and 
measuring 11β-HSD1 expression will also help to address this question.  
- Are tissue glucocorticoid levels altered by UE2316? 
An unfortunate limitation of the present experiments was failure to demonstrate 
tumour-specific glucocorticoid concentrations in animals given the 11β-HSD1 
inhibitor UE2316. The optimisation of mass spectrometry imaging techniques such as 
MALDI (Cobice et al., 2013; 2017) are the best approach to this problem. Determining 
the distribution of steroid throughout tumours will also provide insight into the cell 
types in which enzyme inhibition is most important. 
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6.2 Concluding remarks 
The work presented in this thesis has added to the rich literature already surrounding 
11β-HSD1. In the three decades since its discovery, this enzyme has been shown to 
play a part in many of the most serious diseases that scientists are striving to 
understand. The promise of 11β-HSD1 inhibitors has already been shown in clinical 
trials for type II diabetes and Alzheimer’s disease, but preclinical data suggests that 
they have much more to offer in terms of treating chronic inflammatory conditions. 
Yet, as with any new therapy, caution must always be exercised. The importance of 
this message is highlighted by the discoveries made in SCC. The process of 
demonstrating that 11β-HSD1 inhibitors can promote SCC tumour growth has been an 
interesting one; the discovery that the original pro-angiogenic hypothesis needed to be 
rejected, but that an entirely separate mechanism was still able to promote tumour 
growth, is a perfect example of how science can sometimes both frustrate and fascinate 
in equal measure. 
The effects of 11β-HSD1 inhibition in SCC add to the mounting evidence that reducing 
local glucocorticoid regeneration can have profoundly different effects depending on 
the inflammatory context. Inhibition of 11β-HSD1 in chronic inflammatory situations 
seems to reduce this inflammation. While this may be possible to exploit for clinical 
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